The Metastatic Receptor Status Impact on First-Line Treatment Plans and Outcomes for Recurrent Metastatic Breast Cancer by Pannell, T. Allen
University of Tennessee, Knoxville
Trace: Tennessee Research and Creative
Exchange
Doctoral Dissertations Graduate School
12-2015
The Metastatic Receptor Status Impact on First-
Line Treatment Plans and Outcomes for Recurrent
Metastatic Breast Cancer
T. Allen Pannell
University of Tennessee - Knoxville, tpannell@utk.edu
This Dissertation is brought to you for free and open access by the Graduate School at Trace: Tennessee Research and Creative Exchange. It has been
accepted for inclusion in Doctoral Dissertations by an authorized administrator of Trace: Tennessee Research and Creative Exchange. For more
information, please contact trace@utk.edu.
Recommended Citation
Pannell, T. Allen, "The Metastatic Receptor Status Impact on First-Line Treatment Plans and Outcomes for Recurrent Metastatic
Breast Cancer. " PhD diss., University of Tennessee, 2015.
https://trace.tennessee.edu/utk_graddiss/3599
To the Graduate Council:
I am submitting herewith a dissertation written by T. Allen Pannell entitled "The Metastatic Receptor
Status Impact on First-Line Treatment Plans and Outcomes for Recurrent Metastatic Breast Cancer." I
have examined the final electronic copy of this dissertation for form and content and recommend that it
be accepted in partial fulfillment of the requirements for the degree of Doctor of Philosophy, with a
major in Business Administration.
Russell L. Zaretzki, Major Professor
We have read this dissertation and recommend its acceptance:
Bogdan Bichescu, Mandyam Srinivasan, Timothy Panella
Accepted for the Council:
Carolyn R. Hodges
Vice Provost and Dean of the Graduate School
(Original signatures are on file with official student records.)
The Metastatic Receptor Status Impact on  
First-Line Treatment Plans and Outcomes  
for Recurrent Metastatic Breast Cancer 
 
 
 
 
A Dissertation Presented for the 
Doctor of Philosophy  
Degree  
The University of Tennessee, Knoxville 
 
 
 
 
 
T. Allen Pannell, Jr.  
December 2015 
  ii
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2015 by T. Allen Pannell, Jr. 
All rights reserved. 
  iii
DEDICATION 
 
To Amy 
I love you, I miss you, I adore you. 
 
 
 
 
 
 
 
 
 
  iv 
ACKNOWLEDGEMENTS 
 
There is an old saying that “If you ever see a turtle sitting on a fence post, you 
know it had help getting there.” I am that turtle. I can never fully thank 
everyone for the support I received during the research process and writing this 
dissertation. I am sure by the time this paper is accepted, I will realize people I 
have omitted.  In no particular order, here goes; Jessica Pannell, Nicholas 
Pannell, Melissa Pannell, Amy Adele Foster, Russell Zaretzki, Kitty Cornett, Jane 
Moser, Bobby Mee, Ken Gilbert, Alex Miller, Carolyn Cuddy, Steve Mangum, Tim 
Panella, Ellen Perkins, Ed Miles, Deanne Michaelson, H. Alan Lasater, Richard 
Sanders, Tom Pannell, Jean Pannell, Terri Beaudrot, Tom Beaudrot, Srini, Randy 
Bradley, Bogdan Bichescu, Bruce Behn, Amy Cathey, Jake Fait, James Hurley, 
Tyler Massaro and Anna Cormier. 
 
 
  v 
ABSTRACT 
 
Background: For more than two decades, breast cancer researchers have 
studied the benefits, risks and clinical importance of testing the receptor status 
of metastatic tumors. While there is a growing consensus that the status should 
be re-tested and under what circumstances that re-testing should occur, there is 
little to no evidence that utilizing test results for metastatic tumor receptor status 
improves the clinical outcomes of patients. In fact, there is evidence that 
changes to treatment plans based on this re-testing can be harmful to patient 
outcomes.  
Objective: This dissertation evaluates the current state of evidence related to 
altering patient treatment plans based on the re-test results of metastatic 
tumors, offers an update to existing national and international standards and 
executes a retrospective observational study to provide data that supports better 
informed decisions on first-line metastatic treatment plans where retesting of 
tumors is an option. 
Methods: A thorough literature review was performed on the topic. Afterwards, 
a retrospective observational study was performed at the University of 
Tennessee Cancer Institute. 
Conclusions: The research outcomes documented in this dissertation 
demonstrate that basing first-line treatment plans for metastatic breast cancer 
patients on the receptor status of the primary tumor instead of the metastatic 
tumor receptor status extends the life expectancy of patients. A standard of care 
is proposed that impacts national and international guidelines and reflects the 
risks associated with changing the first-line treatment plans of metastatic breast 
cancer patients based on the receptor status of metastatic tumors.  
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PREFACE 
The Scientific Method Begins With an Observation 
Amy 
On January 8th, 2014 I observed Amy Adele Foster die. Three months earlier, on 
our first wedding anniversary, I observed an x-ray of her lungs taken in the 
Emergency Room of the LeConte Medical Center in Sevierville, TN. That x-ray 
showed two liters of fluid in the pleural space of her lung. Four weeks earlier I 
observed a doctor at a world renowned medical center change Amy’s medication 
from one that was working to a different medication based on the fact that “her 
receptor status has changed from PR- to PR+.” One week prior to the change in 
medicine, I observed her primary oncologist tell her, “Good news, your tumors 
are shrinking. I would estimate your life expectancy to now be four years, 
instead of the one year we originally estimated.” 
Allen 
If the above paragraph were read backwards, one would notice that four months 
after being given four years to live, my wife was dead. In the world of metastatic 
breast cancer, such outcomes occasionally occur without cause; but my instincts 
led me to a different conclusion. I saw correlation and wondered if it was cause 
and effect. I contacted the patient advocacy group at the medical center where 
her medicine was changed and asked for a scientific explanation of that decision. 
It took six months to get a phone call to discuss my concerns. In those six 
months, I prepared for the phone call by doing research on the topic. That 
research became this dissertation.  
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CHAPTER 1 
INTRODUCTION AND GENERAL INFORMATION 
 
 
Critical Medical Decision 
 
This research endeavor focuses on a medical decision. This decision is one that 
oncologists and breast cancer patients must make together regarding 
appropriate treatment plans upon the recurrence of metastatic breast cancer. 
Currently, there is no clear evidence based protocol that indicates how to 
determine the best first-line treatment plan after recurrence when a certain set 
of circumstances exist. These circumstances involve the discordance between 
protein receptors of the primary and metastatic tumors. The purpose of this 
research was to collect and analyze the data that would produce a definitive 
treatment protocol. To understand the complex nature of determining the 
appropriate treatment plan, it is important to understand some basic facts about 
breast cancer. A list of abbreviations is found in Appendix 1.  
 
Breast Cancer 
    
The American Cancer Society defines breast cancer as:  
A malignant tumor that starts in the cells of the breast. A malignant tumor 
is a group of cancer cells that can grow into (invade) surrounding tissues 
or spread (metastasize) to distant areas of the body. The disease occurs 
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almost entirely in women, but men can get it, too ("Breast Cancer," 2015, 
p. 2). 
This dissertation’s focus was exclusively on breast cancer in women. Breast 
cancer generally develops in the milk ducts (ductal carcinoma) or the milk 
producing lobules (lobular carcinoma). Other, less frequent types of breast 
cancer also exist. Breast cancer is detected in several ways, ranging from 
mammography or other imaging technology, self-breast exams, or doctor’s 
physical exams. Any of these methods may detect a potential tumor. Once a 
tumor is suspected, a biopsy is generally performed to determine whether the 
tumor actually exists and whether it is cancerous. In some cases, no tumor is 
found. In other cases, the tumor is benign (non-cancerous). In the remaining 
cases, breast cancer is diagnosed ("Breast Cancer," 2015). 
Breast cancer is the most common form of cancer for women in the United 
States. A woman born today in the U.S. has a 1 in 8 lifetime risk of being 
diagnosed with breast cancer. In 2015, an estimated 232,000 case of breast 
cancer will be diagnosed in the U.S., affecting approximately 1,000 women, and 
a few men, per working day. It is likewise estimated that 40,000 women will die 
from breast cancer, actually metastatic breast cancer, this year ("Breast Cancer," 
2015, pp. 9-10). Approximately 60,000 cases of non-invasive Stage 0 breast 
cancer, sometimes called pre-cancer, will also be diagnosed each year as well. 
These particular cases are not included in most incidence statistics because no 
medical consensus exists that Stage 0 is cancer or whether it will eventually 
transform into invasive cancer ("Breast Cancer," 2015).  
Breast cancer trends can be somewhat difficult to estimate. Arguments among 
experts on measurement techniques and the impact of increased mammography 
testing can cloud the discussion. Figures 1 and 2 illustrate breast cancer trends 
since 1975. The data were obtained from the SEER database and are listed in
  3
 
 
Figure 1. Breast Cancer Incidence Rates 
 
 
Figure 2. Breast Cancer Mortality Rates 
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Appendix 2 (Howlader N, 2015). Overall, the incidence rate of breast cancer in 
the United States has been increasing since 1975, with a peak in 1999 and a 
slight decline over the last ten years. The death rate peaked in 1989 at 33.23 
deaths per 100,000 women. This rate has been decreasing for the last twenty 
five years, primarily due to early detection and chemotherapy (Berry et al., 2005; 
Howlader N, 2015). In 2011, the death rate reached a recent low of 21.5 deaths 
per 100,000 women in. 
Breast Cancer Staging 
Breast cancer is staged using the common Stage 0 – 4 scale which is 
summarized in Table 1 ("Breast Cancer," 2015, p. 42).  
 
Table 1. Breast Cancer Staging 
Stage Description 
0 
Carcinoma In Situ. The cancer is in the original cell structure and has 
not invaded into nearby tissue. Considered “pre-cancer”.  
1 
These cancer is still relatively small and either have not spread to the 
lymph nodes or have a tiny area of cancer spread in the sentinel lymph 
node. 
2 These cancer is larger and/or have spread to a few nearby lymph nodes. 
3 
The tumor must be large (greater than 5 cm or about 2 inches across) 
or growing into nearby tissues (the skin over the breast or the muscle 
underneath), or the cancer has spread to nearby lymph nodes. 
4 
These cancer has spread beyond the breast and lymph nodes (at 
original diagnosis) to other parts of the body. Breast cancer most 
commonly spreads to the bones, liver, brain and lung.  
 
 
Receptor Status.  
A key diagnostic characteristic of breast cancer is determining the receptor status 
of the tumor ("Breast Cancer," 2015, p. 35). Receptors are proteins in or on 
human cells that promote the attachment of other proteins to the cell that fuel 
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growth. Two types of receptors that are of interest in breast cancer are 
progesterone (PR) and estrogen (ER). When present, these receptors, promote 
cancer cell growth by utilizing the naturally occurring hormones in a woman’s 
body. If these receptors are present, the tumor is termed ER+ (ER positive) 
and/or PR+ (PR positive). The absence of these receptors are termed ER- and 
PR-, respectively. Another protein of interest is HER2 (human epidermal growth 
factor receptor 2), also referred to as HER2/neu. If this protein is overexpressed 
in a tumor, that tumor is termed HER2+, otherwise it is termed HER2- ("Breast 
Cancer," 2015, pp. 35-36). 
When a women is first diagnosed with breast cancer, the tumor, referred to as 
the primary tumor, is tested to determine its receptor status. The receptor status 
is one aspect of the patient’s diagnosis utilized to determine an appropriate 
treatment plan. If a patient’s breast cancer recurs as a metastatic tumor(s), it is 
now generally accepted practice to test the metastatic tumor’s receptor status. 
When the metastatic tumor is tested (often referred to as re-tested in the 
literature), the metastatic tumor receptors are compared with the primary tumor 
receptor status. When the assessment of the primary tumor receptor status and 
metastatic tumor receptor status yield the same result, the tumor statuses are 
deemed concordant; when the results differ, the tumor statuses are deemed 
discordant.  
Breast Cancer Treatments 
Breast cancer is treated in a variety of ways. The determination of a treatment 
plan for a particular patient is based on the stage of the cancer at diagnosis and 
other physical and histological characteristics of the tumor. A comprehensive list 
of breast cancer treatments are outlined by the American Cancer Society and 
include those listed below ("Breast Cancer," 2015, pp. 49-92). 
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Breast Surgery. A lumpectomy can remove smaller tumors and conserves a 
majority of the breast, leaving a scar and some change in breast shape. The 
complete removal of the breast by a mastectomy may be required based on the 
size of the tumor or other complications. Occasionally, a patient chooses a 
prophylactic mastectomy (single or double) in order to lessen the risk of a 
recurrence of cancer in the breast. These options will often lead to some sort of 
elective reconstructive surgery (pp. 51-55). 
Lymph Node Surgery. Lymph node surgery is performed to determine if the 
breast cancer has spread beyond the breast to lymph nodes underneath the 
armpit. One or more of these lymph nodes may be removed for evaluation. The 
presence of cancer cells in the lymph nodes indicates a higher probability that 
the breast cancer has spread to the bloodstream and thus to other locations in 
the body, such has the liver, lungs or brain. The more prevalent the cancer is in 
the lymph nodes, the more likely the patient will be prescribed chemotherapy as 
an adjuvant therapy ("Breast Cancer," 2015, pp. 57-59). 
Radiation. Radiation therapy is used to destroy cancer cells with high-energy 
rays. Radiation is often administered to the breast and clavicle area after a 
lumpectomy and sometimes after a mastectomy to the breast and clavicle area 
to increase the probability that any unknown, but remaining cancer cells are 
destroyed (pp. 64–67). 
Chemotherapy. Chemotherapy (chemo) is referred to as a systemic treatment. 
Systemic is a type of therapy that does not attack a known, specific cancer cell 
or tumor; rather it is utilized to reach cells throughout the body when cancer is 
known or suspected to have spread. Chemo is used in an attempt to kill cancer 
cells that may have spread from the breast, beyond the lymph nodes, to other 
areas of the body. Adjuvant chemotherapy is the precautionary use of chemo 
where there is no evidence the cancer has spread; however there exists a 
concern that it has spread, a decision that is generally based on the analysis of a 
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patient’s lymph nodes (pp. 68-70). 
Hormonal Therapy. Hormone therapy is another form of systemic therapy. It is 
most often used as an adjuvant therapy to help reduce the risk of the cancer 
recurrence after surgery if the patient is hormone receptor-positive. It is also 
used to treat cancer that has returned after the initial treatment. Approximately 
2 out of 3 breast cancers are hormone receptor-positive. These cancers contain 
receptors for the hormones estrogen (ER+ cancers) and/or progesterone (PR+ 
cancers). Hormone therapy for breast cancer either lowers hormone levels or 
prevents hormones from assisting breast cancer cell growth. A woman's ovaries 
are the main source of estrogen until menopause. After menopause, smaller 
amounts of estrogen are still made in the body's fat tissue. Estrogen promotes 
the growth of cancers that are hormone receptor-positive. ("Breast Cancer," 
2015, pp. 73-74). Tamoxifen is a common drug prescribed for hormone positive 
patients. Femara is a common drug prescribed for hormone positive, post-
menopausal women.  
Targeted Therapy. This terminology is used to describe systemic therapy for 
HER2+ patients. Herceptin (trastuzumab) is a common drug prescribed to breast 
cancer patients with HER/neu positive tumors (pp. 77-79). 
 
Metastatic Breast Cancer 
  
Metastatic breast cancer (MBC) is defined as breast cancer that has spread 
beyond the breast. If this spreading is observed when the breast cancer is first 
discovered, the cancer will be termed Stage 4. Traditionally, if the cancer recurs 
after the initial discovery and treatments, then it is typically referred to as 
recurrent metastatic breast cancer. Metastatic breast cancer has no cure. A 
person diagnosed with MBC will most likely die of MBC. The median life 
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expectancy of people diagnosed with MBC is between 2-3 years (Dawood, 
Broglio, Buzdar, Hortobagyi, & Giordano, 2010). Metastatic breast cancer is 
further defined by its location. If the cancer is confined to lymph nodes in the 
area of the breast, it is called regional. Otherwise, if it has spread to other 
organs, it is called distant. The statistic cited earlier that approximately 40,000 
woman (and a few men) die annually from breast cancer is somewhat 
misleading. It is more accurate to state that yearly 40,000 people will die of 
metastatic breast cancer. In general, people do not die from cancer in the 
breast; they die when it has spread to other organs, thus metastatic breast 
cancer.   
Impact 
Currently, national databases do not track the number of women who are 
diagnosed with metastatic breast cancer. Given the constant mortality rate of 
approximately 40,000 women per year dying of MBC ("Breast Cancer," 2015), by 
extension, for each woman who dies another woman will be told she has 
metastatic breast cancer. Based on this logic, I estimate 40,000 U.S. women are 
diagnosed with metastatic breast cancer each year.  
 
Problem Statement 
 
For more than two decades, breast cancer researchers have studied the benefits, 
risks and clinical importance of testing the receptor status of metastatic breast 
cancer tumors. While a growing consensus exists that encourages re-testing of 
the metastatic receptor status, and the circumstances under which re-testing 
should occur, there is little to no evidence that changing first-line treatment 
plans based on the metastatic tumor status improves clinical outcomes. In fact, 
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there is evidence that changes to first-line treatment plans based on the re-
tested tumor receptor status can indeed harm patient outcomes. The first-line 
treatment plan is the first treatment after diagnosis of metastatic breast cancer. 
It is common for MBC patients to cycle through many treatment plans over time 
as each treatment will eventually become ineffective. While extensive research 
on this topic exists, the most important question has yet to be addressed: 
Does basing a patient’s first-line treatment plan on the receptor status of 
metastatic tumors, when discordant with the receptor status of the primary 
tumor, improve patient outcomes? 
The above critical question has not been directly or adequately addressed in the 
literature. In Chapter 2, I review the research related to this question and 
summarize both the research results and generally accepted practices that have 
evolved in the medical literature. I also propose an answer to my key question 
based on the literature review, and subsequently substantiate that answer with 
the data analysis provided in this dissertation. 
The essence of this dissertation centers on the key decision that doctors and 
patients must make when all of the following conditions exist: 
1. Metastatic breast cancer has recurred (this excludes an initial stage 4 
diagnosis). 
2. The metastatic cancer has been biopsied. 
3. The receptor status of the metastatic tumor has been determined. 
4. The receptor status of the metastatic tumor is discordant from that of the 
primary tumor. 
5. The first-line treatment plan is being determined. 
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When all the above conditions occur, the oncologist and patient must make the 
following decision: 
Should the first-line treatment plan be based on the receptor status of the 
primary tumor or on the receptor status of the metastatic tumor? 
Currently, there is insufficient research based evidence to inform clear guidelines 
for national and international standards where discordance exists. The vague 
standards that do exist are discussed in the literature review section. I estimate 
6,000 U.S. women a year are diagnosed with discordant receptor results and, 
along with their physicians, must decide among conflicting treatment plans 
indicated by the discordance. This estimate is based on my prior estimate that 
U.S. 40,000 women are diagnosed yearly with metastatic breast cancer and the 
15% of those cases that I found in my data to be discordant. Around 521,900 
people die of breast cancer each year world-wide ("Global Cancer Facts & 
Figures," 2012, p. 37). Using a conservative ratio of 10:1, I also estimate 60,000 
women a year world-wide will have discordant receptor statuses and be faced 
with the decision investigated by this dissertation. 
 
Hypothesis 
 
Based on a thorough review of the literature, I hypothesized that: 
In discordant cases, if the first-line treatment plan is based on the receptor 
status of the primary tumor, the median life expectancy of MBC patients will be 
longer than MBC patients whose first-line treatment plan is based on the 
receptor status of the metastatic tumor. 
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Research Purpose 
 
The purpose of this dissertation was to determine the impact on patient 
outcomes in recurrent metastatic breast cancer diagnoses with discordant 
receptors when the first-line treatment plan is based on the receptor status of 
metastatic tumor(s) instead of the receptor status of the primary tumor(s). My 
ultimate goal is that the results of this dissertation leads to changes in 
international and national standards regarding the determination of first-line 
treatment plans in discordant cases of metastatic breast cancer, and to provide a 
higher level of evidence for those standards. 
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CHAPTER 2 
Breast Cancer Literature Review 
       
Review Criteria and Process 
 
I conducted a thorough literature review on research related to metastatic breast 
cancer tumor retesting published prior to November 2014. Key phrases such as 
“metastatic receptor status,” “metastatic receptor test,” “discordance” and 
“hormone receptor” were queried during the electronic literature search. 
Searches for more recent and most cited publications were performed. The 
purpose of this critical literature review was to a) summarize the current data 
related to the risks and benefits of changing treatment plans based on metastatic 
tumor receptor status, b) assess the efficacy of the current clinical standards for 
assessing and utilizing metastatic tumor receptor status, and c) provide the data 
necessary to form my hypothesis. 
Permissions 
Permissions were obtained for all cited figures and extended quotes. Permission 
information is contained in Appendix 3.  
 
Standards 
 
Two medical standards organizations informed my research, the Advance Breast 
Cancer International Conference (Cardoso et al., 2012; Cardoso et al., 2014), 
and the National Comprehensive Cancer Network® (NCCN.org, 2014). 
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These organizations provide physicians with care standards recommendations 
based on the best available evidence. These standards often inform the clinical 
practice guidelines for medical facilities. Each standards organization has a 
defined level of evidence (LoE) scale to support and add context to their 
recommendations. As stated in Chapter 1, the goal of this dissertation is to 
impact the standards relevant to my hypothesis provided by these organizations. 
Advanced Breast Cancer (ABC) Standards 
“The ABC Consensus Conference was created by the European School of 
Oncology (ESO) with the ambitious goal of improving outcomes for all patients 
with ABC” (Cardoso et al., 2014, p. 1). This organization first met in 2011, 
resulting in ABC1 standards (Cardoso et al., 2012). The conference met again in 
2013 (ABC2) and updated the standards (Cardoso et al., 2014).  These standards 
focus specifically on patients with metastatic breast cancer. The current ABC2 
standards (Cardoso et al., 2014, pp. 10-11) that are relevant to my research are 
found in Tables 2.  
 
Table 2. ABC2 Relevant Standards 
Guideline LoE 
A biopsy (preferably providing histology) of a metastatic lesion 
should be performed, if easily accessible, to confirm diagnosis 
particularly when metastasis is diagnosed for the first time 
1C 
Biological markers (especially HR and HER-2) should be reassessed 
at least once in the metastatic setting, if clinically feasible.  
2C 
If the results of tumour (sic) biology in the metastatic lesion differ 
from the primary tumour (sic), it is currently unknown [emphasis 
mine] which result should be used for treatment-decision making. 
Since a clinical trial addressing this issue is difficult to 
undertake [emphasis mine], we recommend considering 
[emphasis mine] the use of targeted therapy (ET and/or anti HER-2 
therapy) when receptors are positive in at least one biopsy, 
regardless of timing. 
Expert 
Opinion 
  14
Levels of Evidence 
The relevant levels of evidence definitions used by ABC2 are listed in Table 3 
(Cardoso et al., 2014). The levels of evidence definitions utilized by the ABC 
conference were originally published by Guyatt et al. (2006). The meaning of 
expert opinion was not defined in the literature I reviewed. I therefore inferred 
that expert opinion equates to no evidence available as defined by the LoE 
criteria, and the recommended standard is based solely on the clinical opinions of 
those assembled to reach consensus. On most guidelines where a level of 
evidence was defined, cited references supported the guideline. No references 
were cited to support the guideline listed as expert opinion in Table 2. 
NCCN Standards 
The National Comprehensive Cancer Network® (NCCN) is a not-for-profit 
organization consisting of 26 of the world's leading cancer centers. NCCN creates 
clinical practice guidelines for clinicians and healthcare professionals (NCCN.org). 
All NCCN guidelines I reference are reported at a 2A level of evidence, unless 
otherwise noted.  NCCN defines a 2A level of evidence as one with a lower-level 
evidence, with uniform NCCN consensus that the intervention is appropriate 
(NCCN.org, 2014, p. MS1).  
The relevant NCCN guidelines state: 
The NCCN Panel recommends that metastatic disease at presentation or 
first recurrence of disease should be biopsied as part of the workup for 
patients with recurrent or stage IV disease. This ensures accurate 
determination of metastatic/recurrent disease and tumor histology, and 
allows for biomarker determination and selection of appropriate 
treatment. 
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Table 3. ABC2 Levels of Evidence 
LoE Quality of Supporting 
Evidence 
Implications 
1A Randomized Clinical Trials (RCTs) 
without important limitations or 
overwhelming evidence from 
observational studies 
Strong recommendation, 
can apply to most patients 
in most circumstances 
without reservation 
1B RCTs with important limitations or 
exceptionally strong evidence 
from observational studies 
Strong recommendation, 
can apply to most patients 
in most circumstances 
without reservation 
1C Observational studies or case 
studies 
Strong recommendation, 
but may change when 
higher quality of evidence 
becomes available 
2A Randomized Clinical Trials (RCTs) 
without important limitations or 
overwhelming evidence from 
observational studies 
Weak recommendation, 
best action may differ 
depending on 
circumstances or patients’ 
or societal values 
2B RCTs with important limitations or 
exceptionally strong evidence 
from observational studies 
Weak recommendation, 
best action may differ 
depending on 
circumstances or patients’ 
or societal values 
2C Observational studies or case 
studies 
Very weak 
recommendation, other 
alternatives may be equally 
reasonable 
Expert 
Opinion 
No Evidence, just the best guess 
of those on the committee 
(This is my definition based on 
researching the designation) 
Data is needed 
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Determination of hormone receptor status (ER and PR) and HER2 status 
should be repeated in all cases when diagnostic tissue is obtained. ER and 
PR assays may be falsely negative or falsely positive, and there may be 
discordance between the primary and metastatic tumors… 
The NCCN Panel recommends that re-testing the receptor status of 
recurrent disease be performed, especially in cases when it was previously 
unknown, originally negative, or not overexpressed.  For patients with 
clinical courses consistent with hormone receptor-positive breast cancer, 
or with prior positive hormone receptor results, the panel has noted that a 
course of endocrine therapy is reasonable, regardless of whether the 
receptor assay is repeated or the result of the most recent hormone 
receptor assay (NCCN.org, 2014, p. MS45). 
Discussion of Standards  
The level of evidence relating to a first-line treatment plan choice for MBC 
patients with discordant receptor results is insufficient, and lacks citations to 
literature to support decision making. ABC2 states the level of evidence is expert 
opinion. The NCCN standard states the level of evidence is 2A; however there 
are no citations supporting that recommendation. These standards also contain 
weak language such as reasonable, currently unknown, and recommend 
considering. Further research is needed to better inform standards, and to 
improve patient outcomes related to treatment decisions.  
 
Retesting of Metastatic Tumor Receptors 
 
Numerous papers have been published addressing the question of whether 
metastatic tumors should be biopsied and tested for receptor status 
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determinations. The overwhelming consensus in the literature points to re-
testing and is best summarized as follows: 
While biopsy of the metastatic site may not be prospectively able to 
demonstrate improved outcome for each patient – at least for the time 
being – it is paramount to introduce a culture of systematically biopsying 
(sic) metastases in order to gain information on the biology of the disease 
and, accordingly, select the best treatment option for our patients 
(Criscitiello et al., 2014, p. 6). 
One of the key reasons re-testing has become more prevalent is the use of fine 
needle aspiration (FNA) which makes biopsies of smaller tumors more accessible 
and less painful to patients (Foukakis, Astrom, Lindstrom, Hatschek, & Bergh, 
2012). Routine FNA, coupled with researchers’ desire for more robust clinical 
data, has recently led to protocol revisions by ABC2 and NCCN that include 
recommendations for performing biopsies and comparing primary and metastatic 
tumors’ receptor statuses. Until such metastatic biopsies became common, MBC 
patients’ first-line treatment plans were based on the receptor status of the 
primary tumor, since the metastatic tumor status was not able to be assessed 
without the biopsy.  
Criscitiello et al. (2014), provides an instructive review of the benefits, risks, and 
the how and when to biopsy metastatic tumors. These topics are also well 
covered by Foukakis et al. (2012). Articles by Penault-Llorca et al. (2013) and 
Turner and Di Leo (2013) provide excellent decision flowcharts for making biopsy 
and treatment determinations.  Based on the weight of the evidence, biopsies of 
the metastatic tumor(s) and re-testing the receptor status has become standard 
practice. The NCCN guideline on re-testing metastatic tumors recommends “that 
metastatic disease … be biopsied … This … allows for biomarker determination 
and selection of appropriate treatment” (Carlson et al., 2012, p. 3). As a 
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consequence of following the NCCN or ABC2 standards on re-testing, the 
determination of the proper treatment plan to prescribe when the receptor status 
of the metastatic tumor and the primary tumor are discordant is a common 
conundrum in current clinical practice.  
 
Discordance 
 
Many researchers study the percentage of discordance between the receptor 
status of the primary tumor and the metastatic tumor (Amir, Clemons, et al., 
2012; Aurilio et al., 2014; Dieci et al., 2012; Farolfi, Ibrahim, Scarpi, & Amadori, 
2013; Niikura et al., 2012). A recent meta-analysis by Aurilio et al. (2014) 
summarizes 48 articles totaling 3,000 – 4,000 tumors. Table 4 shows the pooled 
discordance rate found in that article. 
 
Table 4. Receptor Discordance Rates 
 
 
 
 
How is Discordance Measured? 
A cancer tumor contains three receptors of interest, and each can be positive or 
negative, thus there are eight (23) total combinations. In the literature, most 
authors call a difference in any receptor status, primary versus metastatic, a 
discordance. Thus, a change from one of the possible eight combinations to one 
of the remaining seven combinations, is considered a discordance There are 56 
(8x7) such discordances. However, not all of those discordances would dictate a 
Receptor Discordance 
ER 20% 
PR 33% 
HER2 8% 
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treatment change. For example, if a patient’s receptor status is ER+, PR+ and 
HER2- in their primary tumor and ER+, PR-, HER2- in their metastatic tumor, the 
treatment plan will be the same, since the ER+ status indicates the same 
treatment for either set of results. Thus, not all discordances are clinically 
important for determining treatment plans. However, very few authors delineate 
between the possible discordant patterns. The receptor combinations and their 
corresponding descriptions are listed in Table 5. Clearly and strictly defining 
discordance and its impact on treatment plans is an important issue in this 
research, and a weakness in the current literature.  
 
Table 5.  Receptor Combinations 
Receptor Combination Description 
ER-, PR-, HER2- Triple Negative (TNBC) 
ER+, PR+, HER2- Hormone Receptor Positive (HR+) 
ER+, PR-, HER2- ER positive, PR negative (HR+) 
ER-, PR+, HER2- ER negative, PR positive (HR+) 
ER-, PR-, HER2+ HER2 Positive, HR- (HER2+) 
ER+, PR+, HER2+ Positive Breast Cancer (PBC) 
ER-, PR+, HER2+ HR positive, HER2 positive (PBC) 
ER+, PR-, HER2+ HR positive, HER2 positive (PBC) 
 
What Causes Discordance? 
Ultimately, it may or may not be important to understand the causes of 
discordance. Some theories in the literature as to the causes of discordance are 
outlined in this section for completeness. However, for my particular research, 
the cause of discordance is not considered. My research interest lies in whether 
there is discordance, not why, and whether that discordance leads to altered 
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patient treatment plans, and whether those altered plans lead to better or worse 
clinical outcomes.  
One of the most common reasons proposed for discordance is the possibility of 
measurement error. That is, the two tumor receptor status results differ not 
because the tumors are different, rather there exists variation (inaccuracy) in the 
measurement process itself. The primary tumor can usually be measured based 
on the extraction of the full tumor. The metastatic tumor is measured on the 
basis of a FNA biopsy, given that a metastatic tumor can rarely be removed. A 
tendency in the literature is to assume the metastatic receptor status 
measurement is subject to more error (Foukakis et al., 2012). 
Sighoko, Liu, Hou, Gustafson, and Huo (2014), use Bayesian methods to extract 
measurement error in order to estimate the true discordance rates. Their study 
provides some insight into the question of what percent of discordance may be 
due to measurement error. Liedtke et al. (2009), is an excellent example of a 
study where measurement error is contemplated as a key cause of discordance. 
The authors state: 
We hypothesize that the poor survival outcome of patients with discordant 
receptor results may be due to both false-negative results that could lead 
to withholding endocrine therapy (or trastuzumab) and false-positive 
receptor results may also contribute some by leading to an initial period of 
ineffective therapy with targeted agents in patients who do not benefit. 
…mistakes in receptor determination can lead to suboptimal therapy. 
...our results illustrate the need to increase standardization and 
implementation of guidelines for hormone and HER2 receptor 
determination” (p. 1957). 
 
  21
There is not a consensus in the literature on the percentage of discordance that 
is due to true biological difference and the percentage due to measurement 
error. Based on the data I evaluated, I estimate that measurement error 
accounts for 33% to 50% of discordances. This range is a qualitative estimate 
only; thus it is not possible to put statistical confidence on the estimate. 
Discussions about other causes of discordance are less conclusive. A good 
example of other hypothesized reasons for discordance is found in Dieci et al. 
(2012) where they indicate that in addition to measurement errors, the 
heterogeneity of cancer tumors and the impact of previous treatments could also 
be reasonable explanations for a change in receptor status (p. 4). 
Foukakis et al. (2012) also outlines the potential causes of discordance: 
However, the reason for this discrepancy is less clear and both technical 
and biological explanations have been discussed. The use of various 
methods for ER (biochemical versus IHC assays) and HER2 (IHC versus 
FISH), the variability caused by sampling methods (fine-needle aspiration 
(FNA) or core biopsy versus surgical excision in the primary tumour (sic)) 
and differences in analysis of samples from different tissues are all 
possible technical caveats that could cause a false discrepancy (pp. X351-
X352). 
Hoefnagel et al. (2013), demonstrate that tumors among different metastases 
within the same patient have 10% discordance with clinical consequences. This 
result supports the heterogeneity of breast cancer and casts some concern about 
relying on just one metastatic sample site for testing receptor status when 
multiple sites exist. The data is clear that discordance exists, yet it is unclear as 
to why. However, for this dissertation, the key question remains whether 
discordances affect treatment decisions for patients and what are the 
implications such decisions have on clinical outcomes. 
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Impact on Treatment Decisions 
 
First-line treatment plans in the metastatic setting are based on the receptor 
status of the disease, along with other factors. Several authors, directly or 
indirectly, explore the impact that retesting tumor receptors has on the 
establishment of first-line treatment plans. These authors estimate the percent of 
treatment plan decisions that occur based upon the receptor status of the 
metastatic tumor, when that status is discordant with the primary tumor. Table 6 
summarizes five articles that expressly address the impact of discordance on 
first-line treatment plans.  
 
Table 6. Change in Treatment Plans 
Author Year 
Percent of First-line 
Treatment Plans Changed 
for MBC Patients Because 
of Discordance 
(Lindstrom et al., 2012) 2012 estimated > 50% 
(Aurilio et al., 2013) 2013 17 of 27 discordances 
(Dieci et al., 2012) 2012 13 of 27 patients 
(Thompson et al., 2010) 2010 24 of 34 patients 
(Amir, Clemons, et al., 2012) 2012 41 of 113 discordances 
 
The Aurilio et al. (2013) article reports 17 of 27 discordances resulted in changes 
to treatment therapies for MBC patients. Based on the reported data, it is not 
possible to determine whether some changes are for the same patient, as the 
data was reported by discordance, not by patient. While many changes to 
treatment plans are also made for concordant receptors, the authors imply that 
those changes are based on “… disease progression …” instead of the re-tested 
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receptor results (Aurilio et al., 2013, p. 1651). Amir, Clemons, et al. (2012), 
indicated 41 patients had their treatment plans changed after a metastatic biopsy 
resulted in discordant results. One hundred thirteen changes in receptor statuses 
were documented in the study. Because discordance is not clearly defined by the 
authors, the 113 changes in receptor status can be interpreted in several ways. 
That is, some of the changes may not indicate a change in standard therapy and 
some changes may occur in the same patient (i.e. both ER and PR changed from 
plus to minus). Thus, the 113 changes do not necessarily indicate 113 patients 
had changes. The authors indicate that 14% of those patients whose tumors 
were biopsied had their treatment changed based on the receptor status of the 
metastatic tumor (Amir, Clemons, et al., 2012). It is important to note that this 
14% is of patients whose tumors were biopsied, not the percent of those with 
tumor receptor status discordance. It is unclear what percent of patients with 
discordant results had their treatment plan changed. 
Based on the body of research reviewed, I estimate that currently 60% to 75% 
of MBC patients with discordance have their treatment plans changed based on 
the receptor status of the metastatic tumor. Again, no statistical confidence can 
be provided to this range due to the variation of, and uncertainty in the reporting 
methods utilized by the authors included in this literature review. In chapter 4, I 
report the percentage of discordant cases where the treatment plans are 
changed in my retrospective study. Based on the current literature and 
recommended clinical standards, doctors are performing more biopsies of 
metastatic tumors, re-testing the receptor status and evaluating the discordance 
with the primary tumor when determining first-line treatment plans.  This 
increased testing warrants the examination of clinical outcomes for patients with 
first-line treatment plans based on metastatic tumor receptor statuses. 
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Clinical outcomes 
 
In the Conclusion sections of several articles, the authors summarize their 
findings regarding the clinical outcome of discordant receptors (Chang et al., 
2011; Duchnowska et al., 2012; Idirisinghe et al., 2010; E. E. Lower, Glass, Blau, 
& Harman, 2009; Montagna et al., 2012; Wilking et al., 2011). These particular 
authors focus on the impact of discordance on life expectancy, without directly 
testing the impact of changing treatment plans based on that discordance. 
Additionally, some researchers note the clinical implications of changing 
treatment plans in the Discussion sections of their papers, yet offer no definitive 
statements in the Conclusion sections of their research. The lack of clearly stated 
conclusions related to the clinical benefits of changing treatment plans make it 
difficult to quantitatively summarize the literature. I utilized all the information in 
the literature search, not just the authors’ stated conclusions, to ensure a 
comprehensive analysis. The inclusion of all information led to clear, emergent 
patterns that inform the clinical consequences of changed treatment plans.  
The research derived from my literature review provides clear evidence that 
changing treatment plans based on the metastatic tumor receptor status is more 
harmful than helpful.  A strong illustration of this finding is found in Liedtke et al. 
(2009, p. 1953) where the authors assert that “discordant cases have poor 
survival probably due to inappropriate use of targeted therapies.”  The 
implication is that patients with discordant receptor statuses are given 
treatments contrary to what their primary tumor statuses indicate, and thus this 
change is the likely cause of the poor results in life expectancy. The authors 
report that the median post recurrence survival (PRS) rate for triple negative 
breast cancer (TNBC) patients who have concordant receptors (thus no change 
made to treatment based on metastatic tumor status) is 43 months. TNBC 
  25
patients (primary tumor) whose metastatic tumor receptors were discordant, 
experienced a 15.6 month median PRS (Liedtke et al., 2009, p. 1956). PRS 
represents the survival rate of patients over time, calculated from the time the 
metastatic recurrence is documented. This is the best and most common 
measurement for clinical outcomes in the literature. Graph A in Figure 3 depicts 
the TNBC patients only. Graph B represents the entire research sample.  
 
 
Figure 3. Liedtke Discordance Results (p. 1956) 
 
The authors imply that altering treatment plans for discordant patients translates 
to poor clinical outcomes. Another example supporting the harmful outcomes 
that result from changing treatment plans based on discordance is discussed by 
Dieci et al. The authors indicate that “the impact of this approach on patient 
management and outcome is not yet clear, (and) induce(s) clinicians to modify 
the treatment choice in ~14% of the cases and that a change in the receptor 
status is associated with poorer survival” (Dieci et al., 2012, p. 1). As noted 
  26
earlier in this chapter, the 14% refers to the percentage of all biopsied patients, 
not the percentage of patients with discordant receptors.  
Niikura et al. (2012, p. 598), finds that “patients with HER2 discordance between 
their primary and metastatic tumors have shorter OS. However, for our data, 
inaccurate testing may have caused discordance between primary and metastatic 
sites.” OS is the authors’ abbreviation for Overall Survival, which is equivalent to 
Post Recurrence Survival (PRS).  The authors’ reference to inaccurate testing 
refers to measurement error. Figure 4 contains Niikura’s results.  
 
 
Figure 4. Niikura Discordance Results (p. 597) 
 
Karlsson et al. (2014, p. 1), notes that changes from ER+ or PR+ in the primary 
tumor to ER- or PR- in the metastatic tumor result in an increased risk of death 
with hazard ratios of 3.62 and 2.34, respectively. These patients had their 
treatment plan changed and were denied endocrine therapy because of the 
receptor status of the metastatic tumor. The authors note that none of the 
  27
patients whose ER+ status changed to ER- received the endocrine therapy they 
would have received had their receptors been concordant. This important result 
supports my overall hypothesis and is shown in Figure 5. Note that in Figure 5 
the worst performing patients are those whose ER status changed from positive 
to negative.  
 
Figure 5. Karlsson (p. 6) 
 
In a study on HER2 discordance, Chang et al. (2011, p. 598), states that 
changing treatment plans has “…an inferior outcome…” when compared to 
concordant cases.  While their sample size is small (n=18), the data analysis 
supports my hypothesis. Those patients in Chang’s sample whose treatment plan 
is based on the receptor status of the metastatic tumor in discordant cases had 
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negatively impacted survival rates. Chang’s graphs are provided in Figure 6, 
where Group 2 has concordant results and Group 3 has discordant results 
(Chang et al., 2011, p. 597). 
The weight of the literature review evidence indicates that changing treatment 
plans based on discordant receptor status results yields poorer clinical 
performance as measured by patient survival time post recurrence.  
 
 
Figure 6. Chang (p. 597) 
 
Potential Contradictory Data 
Several articles provide some evidence that discordant results lead to equal or 
better outcomes for patients. Amir, Miller, et al. (2012), find no difference in 
survival rates for concordant and discordant results in MBC patients’ tumors. 
They state “…after a median follow-up of 12 months, there were no trends for 
an association between receptor discordance and either time to treatment failure 
or overall survival” (p. 587). I have two concerns about their data. First, only 
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about 30% of the discordant cases had their treatment changed based on the 
receptor status of the metastatic tumor, as opposed to the 60% to 75% of cases 
found in most of the literature review. Therefore, discordant and change in 
treatment are not as confounded here as opposed to the typical studies in this 
review, thus supporting the notion that no change in treatment plans leads to 
better results. Additionally, the median patient follow-up is only 12 months, 
which is not sufficiently long enough for estimating 5 year survival curves. 
See Figure 7 for their results (p. 591).  
  
 
Figure 7. Amir, Miller (p. 591) 
 
E. E. Lower et al. (2009), researching only HER2 status finds that “… fifteen 
percent of patients with primary tumors negative for HER-2/neu distant 
metastasis had HER-2/neu overexpression. These patients experienced improved 
survival compared to those patients with HER-2/neu negative primary and 
metastatic lesions” (p. 305).  In other words, 15% of the patients changed from 
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HER2- in their primary tumor to HER2+ in their metastatic tumor. The authors 
do not describe how patients’ metastatic treatment plans are determined. 
Therefore it is not possible to determine the effect of first-line treatment 
decisions in this study. 
Duchnowska et al. (2012), find no difference in survival for discordant cases 
when measured from the time of the initial diagnosis with breast cancer. 
Evaluating survival from the time of initial diagnosis is not prudent in this 
research. There are too many variables that affect overall survival times before 
the recurrence, such as initial treatments, adjuvant therapies, age at diagnosis 
and BRCA status. Survival time from recurrence is the best metric and the one 
used in all other research I reviewed.  
One article does conclude that better results are obtained by retesting receptors 
and utilizing the metastatic tumor results. Their conclusion is “we observed that 
18 out of 100 biopsied patients (18.0%) had a conversion of predictive factors 
which allowed adjusting for therapy, … Those 18 patients showed a better 
survival compared to the other 82 biopsied patients …” (Botteri et al., 2012, p. 
284). The authors imply that 18 patients have discordant results and that those 
patients’ treatment plans are changed based on the metastatic tumor status, and 
those changes result in better clinical outcomes. My analysis of this article 
exposed several research flaws. First, this study is restricted to patients with liver 
metastases. Thus, it is not prudent to infer these results are applicable to other 
locations of metastases. Second, the sample size of patients with changed 
treatments is small, (n = 18). Third and most importantly, 10 of the 18 patients 
with adjusted treatment plans do not necessarily have a change in HER2 status. 
These 10 patients did not have their primary tumor tested for HER2 because 
HER2 testing was not yet developed at the time of their initial cancer diagnosis. 
These particular patients are HER2 positive in their metastatic tumor and they 
  31
received Herceptin for the first time. The authors believe it is reasonable to 
assume these patients were originally HER2- because about 80% of the current 
patient population is HER2- in their primary tumor (p. 287). It is unreasonable to 
make an assumption that impacts over half of the data (10 of 18). Additionally, 
one could argue that since these patients had not initially been treated with 
Herceptin and eventually had a recurrence, they are therefore more likely to 
have been HER2+ in their primary tumor. 
Summary of Clinical Implications 
Foukakis et al. (2012), notes that, “…carrying out a metastatic biopsy had an 
impact on treatment decisions … no conclusions could be drawn from these 
analyses regarding the impact of this practice on survival” (p x351). 
I disagree with Foukakis about drawing conclusions regarding the impact on 
survival. The weight of the evidence is clear and indicates that basing first-line 
treatment plans on the metastatic receptor status when discordant with the 
primary tumor receptor status has an overall negative impact on survival.  
 
Challenges Interpreting the Literature 
 
I encountered two primary difficulties interpreting the findings and conclusions of 
articles in the literature review. First, the definition of discordance often varies 
from author to author and is sometimes not clearly defined. Additionally, it is 
rare for an author to offer a definitive discussion about the impact of basing first-
line treatment plans on metastatic receptors for patients with discordant 
receptors. Together, these two challenges make it impossible to conduct a 
precise quantitative meta-analysis of the literature review or easily make 
comparisons between studies. The impact of the variation and ambiguity in 
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discordance definitions has been discussed throughout this chapter. The difficulty 
measuring the impact of changes in treatment plans based on inconsistent and 
confusing reporting is best illustrated by Wilking et al. (2011). The key results 
from this study are reflected in their graphical analysis presented in Figure 8. The 
inserted note in Figure 8 is mine and not the authors. 
 
 
Figure 8. Wilking Survival Curves (p. 558) 
 
The authors indicate that there is indeed discordance in their dataset with 
respect to HER2 and that changes in HER2 status resulted in a “significantly 
increased risk of dying” for those patients (Wilking et al., 2011, pp. 557-558). My 
interpretation of the authors’ description of the data is that each patient with 
discordant metastatic receptors also had their first-line treatment plan based on 
the metastatic receptor status instead of the primary receptors. Thus, change in 
treatment plan is completely confounded statistically with discordance. A 
statistical finding about discordance is also a statistical finding about changing 
treatment plans based on the metastatic tumor receptors. This confounding is a 
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problem throughout the literature and highlighted by Turner and Di Leo’s 
literature review when they state that the “interpretation of the prognostic 
impact of discordance is limited by the confounding influence of any treatment 
alteration based on the metastatic biopsy result” (Turner & Di Leo, 2013, p. 
950). The curves in Figure 8 indicate worse survival results for discordant 
patients when compared to HER+ concordant patients. The key question is 
whether that difference in survival can be attributed to the discordance or to 
changes in patient treatment plans based on the discordance.  That is, what 
would the survival curves demonstrate if they are plotted based on whether the 
patients’ first-line treatment plan is based on the primary or metastatic tumor 
receptor statuses? In order to attempt to recast the analysis based on treatment 
plan determination, I carefully reread the article to determine the first-line 
treatment plans for the discordant patients; that is, are their treatments based 
on the metastatic tumor or the primary tumor receptor status? This analysis 
became a futile exercise. The authors’ data flow diagram is reproduced in Figure 
9 (Wilking et al., 2011, p. 556). I inserted the lettering in Figure 9 for discussion 
purposes.  From the flowchart, it is clear that 43 patients (box E) have HER2+ 
primary tumors and 42 (boxes A and D) have HER2+ metastatic tumors. Fifteen 
patients (boxes B and D) have discordant tumors. Utilizing the authors’ flowchart 
and their commentary about that flowchart, I first concluded that 27 to 29 of the 
43 patients with HER2+ primary tumors received trastuzumab (prescribed for 
HER2+ cancer) after recurrence (p. 557). Based on this calculation, one would 
assume that a maximum of 29 of the 42 patients with HER2+ metastatic tumors 
received trastuzumab. The authors also indicate that all patients (42) with 
HER2+ metastatic disease received trastuzumab (p. 557). The possible number 
of patients treated for HER2+ metastatic cancer is now 27, 29 or 42. In another 
section of this article, it is indicated that 23 to 26 patients are treated for HER2+ 
cancer (p. 557). After stating that all 15 discordant patients receive trastuzumab, 
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Figure 9. Wilking Data Flowchart (p. 556) 
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the paper indicates that “… of the 15 patients with change in HER2 status, 5 
(33%) received trastuzumab” (Wilking et al., 2011, p. 557).   
Based on the confusing information in the article, I cannot clearly determine the 
number of discordant patients who had their treatment plans changed. A 
reasonable interpretation is that most or all discordant patients have their 
treatments changed based on the metastatic tumor status instead of the primary 
tumor HER2 status. Figure 8 illustrates that discordant patients fared worse than 
concordant ones. Thus, the obvious conclusion is that retesting the HER2 
receptor status and basing first-line metastatic treatments on that test is harmful 
to patients and should not be done. However, the authors state “the conclusion 
of our study is that a number of patients, who experience a recurrence, will not 
be managed correctly, if therapy is only based on characteristics of the primary 
tumor” (p. 559). This type of confusion and confounding found in the data of the 
relevant literature makes the study in this dissertation all the more necessary 
and important. 
 
Progress in the Literature 
 
When I began the literature review, I expected to find that someone had 
discovered the answer to my proposed research question: Does basing a 
patient’s first-line treatment plan on the receptor status of metastatic tumors, 
when discordant with the receptor status of the primary tumor, improve patient 
outcomes? Most authors are researching the clinical impact of discordance, but 
are not investigating how clinical outcomes are affected when the first-line 
treatment plans of metastatic patients are based on the receptor status of the 
metastatic tumor instead of the primary tumor. The most current research is still 
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focused on the survival impact of discordance, rather than the survival impact of 
changing treatment plans based on the discordance. 
One of the earliest articles I found on this subject was published in 1989 and the 
stated purpose of the study in the article is to determine the prognostic impact of 
ER discordance (Kamby, Rasmussen, & Kristensen, 1989, p. 1). Three years 
later, Spataro et al. (1992), seeks to “… determine the clinical relevance of the 
subsequent ER determination” (p. 733). Next, Kuukasjarvi, Kononen, Helin, Holli, 
and Isola (1996) attempt to determine if a failure to respond to endocrine 
therapy was due to discordance between primary and recurrent receptor status 
(p. 2584). In 2005, the impact of changes in metastatic receptors on “… change 
on survival” is investigated (Elyse E. Lower, Glass, Bradley, Blau, & Heffelfinger, 
2005, p. 65). 
Some 25 years after Kamby’s research, Yang et al. state: 
The aim of this study was to evaluate the frequency and prognostic 
impact of changes in the estrogen (ER), progesterone (PR) and human 
epidermal growth factor receptor 2 (HER2) status between primary and 
recurrent/metastatic lesions (RML) (Yang et al., 2014, p. 1). 
After 25 years of research, Turner and Di Leo (2013) conclude that the data on 
the clinical impact of discordance and changing treatment plans is “…limited, 
inconclusive and conflicting” (p. 954). I disagree with this conclusion. Careful 
reading of the available literature, which is not limited, indicates a conclusive 
pattern that changing treatment plans based on the receptor status of the 
metastatic tumor results in more harm than good, shortening the life expectancy 
of metastatic breast cancer patients. The research in the literature that conflicts 
with this pattern is limited and weak.  
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Clinical Standards Recommendation  
 
The current medical standards that relate to the topics of this dissertation are 
discussed earlier in this chapter. Based on my review of the literature, I offer the 
following over-arching standard of care for metastatic breast cancer patients with 
discordant receptor status results: 
Where discordance between the primary and metastatic tumor receptor status 
would indicate different treatments, the status of the primary tumor should take 
precedent when developing the first-line treatment plan for a newly diagnosed 
recurrent metastatic breast cancer patient. Strong clinical evidence to the 
contrary must be present to warrant basing the treatment plan on the metastatic 
tumor receptor status. 
This statement, combined with the non-contradictory standards of ABC2 and 
NCCN, coupled with the excellent decision flowcharts of Turner and Di Leo 
(2013) and Penault-Llorca et al. (2013) provide clear direction for the best 
course of action based upon current available literature and supporting data. My 
proposed standard is challenged for efficacy in the data analysis phase of my 
research. 
 
Statistical Literature Review 
 
In preparation for the analysis phase of this dissertation, I performed a brief 
literature review on the Kaplan-Meier (KM) method of survival analysis and the 
log rank method of testing KM survival curves (Lakatos, 1988). Most papers on 
this subject are either theoretical (the mathematical theory, or new theories 
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about calculating sample size) or theoretical with some practical examples. The 
methods referencing sample size estimation ultimately rely on some form of a 
normal approximation of the sum of hypergeometric probabilities based on the 
number expected deaths. The number of deaths is manipulated by the censor 
and death percentages to obtain an estimate of sample size and power 
calculations (Lakatos, 1988, pp. 223-224). Several practical points are found in 
the articles reviewed.  With respect to the number of time intervals utilized in an 
analysis, “there are no big differences in power if the subjects are observed in 2, 
4, or 8 time intervals” (Jozwiak & Moerbeek, 2011, p. 637). Additionally on time 
intervals, “ …increasing the sample size generally has a greater effect on power 
than increasing the number of time points. …it is better to recruit a large number 
of participants in the trial and observe them infrequently, for example, two or 
three times during the study” (Jozwiak & Moerbeek, 2011, p. 651). The impact 
that the hazard rate has on power depends on how close the rate is to zero or 
one, not just the difference between the two proportions (p. 650).  
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CHAPTER 3 
Materials and Methods 
 
Research Purpose 
 
The goal of my research is to influence change in international and national 
medical standards that determine the first-line treatment plans in discordant 
cases of metastatic breast cancer, and provide a higher level of evidence for 
those standards. The purpose of this dissertation was to determine the impact on 
patient outcomes in recurrent metastatic breast cancer diagnoses with discordant 
receptors when the first-line treatment plan is based on the receptor status of 
metastatic tumor(s) instead of the receptor status of the primary tumor(s).  
For my particular study, the first-line treatment plan was defined as the first 
treatment strategy administered after the diagnosis of a metastatic recurrence, 
when the receptor status of the metastatic tumor is discordant with the primary 
tumor, or the first treatment plan after establishing discordance if the testing of 
the metastatic receptors is performed routinely and not ordered because the first 
treatment plan is failing.  (In the metastatic setting, treatment plans will 
inevitably change over time as the efficacy of one strategy fails and another is 
employed).  
For the purpose of this study, patient outcomes was defined in two ways: 1) five 
year post recurrence survival time (PRS) curves, which will be calculated as the 
time from metastatic recurrence to the time of death or censoring, and 2) the 
first-line follow-up scan results using the RECIST (Eisenhauer et al., 2009) 
standard, defined in Appendix 4. The first follow-up scan typically occurs 90 days 
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after the first-line treatment is initiated. Scan refers to some form of imaging to 
assess the growth of the metastatic tumors. 
It is important to note that in the absence of re-testing the metastatic tumor 
receptor status, first-line treatment plans are based on the receptor status of the 
primary tumor, previous treatments and the clinical observation of the patient. 
When the metastatic tumor is retested, sometimes the receptor status of the 
metastatic tumor is utilized instead of the status of the primary tumor when 
determining treatment plans. In this study, the first-line treatment plan was 
considered to be based upon the test results of the metastatic tumor(s) if: a) 
there was a discordance between the primary tumor receptor status and the 
metastatic tumor status, and b) that discordance indicated a different treatment 
plan, and c) the plan was based on that discordance. All three of these 
conditions must have existed to consider the first-line treatment plan to have 
been based on the metastatic tumor instead of the primary tumor. 
 
Key Research Questions 
 
Two research questions are postulated for my study: 
1. Does basing a patient’s first-line treatment plan on the receptor status of 
metastatic tumors, when discordant with the receptor status of the 
primary tumor, improve patient outcomes? 
2. Should the first-line treatment plan in metastatic cases be based on the 
receptor status of the primary tumor or the metastatic tumor? 
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These two questions guided the research methodology of this study and are 
critical questions not addressed in the literature.  
 
Hypothesis 
 
In discordant case, if the first-line treatment plan is based on the receptor status 
of the primary tumor, the median life expectancy of MBC patients will be longer 
than MBC patients whose first-line treatment plan is based on the receptor status 
of the metastatic tumor. 
 
Study Design 
 
A retrospective observational study was designed utilizing the data of the 
patients diagnosed with recurrent metastatic breast cancer in The University of 
Tennessee Cancer Center’s tumor registry. A retrospective study was the 
appropriate design since a prospective study could take 10-15 years to complete 
and ensuring sample randomness would be difficult. That is, the medical staff’s 
awareness that a study was being conducted and exposure to the hypothesis 
could theoretically impact the decision making process and bias the data. A 
clinical trial would be possible, but again would likely take more than 10 years to 
complete. Additionally, ethical concerns have been proposed by other authors. 
Amir, Clemons et al. (2012) state “a more definitive assessment of biopsy would 
require a randomized trial… …for such a trial would likely it (be) unfeasible” (p. 
713).  Aurilio et al. (2013) state “in our opinion, only high powered prospective 
and randomized trials could clarify the outcomes in this field and finally 
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demonstrate a survival benefit; however, they should involve large sample size 
and ethical controversies may be unsolvable” (p. 1655). I disagree with the 
statement that only prospective randomized trials could clarify the outcomes. I 
contend that my retrospective study, and other similarly executed retrospective 
studies, can provide the necessary data to address the hypothesis and research 
questions posed in this paper.  
 
Discordance 
 
Discordance was a critical concept introduced and discussed in Chapter 2. The 
most common definition of discordance in the literature is defined as a difference 
in the receptor status of the primary and metastatic tumor tests. Of the eight 
combinations of receptor status listed in Table 5, Chapter 2, there are only four 
combinations (called phenotypes) that traditionally dictate treatment decisions. 
Those four phenotypes are displayed in Table 7.  
Phenotypes and Discordance 
This study focused on patients whose metastatic tumors were reassessed and 
determined discordant. Discordance was strictly defined as a difference in the 
primary tumor receptor status and the metastatic tumor status that warrants a 
change in treatment plan based on current NCCN standards (NCCN.org, 2014, 
pp. BINV-4). The four phenotypes utilized for this study are TNBC (Triple 
Negative Breast Cancer), HR+ (Hormone Receptor positive and HER2 negative), 
HER2+ (HER2/neu positive and HR negative), and PBC (Positive Breast Cancer). 
Radiation treatment was not considered in my study because it is agnostic to 
receptor status. Table 8 delineates the basic treatment strategy descriptions by 
phenotype. Dieci et al. (2012), also uses these four phenotypes in their research.  
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Table 7. Receptor Phenotypes 
Receptor 
Combination Description Phenotype 
ER-, PR-, HER2- Triple negative  TNBC 
ER+, PR+, HER2- Hormone Receptor (HR) positive  HR+ 
ER+, PR-, HER2- ER positive, PR negative  HR+ 
ER-, PR+, HER2- ER negative, PR positive HR+ 
ER-, PR-, HER2+ HER2 positive, HR negative HER2+ 
ER+, PR+, HER2+ Positive Breast Cancer PBC 
ER-, PR+, HER2+ HR positive, HER2 positive PBC 
ER+, PR-, HER2+ HR positive, HER2 positive PBC 
 
Table 8. Phenotype Treatments 
 
ER PR HER2 Phenotype Primary Treatment 
1 - - - TNBC Chemo 
2 + + + PBC Chemo+Targeted, Endocrine 
3 + - + PBC Chemo+Targeted, Endocrine 
4 - + + PBC Chemo+Targeted, Endocrine 
5 + + - HR+ Chemo, Endocrine 
6 + - - HR+ Chemo, Endocrine 
7 - + - HR+ Chemo, Endocrine 
8 - - + HER2+ Targeted 
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Liedtke et al. (2009), report an analysis of TNBC and RPBC, which the authors 
define as any positive receptor and de Duenas et al. (2014), utilizes three 
phenotypes (HR+, HER2+, TNBC). In this dissertation, discordance was strictly 
defined as a change from one of the four phenotypes to one of the remaining 
three; thus there were 12 (4x3) possible discordances. 
 
Study Decision Flow 
 
Figure 10 is a graphic depiction of the study protocol flow and cohorts. This 
study began with isolating patients in the Tumor Registry who had a recurrence 
of metastatic breast cancer. The next step was to determine whether or not the 
MBC patient had their receptor status re-tested (cohorts A and B in Figure 10),  
 
 
Figure 10. Study Decision Flow 
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and if available, the rationale for such re-testing. For retested patients, a 
determination was made to whether their primary and metastatic tumor receptor 
statuses were concordant or not (C and D). For patients who tested discordant, it 
was then determined whether their first-line medical treatment plan was based 
on the primary or the metastatic tumor receptor status. These two groups are 
represented as cohorts E and F in Figure 10.  
The main objective of this study was to compare groups E and F (treatment plan 
based on primary versus metastatic tumor).  My literature review revealed 
studies that compared groups A and B, and C and D as depicted in Figure 10, 
however no research explicitly carried out a protocol to compare survival rates of 
groups E and F.  For example, one article on liver metastases compared the 
survival impact on patients with re-tested tumors to those patients whose tumors 
are not re-tested (A and B). The researchers found no difference in overall 
survival rate between these two groups (Botteri et al., 2012).  My research 
project also evaluated groups A and B to determine any difference in survival 
rates, and to determine whether that difference indicated a potential bias in the 
data. My concern was that it might be possible that patients were re-tested 
because the doctor’s clinical intuition indicated that a more aggressive treatment 
was needed. This type of bias was important to understand in a retrospective 
study because if patients in branch B were not representative of the population 
of all metastatic patients, then this bias could impact the interpretation of 
comparisons of groups C to D and E to F. 
The articles in the Literature Review section that evaluate the clinical impact of 
discordance did so by comparing patients with concordant versus discordant 
tumors (groups C and D). In studies that evaluate the survival rates of patients 
in cohort C versus cohort D, cohort D patients are always, to some degree, 
confounded with cohort F.  My analysis is unique since this confounding effect is 
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removed by specifically comparing the survival curves of groups E and F.  
 
Data Parameters 
 
Based on my protocol, I identified the list of variables necessary to conduct my 
research. The information needed for my variables was found in The University 
of Tennessee Cancer Center Tumor Registry, the electronic medical record and 
paper charts of the patients in the study.  
Variables in the Tumor Registry 
The data collection began with a request to the Tumor Registry manager to 
export variable information based upon my protocol criteria for patients with 
recurrent metastatic disease (local recurrence in the breast was not considered).  
I requested records on patients with recurrences after January 1st, 2000 and 
before November 1, 2014.  This time period was chosen for my study because 
HER2 testing was not available until 2000.  However, I suspected I would 
encounter missing data in the early records since HER2 testing was also not 
routinely performed until around 2005 (Harries & Smith, 2002). In order to 
ensure accuracy, I eventually asked the manager for access to all patient data in 
the tumor registry.   I then personally managed the data to extract the variable 
information I sought.  The manager informed me that some new information 
fields were added to the tumor registry database in 2010.  Therefore, this 
additional information was missing in records dated prior to 2010, thus rendering 
the data problematic to utilize if it could not be found in other sources.  Further 
discussion and definitions of the variables actually used in the analysis are 
provided in the Results section of this dissertation.  
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Variables in Electronic and Paper Charts 
Some of the key variables necessary for my research were not routinely stored in 
the Tumor Registry. These particular variables were obtained from a review of 
patient charts (both electronic and paper). Additionally, I was able to verify and 
often complete missing variables in the Tumor Registry data through these chart 
records. I performed all the tumor registry, electronic records and paper chart 
reviews with assistance and quality control from the Tumor Registry manager. 
Further discussion and definitions of the variables actually used in the analysis 
are provided in the Results section of this dissertation.  
 
Quality Control 
 
Operational definitions of key variables were established and are found in 
Appendix 4. These definitions were vetted by the Tumor Registry manager, and 
aligned with industry standards. The registry manager and I reviewed the first 
ten patient records together to establish a common practice.  
Record Keeping 
Both paper and electronic records were created during the data collection 
process.  I created a paper data collection form that listed the key variables 
sought from each patient record review. A copy of the form is found in Appendix 
5. The form did not contain a direct patient identifier; only a code number, 
connecting the sheet to the patient, was employed. The code numbers and 
patient identifiers were maintained separately from the data collection sheets. 
Data collection forms will be destroyed once the electronic data set is complete, 
the quality control has been performed, and this dissertation is complete. Each 
electronic patient record’s code number was assigned by random number to 
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ensure confidentiality. Separate Excel spreadsheets were created that contain 
the decoding information in one file and the raw data without identifiers in 
another file. The decoding file was password protected and kept separate from 
the raw data. JMP files for analysis will not contain patient identifiers.  
 
Confidentiality and Compliance 
 
Confidentiality is important in any medical research. I followed and completed 
the requisite procedures for IRB approval as required by both the University of 
Tennessee Medical Center and the University of Tennessee, Knoxville. Both IRB 
protocols required for my research were approved by expedited review.  
 
Statistical Considerations 
 
A priori statistical methods, hypotheses and sample size considerations are 
outlined in this section.  
Sample Size and Power 
It is important to determine the sample size in any research endeavor to ensure 
the objectives of the experiment are achieved and the hypothesis can be proven 
or not. In order to estimate sample size needs with respect to statistical power 
for survival analyses, several statistics needed to be known or estimated (power 
and other terms used in this section are defined in Appendix 12). Estimate of the 
survival curve characteristics under the null hypothesis, a hazard ratio (HR) for 
the alternative hypothesis, and the risk of a false positive were required to 
estimate the needed sample size. For my sample size considerations, I assumed 
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that a potential difference in median life expectancy greater than one year 
existed between those metastatic patients with discordant receptors whose first-
line treatment plan was based on their primary tumor receptor status as opposed 
to the metastatic tumor receptor status.  The hypothesized one year median 
difference was supported by the evidence in my Literature Review section 
(Chang et al., 2011; Liedtke et al., 2009; Niikura et al., 2012). This median 
difference translated to an approximate hazard ratio of 1.4. Therefore, at any 
point in time, a metastatic breast cancer patient was 40% more likely to die if 
their treatment plan was based on their metastatic tumor receptor status instead 
of their primary tumor results.  
Major databases such as SEER do not currently collect data on recurrent 
metastatic breast cancer survival statistics. A few estimates of overall survival 
curves are found in the literature; however, I elected to combine and average 
data from five articles in the literature review to estimate the survival curve for 
recurrent metastatic breast cancer. The exact raw data required to calculate the 
survival curve was not always delineated in these papers. In some cases, I 
extrapolated data from graphical representations. It was important to recognize 
that this combined data produced a biased sample for the overall population 
because the samples in each study only contained cases where receptors were 
re-tested. However, this was a logical solution to establish survival curves for my 
research since I was only concerned with cases where tumors were re-tested. 
Table 9 summarizes the data extracted from the four articles and the (CTCA, 
2014) website that was then utilized to establish an average survival curve. The 
CTCA data was the only available survival curve I located in my search that 
directly focused on metastatic breast cancer. The resultant average survival 
curve, depicted in Figure 11, had a median survival of 1.85 years and produced a 
five year survival rate (x-axis) of approximately 20% of the data population (y-
axis). 
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Table 9. Literature Survival Data 
CTCA Tev Daw 08 Chia Daw 10 Year Average 
1 1 1 1 1 0 100.0% 
0.78 0.8 0.78 0.79 0.81 0.5 79.2% 
0.66 0.68 0.65 0.62 0.72 1 66.6% 
0.57 0.57 0.54 0.5 0.62 1.5 56.0% 
0.5 0.5 0.47 0.39 0.52 2 47.6% 
0.42 0.39 0.42 0.32 0.47 2.5 40.4% 
0.37 0.31 0.38 0.295 0.39 3 34.9% 
0.32 0.28 0.32 0.22 0.32 3.5 29.2% 
0.29 0.2 0.295 0.2 0.28 4 25.3% 
0.25 0.19 0.25 0.18 0.26 4.5 22.6% 
0.23 0.18 0.2 0.17 0.22 5 20.0% 
 
 
Figure 11. Null Survival Curve 
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The overall average survival curve postulated in Figure 11 was a combination of 
patients with concordant and discordant receptor statuses and different 
treatment plans based on either the primary or metastatic tumor receptor status. 
Because the overall average survival curve depicted patients with different 
receptor statuses and treatment plans, I then extrapolated two survival curves 
from the overall average survival curve. These curves represented the null and 
alternative hypotheses consistent with my estimate of one year median survival 
difference between patients whose treatment plans were based upon their 
primary or metastatic tumor receptor status, represented by cohorts E and F in 
Figure 10. Figure 12 illustrates the two hypothesized curves for groups E and F. I  
 
 
Figure 12. Null and Alternative Curves 
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chose .01 as the risk of a false positive in my analysis. With an estimated survival 
curve, a hypothesized HR and the risk of a false positive, the statistical power 
could be calculated for any given sample size; conversely, for a given power the 
required sample size could be calculated. 
Both SAS and JMP software were utilized to determine sample size needs for my 
research. SAS software’s two sample survival piecewise application allowed for 
calculating the optimal sample size estimate for my study. This methodology 
required the input of the average survival rates in half-year increments, utilizing 
data from Table 9. The resulting SAS power curve estimates yielded an optimal 
sample size of approximately 50 patients per cohort (E and F) of the study. 
These curves are shown in Figure 13, Utilizing JMP, a sample size was estimated  
 
 
Figure 13. SAS Power Curves 
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using a two sample proportion test based on the percentage of patients surviving 
after five years under the null and alternative hypothesis and a chosen type I risk 
of .01 and power of .90. This calculation also yielded an optimal sample size of 
50 for each cohort in the study (groups E and F), as shown in Figure 14. 
 
 
Figure 14. JMP Power Calculation 
 
Sample Size Discussion 
The above statistical exercise was important to determine the optimal sample 
size for this study.  The fact that both calculations resulted in a consistent 
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answer of 50 patients per cohort was validating.  At the time I wrote the 
research proposal to examine MBC patients, receptor statuses, and treatment 
plan decisions, the tumor registry manager estimated that my total sample size 
for the project would be between 100 and 200, yielding only 10 to 20 patients in 
each cohort of the study (E and F).  These numbers were disappointing, but not 
a surprise.  The available sample size for sub sample categories A-F in Figure 10 
were certainly bound by the existing data in the Tumor Registry and the 
accessible paper and electronic charts at the time of data collection for this 
dissertation. The actual sample sizes are reported in Chapter 4.  
A Priori Analysis Plans 
During the proposal stage of this dissertation, my a priori analysis plans were as 
follows:  The first analysis will be a Chi-square test, analyzing the null hypothesis 
asking whether the two patient groups, E and F, have the same percentages of 
patients in five categories, 4 RECIST categories plus the deceased category I add 
to the study, (as defined in Chapter 1). Statistically significant results may lead to 
further refined tests. The five categories will then be combined into two 
categories:  Complete Response (CR), Partial Response (PR) and Stable Disease 
(SD) will be combined into one category; Progressive Disease (PD) and Deceased 
(D) will be combined into a second category and analyzed with a Chi Square test. 
Next, utilizing the groups identified in the study decision flow, Kaplan-Meier 
survival curves will be calculated for all paired comparisons (A and B, C and D, E 
and F). The sample will also be examined using Cox Proportional regression in an 
effort to account for the effect of covariates, since this is not a randomized trial. 
All available covariates will be tested. The literature review indicates possible 
significant covariates will be age, time to recurrence, HR status, initial stage and 
initial lymph node involvement. 
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Log Rank, Wald and other generally accepted tests for survival analysis will be 
executed. Univariate tests will be performed and reported on available 
covariates. Descriptive statistics will be reported on each group of patients 
(cohorts E and F). JMP Pro version 10.0 will be used for all analyses. Other 
software may be used for graphics and data management. 
Statistical Significance 
Surprisingly, a p-value (or critical value) of .05 was the most frequently utilized 
value of statistical significance in the literature. Given the randomization 
limitations of observational studies and the risk that non-significant results do not 
get published, a critical value of .01 would be a more prudent statistical measure 
in medical research. In other words, if 20 experiments are performed with a type 
1 risk of .05, then one experiment is likely to be deemed statistically significant 
by chance. If the other 19 experiments are not published, a literature review 
would find one paper supporting a hypothesis and not reveal the 19 that do not 
support the hypothesis. One article recently reported a study showing that only 
17% of clinical trials had been published one year after completion ("Spilling the 
Beans," 2015). The use of p-values has also come under scrutiny. Gigerenzer 
and Marewski (2014), offer several criticisms of p-values, including the 
cumulative risk of performing numerous tests and that spurious correlation can 
lead to statistically significant results, yet non-reproducible results . Based on the 
works just cited and holding myself to high standards, I elected a priori to pair 
evaluative statements with the varying degrees of possible statistical significance 
values my data might yield.  
The following are my evaluative statements I developed based on possible p-
values for key analyses of my research. Test results numerically consistent with 
my hypothesis that patients live longer when their first-line treatment plans are 
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based on the primary tumor receptor status instead of the metastatic tumor 
receptor status in discordant cases will be described as: 
• consistent with the hypothesis for p-values greater than .05;  
• supporting (providing corroborating evidence) the hypotheses for p-values 
between .01 and .05; and  
• demonstrating (shown to be true by reasoning or adducing evidence) the 
hypotheses for p-values less than .01. 
For sample data numerically inconsistent with my hypothesis showing that 
patients die sooner when their first-line treatment plans are based on the 
primary tumor receptor status instead of the metastatic tumor, my results will be 
described as: 
• not consistent with the hypothesis for p-values greater than .05; 
• not supporting the hypothesis for p-values between .01 and .05; and 
• refuting (thus proving to be false or erroneous based on the data) the  
hypothesis for p-values less than .01. 
 
Statistical Methods Review 
 
The Kaplan-Meier (KM) method of survival analysis has been a standard in 
medical industry research literature (Richard Van Noorden & Brendan Maher, 
2014). All articles that compare survival curves in my literature review utilize this 
method. In my review of the literature, statistical conclusions were being 
reached using small sample sizes; thus I decided to research the key features 
impacting the statistical power of the Kaplan-Meier method and perform Monte-
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Carlo simulations to add to my practical knowledge of the KM technique. The 
research was performed and the simulations designed to answer several 
important questions: 
• What is the power of KM tests with sample sizes smaller than 20? 
• How is power affected by binning the data versus having continuous 
measurements? 
• Does the number of bins (time intervals) affect power? 
• How is power affected by censoring? 
• How is power affected by unequal sample sizes when comparing two 
survival curves? 
Simulation 
While the statistical literature review provided some insight into the attributes of 
statistical power associated with the KM method of survival analysis, none of the 
articles reviewed provided a clear clarification of my questions about power. I 
therefore elected to utilize simulation to address my questions on the statistical 
power of the KM method.  Key definitions for terminology used in the simulation 
are in Appendix 12. For simulation purposes, I translated the average survival 
curve previously discussed in this chapter to a statistical model utilizing an 
exponential distribution [(1/λ) e1/λ] parameterized with lambda = 3.5. This 
function provided a reasonable estimate of the hypothesized survival curve. In 
order to explore the power of the KM method using the log rank statistic, the 
following six attributes were manipulated: sample size (n1=n2= 10, 20, 30, 50, 
100, 200, 500, 1000), sample size distribution (p1 = p2 = 50%; p1 = 70%, p2 = 
30%; p1=85%, p2=15%), hazard ratio (delta = 1.0, 1.25, 1.5, 1.75, 2.0, 3.0), 
survival function (exponential, lambda = 2, 3.5, 5), binning (continuous 
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recording, 10 bins, 5 bins, 2 bins) and censoring (none, 25%, 50%). 
MATLAB R2015a was used to conduct the simulation. All programs were used 
with permission. Figure 15 provides a flowchart of the simulation process. For 
the power calculations, the simulation was executed 10,000 times, giving the 
maximum width 95% confidence interval for the estimates using the normal 
approximation to the binomial as +/- .0049 or .49%. Appendix 13 contains the 
MATLAB file names and descriptions used in the simulations. The code for each 
program is found in Appendices 14-21.  
Simulation Results  
The simulation results clearly indicated that sample sizes less than 20 per group 
yielded insufficient statistical power. The simulation results in Table 10 (alpha = 
.01) and Table 11 (alpha = .05) detail the power estimates with the following 
conditions: no censoring; lambda = 3.5; equal sample sizes; and continuous 
recording of data. These tables show a hypothesized hazard ratio of two or more 
would be necessary to reach any reasonable level of power. From a practical 
standpoint in breast cancer research, an HR of 1.25 would be medically 
important. For instance, in the much cited Journal of American Medical 
Association (JAMA) article on hormone replacement therapy and breast cancer, 
the sample HR supporting hormone replacement therapy is a cause of breast 
cancer is 1.26 (Rossouw et al., 2002). In Table 11, for n1=n2= 10 and HR = 
1.25, the assumed probability of a false positive (alpha = .05) and the chance of 
a true positive (power) are both 5%. Thus ½ of the positive results under these 
conditions would be false. To ensure the kind of power needed to produce a 
successful research outcome with HR = 1.25, sample sizes of greater than 500 
sizes were needed. This demonstrated why important clinical trials involve large 
sample sizes, illustrated by the hormone replacement study that involved over 
8,000 women in each cohort of the study (Rossouw et al., 2002). Observational 
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Figure 15. Simulation Flow 
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Table 10. Power Table for L3.5 C0 C .01 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0067 0.0116 0.0249 0.0467 0.0736 0.234 
20 
0.006 0.0179 0.0542 0.122 0.2256 0.6535 
50 
0.0088 0.0448 0.1994 0.4516 0.6989 0.9933 
100 
0.007 0.1021 0.4804 0.8282 0.9702 1 
200 
0.0086 0.2582 0.854 0.9929 1 1 
500 
0.0069 0.7015 0.9997 1 1 1 
1000 
0.0117 0.9693 1 1 1 1 
 
Table 11. Power Table for L3.5 C0 C .05 
 Hazard Ratio 
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0342 0.047 0.0882 0.1408 0.2016 0.4819 
20 
0.0349 0.0744 0.1599 0.2992 0.4566 0.8585 
50 
0.0437 0.1439 0.4075 0.6893 0.8752 0.9994 
100 
0.0394 0.2584 0.7111 0.9447 0.9946 1 
200 
0.0434 0.4881 0.952 0.9989 1 1 
500 
0.0436 0.8761 0.9999 1 1 1 
1000 
0.0511 0.9931 1 1 1 1 
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studies tend to have smaller sample sizes and are generally based on the data 
available to the researcher, as Table 20 in Chapter 4 illustrates.  
The simulation results indicated there were no practical differences in power 
when continuously recording each data point or binning the data. Tables 11 and 
12 illustrate this result and show that any differences in the simulated power 
were either within the margin of error or of no real practical significance.  As a 
scientist, I intuitively wanted to know the exact time of failure (death) for each 
data point, believing that information would have provided a more detailed 
analysis than just knowing the failure occurred within a certain time interval. 
However, since the ultimate measure was binary, it was important to realize that 
similar statistical results applied to both the percent of events that occurred over 
time versus at the end of a time period.  Knowing exact time of death was  
 
Table 12. Power Table for L3.5 C0 B10 .05 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0315 0.0429 0.0808 0.131 0.1918 0.4611 
20 
0.0334 0.0697 0.1498 0.2899 0.4401 0.8472 
50 
0.0433 0.1415 0.4035 0.6843 0.8708 0.9994 
100 
0.0383 0.2559 0.7075 0.943 0.9938 1 
200 
0.0435 0.4829 0.9503 0.9988 1 1 
500 
0.0431 0.8735 0.9999 1 1 1 
1000 
0.0515 0.9931 1 1 1 1 
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therefore inconsequential to the power. A priori, I assumed that the loss of 
information resulting from utilizing less instead of more bins would have a 
tremendous impact on power. The literature and my simulation indicated that 
the number of bins was not that important to power.  
The literature states larger samples observed less frequently (binned) are better 
than smaller samples observed more frequently. My simulation results supported 
the statistical literature review outlined in Chapter 2. While there were some 
differences in power based on the number of bins, those differences were 
negligible when compared to the impact sample size had on power. To illustrate 
this point, in Table 12 the power for n1 = n2 = 20 and a HR of 3 is 85% for ten 
bins and for the same set of variables with only two bins is 69% (Table 13). 
These differences warranted scrutiny, but were not as large as I expected. Once 
 
Table 13. Power Table for L3.5 C0 B2 .05 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.018 0.028 0.0489 0.083 0.1141 0.2697 
20 
0.0253 0.0513 0.1182 0.2218 0.3333 0.689 
50 
0.035 0.1145 0.3502 0.6027 0.8041 0.9947 
100 
0.0367 0.2317 0.6534 0.9081 0.9842 1 
200 
0.0401 0.4556 0.9289 0.9977 1 1 
500 
0.0436 0.8499 0.9999 1 1 1 
1000 
0.0469 0.9909 1 1 1 1 
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the sample size reached 50, the power differences between 10 and two bins was 
minimized. The primary concern with binning, (especially with less than 5 bins), 
is that the statistical significance between two populations can still be tested, but 
the visual evaluation of proportional hazards is hindered as the number of bins is 
reduced. The extreme case of utilizing only one bin in which results were 
observed once at the end of a time period provides excellent statistical 
knowledge when comparing two groups at that point in time, but would garner 
no information about the comparative shapes of the survival curves over time. 
I had no experience with analyzing data that might be censored, so when I 
investigated survival techniques, censoring was a concern, especially its affect 
upon power.  Descriptions of the KM method and the log rank test indicate that 
these methods were created for censored data, so I utilized the simulations to 
better understand the impact censoring had on data analysis results. Tables 11 
and 14 best illustrated the effect of censoring. Table 14 was the result of 50% 
censoring; thus these numbers could be compared to Table 11 that had no 
censoring. Stated differently, sample sizes of 50 with no censoring could be 
compared to sample sizes of 100 with 50% censoring. These two results were 
nearly identical with respect to power. This outcome was consistent with the 
literature which indicates the real issue at stake is the number of events (deaths) 
not the pure sample size.  
Common statistical calculations and concepts indicate that sample sizes of equal 
value are optimal when comparing two groups (Snedecor & Cochran, 1967, p. 
104). In other words, if the total sample size is 20 for two groups, then it is 
statistically more effective to have an equal division between those two groups 
(i.e. 10 in each group), than any other combination. If the two groups’ samples 
were split 16 and 4 respectively, the lack of data in the second group (n2=4) 
would negatively impact the ability to compare that group with the other, even 
  64
Table 14.  Power Table for L3.5 C50 C .05 
 Hazard Ratio 
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0277 0.0361 0.0512 0.0738 0.0966 0.2133 
20 
0.029 0.0482 0.0872 0.1497 0.2081 0.4711 
50 
0.0348 0.0856 0.209 0.3738 0.539 0.9059 
100 
0.0396 0.1429 0.4006 0.6915 0.8648 0.9981 
200 
0.0448 0.269 0.7135 0.9439 0.9926 1 
500 
0.0444 0.5867 0.9801 1 1 1 
1000 
0.0438 0.8722 0.9999 1 1 1 
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though the other group had more data (n1=16). The simulation results strongly 
supported the concept of equally distributed sample sizes for comparative 
purposes. Tables 11 and 15 best illustrate this concept, where n1 is the sample 
size of the null distribution. Comparing n1 + n2 = 100, where one sample is split 
evenly (n1+n2=50) and the other sample is split disproportionally (n1=85 and 
n2= 15), dramatic differences in power occurred. Power was reduced over 50% 
when employing unequal sample sizes in the simulation even though the total 
sample sizes were the same. 
 
Table 15. Power Table for L3.5 C0 C N85/15 .05 
 Hazard Ratio 
n1,n2 1 1.25 1.5 1.75 2 3 
3, 17 
0.035 0.031 0.0358 0.0486 0.0641 0.1487 
6, 34 
0.0377 0.0387 0.0628 0.1097 0.1666 0.4378 
15, 85 
0.0374 0.0622 0.1773 0.33 0.5009 0.9019 
30, 170 
0.0439 0.1194 0.3555 0.6332 0.825 0.9972 
60, 340 
0.0392 0.231 0.6571 0.9212 0.9858 1 
150, 850 
0.0423 0.5445 0.9714 0.9998 1 1 
300, 1700 
0.0479 0.843 0.9999 1 1 1 
 
 
Type 1 Error 
An interesting pattern appeared in all the data and is illustrated in Table 14. A 
hazard ratio of one meant that the two groups did not differ in hazard rate.  
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Thus, the type 1 error rate in the simulation was estimated where HR = 1.  For 
all simulation runs, the actual type 1 error rate was lower than the declared rate 
for sample sizes under 1,000. The simulation’s actual rate came close to the 
declared rate as n1 + n2 approaches 2,000. For example, in Table 14, with n1 = 
n2 = 10, the simulated alpha is .028 versus the declared rate of .05. That is, 
there were only 2.8% of the 10,000 p-values in the simulation exercise less than 
.05 where the HR = 1. For n1 = n2 = 1,000, the simulated rate is .044, 
approaching the declared rate of .05. These results, as simulated, would indicate 
the log rank test is conservative with respect to the type 1 error.  
In summary, when comparing the data of two groups of subjects utilizing the KM 
and log rank methods, the key issue is the number of events (deaths) that will 
occur over the time of study. For estimating the sample size needed ahead of the 
research project’s implementation, to calculate power or desired sample size, an 
estimate of the rate of events (deaths) occurring and the potential censoring rate 
are needed. Of less importance is the number of observation intervals, so that 
given the choice, it is better to have more subjects observed less often, than to 
have fewer subjects observed more often. However, for a clear picture of 
survival curve shapes, five to 10 bins are recommended. The most important 
factor to consider and attempt to control is obtaining even splits of the total 
sample size. This split is easier to control in a prospective study. In a 
retrospective study, the researcher may not be able to control the split of data at 
all, as the sample is based on the data available. All power tables for the various 
simulation combinations are shown in Appendix 11. 
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CHAPTER 4 
RESULTS AND DISCUSSION 
 
Data Acquisition 
 
After receiving IRB approval, The University of Tennessee Cancer Institute 
provided access to the tumor registry data, electronic records and where 
possible, paper patient charts. The tumor registry was queried for recurrent 
metastatic breast cancer patients. Several initial queries were performed by the 
Tumor Registry manager that yielded varying sample size results each time. 
Based on these queries, I requested a wider query that allowed me to pare down 
the data manually where needed, yet was more likely contain all possible records 
for review. Appendix 6 contains a flowchart view of the data collection process. 
Data Cleaning 
All data analysis processes must begin with the cleaning of the data. Table 16 
shows a listing of file names that represent the progression of the cleaning of the 
data. Each step in the data cleaning process is described below. 
 
Table 16. Key Data File Names 
Step Excel File Name 
Number 
of Rows 
1 1 Copy of Breast Recurrs from 1990 As Received 3183 
2 1.1 Copy of Breast Recurrs from 1990 SORTED 3182 
3 1.3 Copy of Breast Recurrs from 1990 SORTED 605 
4 1.4 Copy of Breast Recurrs from 1990 SORTED 587 
5 1.521 Breast Recurs START 586 
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Step 1. A copy of the file received from the Cancer Center was made. This file 
had 79 columns (variables) of data.  
Step 2. Two columns were added to the original file and one blank row deleted. 
A column to number (order) the rows as a safety precaution was added, in case 
the data was ever erroneously sorted in a way that could cause a loss of 
structure. An additional column entitled Group was inserted to combine records 
that appeared to cover several rows.  
Step 3. Rows that were blank or duplicated based on the query output were 
removed. Records in which a diagnosis was initially Stage 4, thus not recurrent, 
were removed. A few records were deleted that had no recurrence data, 
incomplete data and contained phrases like “disease free” and “never” in the 
recurrence description. All records with the recurrence date prior to the year 
2000 were deleted. Another column was created to store additional recurrence 
date(s) for patients with more than one recurrence. Patient records that 
appeared in more than one row were combined into one row.  
Step 4. Additional duplicate patient records were discovered and removed. The 
586 remaining records consisted of the following combination of records: 
a. Recurrence dates 
i. 114 with 11/11/11 as the recurrence date (this was deemed 
a filler date for incomplete records) 
ii. 212 with missing recur date 
iii. 260 with a recur date 
b. Recurrence location 
i. 151 distant 
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ii. 41 distant with a long description 
iii. 115 unknown 
iv. 40 regional 
v. 30 local (not intended to be included in this study) 
vi. 210 never disease free (possibly originally stage 4) 
Step 5. The medical record number for each patient was stripped from the 
original file and placed into a separate password protected file. New columns 
were added to match the variables that would be added based on chart reviews 
(see Appendices 4, 5 and 7). A column was added to indicate when the data 
collection was complete. Color coding was applied to indicate whether the data 
came from the registry, electronic records or paper records. With the data 
cleaning completed for the Tumor Registry data, the collection process from 
electronic records and paper patient charts began.  
Limited Data Set 
A small subset of electronic records were chosen to practice the data collection 
methods, learn the electronic medical record system and determine whether 
paper charts were necessary. This limited data set exercise revealed several 
challenges. First, around 30% of the records required paper charts to complete 
the record. Second, some data in the registry was found to be erroneous, such 
as a record showing that a recurrence had occurred, when in actuality there 
never was a recurrence at all. Last and importantly, I learned that some of my 
preconceived operational definitions would not handle all situations. In some 
cases, there was variation between lab reports and doctors’ notes (to be 
discussed later) and a judgement had to be made on how to code the data and 
whether to use it in the analysis. Therefore, I decided to review those cases with 
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the Tumor Registry manager and adhered to her interpretation which she based 
on industry standards.  
Finalizing the Data 
The data collection process was slow and arduous. I double-checked records 
with the Tumor Registry manager to ensure quality and found that access to 
paper charts (when needed) was somewhat limited, since many reviews dated 
back to the year 2000 and most patients in this study were now deceased. The 
physicians’ offices most closely associated with the Cancer Center and with the 
longest tenure were able to provide many of the charts I needed. Charts from 
private practice physicians or with patients pre-dating their association with UT 
were harder to obtain. While I did not get access to all the data in the patient 
population set, I was confident that the data I did obtain was a representative 
sample of that population, even though my sample was not a statistically 
designed random sample. The data collection progression is described in Table 
17. The key activities for each step data collection are documented below. 
 
Table 17. Data Collection Files 
Step Excel File Name 
Number 
of 
Complete 
Records 
Records 
to 
Exclude 
Records 
with 
Data not 
Useable 
Records 
that 
Remain 
to 
Review 
1 
1.521 Breast Recurs 
START 32 0 11 543 
2 
1.55 Breast Recurs 
START 66 98 74 305 
3 
1.60 Breast Recurs 
START 13 171 74 37 
4 
1.742 Breast Recurs 
START 
No Change 
(NC) NC NC NC 
5 
1.82 Breast Recurs 
FINAL 3 0 34 0 
 Totals (586 records) 124 269 193 N/A 
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Step 1. The initial collection of data in the limited data set yielded 32 completed 
records and 11 unusable records. Unusable records fell into three categories: a) 
insufficient data, when the electronic record was woefully incomplete and the 
prospect of obtaining the paper chart was not deemed plausible; b) no evidence 
of recurrence, where a thorough review of the electronic records did not confirm 
a metastatic recurrence; and c) not applicable, in cases where cancers other 
than breast cancer presented, stage 4 was diagnosed initially, or men were 
included the data set.  
Step 2. Several groupings of records were identified in the data that had similar 
characteristics. Records in these groups were eliminated, where as a group, 
there was a very low probability of obtaining complete and useful data. My 
decision to eliminate groups of records was based on a sample review of the 
group records. Seventy-four records were eliminated based on the analysis of 
these groups. Additionally, 98 total records were excluded where: a) 33 had a 
filler recurrence date of 11/11/11 and the last contact was before the year 2000; 
b) 42 had no recurrence data and last contact before the year 2000; and c) 23 
had a filler recurrence date of 11/11/11, the patient was deceased, and the 
record did not fit the protocol of this study. 
Step 3. One hundred and seventy-one records were excluded because a 
sampling of those records showed either no evidence of recurrence or insufficient 
data. The excluded records contained: a) 50 records with a recurrence date of 
11/11/11 and the patient was listed as alive; b) 34 records that had a no 
recurrence date and the patient was listed as alive; and c) 87 records containing 
no recurrence date and no other data indicating a recurrence. This extensive 
effort produced only 13 useable records. The 37 remaining records required that 
I request paper copies of the patients’ records. 
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Step 4. Columns with extensive missing values and un-needed columns were 
removed. New variables that were a combination of columns, like subtracting 
two dates, were created. Data in the spreadsheet was compared with the data 
collection sheets for an additional quality control check.  
Step 5. Completion of the data record was possible for only three of the 37 
remaining records. The other 34 were unusable because of insufficient data. 
Data Collection Summary 
The final dataset was named 1.9 Breast Recurs FINAL. The breakdown of the 
124 records in the completed dataset is illustrated in Figure 16 for each cohort of 
the study. As noted in Figure 16, 14 of 92 (15%) patients had discordant 
 
 
Figure 16. Actual Sample Sizes 
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receptor statuses. This sample result was slightly lower than the 20% I 
expected, but not out of line given that my definition of discordant was more 
restrictive than all but two of the relevant articles cited in the literature review. 
Of the 14 patients whose results were discordant, eight patients had their first-
line treatment plan based on their primary tumor receptor status and six 
patients’ treatment was based on the metastatic tumor receptor status. The 
sample result of 6 of 14 (43%) patients with a first-line treatment plan based on 
the metastatic tumor receptor status was lower than the 60% to 75% I 
estimated using data found in the current literature as discussed in Chapter 2. 
One reason for this discrepancy could have been the nature of variation in 
sample percentages estimated with small sample sizes. Additionally, my 60% to 
75% estimate was based on current practices, while my data represented 
records evaluated over a 15 year period. 
List of Variables in the Final Dataset 
The list of variables utilized in the final dataset, the available source(s) of the 
data for each variable, and the purpose for each variable is shown in Appendix 7. 
Appendix 8 contains a list of variables maintained in the dataset for information 
purposes only, and not utilized in any analysis. 
Preparing the Data for Analysis 
Once the final Excel spreadsheet was complete, the data was moved to a JMP 
file for final processing and analysis. Histograms of all key variables were made 
as a visual quality check that ensured correct data entry and assessed the data 
for outliers. No outlier was revealed. Table 18 compares the number of valid 
variable responses against the total sample size available (n of N). Four records 
in the discordant cohort presented coding challenges when the records were 
investigated. That is, there were difficulties applying the a priori operational 
definitions to the actual data, such that alternative evaluations of the 
  74
Table 18. Sample Size Completeness 
Variable Name (n of N) 
PRS 124 of 124 
Status 124 of 124 
FSD 124 of 124 
Rdate 124 of 124 
Retested 124 of 124 
mPheno 14 of 14 
pPheno 121 of 124 
FLTP 14 of 14 
FLD 13 of 14 
LocoRegion 117 of 124 
Visceral 116 of 124 
rLocation 84 of 124 
RECIST 14 of 14 
Age 124 of 124 
TTR 124 of 124 
pER 119 0f 124 
pPR 119 of 124 
pHER2 107 of 124 
SSS 78 of 124 
Hormone 114 of 123 
Chemo 118 of 123 
Rad 121 of 124 
Herceptin 102 of 124 
Grade 110 of 124 
Size 120 of 124 
nPos 121 of 124 
AJCC 123 of 124 
Type Chemo 113 of 124 
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values of key variables were possible. Those records and the challenges are 
outlined in Table 19. Those four records were first analyzed as they were coded 
with my best effort to apply the a priori definitions. In order to ensure an 
unbiased evaluation, a sensitivity analysis was performed based on these four 
data points. This sensitivity analysis was accomplished by changing the coding 
interpretation of those four records such that those records were not supportive 
of my hypothesis and then conducting the data analysis. Next, those four records 
were changed such that the coding interpretation was supportive of my 
hypothesis and reanalyzed. Those results are reported later in this section.  
 
Table 19. Sensitivity Analysis Records 
ID 
Code 
Best 
Judgement 
Coding 
Not Support 
Coding 
Support 
Coding 
103 Concordant 
Discordant, 
Metastatic 
Discordant, 
Primary 
188 
Discordant, 
Metastatic  
As is Concordant 
312 
Discordant, 
Primary 
Concordant As is 
558 
Discordant, 
Metastatic 
Discordant, 
Primary 
As Is 
 
 
For the patient with ID code 103, the primary tumor was ER and PR negative. 
The metastatic ER and PR test results were 1% and 5% respectively. Historically, 
these values were interpreted as negative, but standards have changed over 
time such that these results would currently be deemed positive. The physician 
noted the results were weak in the patient chart. He prescribed chemotherapy as 
the first-line treatment plan and then switched to endocrine therapy, even 
though the chemo was working. In my judgement, this change in therapy was 
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planned ahead of time and not based on a patient assessment; however I was 
unable to verify my assumption. The record would have be coded concordant 
based on the lab report. The record would have been coded discordant based on 
the physician’s interpretation. If I assume the physician’s original plan was to 
switch to endocrine therapy, then the treatment plan was based on the primary 
tumor. If I assumed the switch occurred because of a clinical judgement after 
assessing the patient’s progress, then the original plan would have been coded 
as based on the metastatic tumor receptor status.  
The primary tumor in patient ID code 180 was reported equivocal at 2+ on 
HER2. General practice indicated an equivocal result as HER2-; however the 
patient received Herceptin per the doctor’s orders, which indicated a HER+ 
judgement ("Breast Cancer," 2015, pp. 36-37). The metastatic tumor was TNBC, 
and Herceptin was not prescribed for treatment. 
Her2 in the primary tumor for patient ID code 312 was measured as negative. 
Her2 in the metastatic tumor was measured as 2+, which is judged equivocal by 
current practices and requires an alternate test to confirm the results. The lab 
report called the metastatic result positive and noted that the tumor sample was 
not large enough to perform the alternate test. 
Patient ID code 558 was ER/PR positive in her primary tumor. The recurrent 
tumor was TNBC. I was not able to review this chart, but the Tumor Registry 
manager did and indicated that endocrine therapy was not utilized upon 
recurrence. The lack of endocrine therapy indicated the treatment was based on 
the metastatic tumor. Given that I did not review the chart myself, and that the 
possibility existed that the patient was already on endocrine therapy at 
recurrence, I included this patient in the sensitivity analysis. Key variables for all 
the discordant patients are in Appendix 9, Table 26.
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Comment on Sample Size 
The final sample size of 14 discordant cases was disappointing, and on the lower 
end of the range I believed I would find a priori. Previous discussions in Chapter 
3 on statistical power addressed the desired sample sizes for this study. I 
compare the sample size of 14 to sample sizes in the literature review in Table 
20. These values are sample sizes for five key papers referenced in this 
dissertation and include two of the most cited articles in my review. In these 
papers, the primary statistical comparison the authors make is comparing 
concordant versus discordant patients (last column in Table 20). However, my 
hypothesis required a further breakdown of the discordant data into two parts 
(based on the first-line treatment plan), thus further reducing sample size of the 
two groups that were statistically compared. While my sample was small (n=14 
discordant cases), it was consistent with sample sizes found in the literature.   
 
Table 20. Sample Size Examples 
Author 
Number 
of 
Citations 
Total 
Sample 
Size of 
Interest 
Sample Sizes 
of Relevant 
Group 
Comparisons 
Discordant 
Sample 
Size 
Niikura(Niikura 
et al., 2012) 
106a  182 139,43 43 
Liedtke(Liedtke 
et al., 2009) 
127 231 134,42,22,33 22 
Simmons(Simmo
ns et al., 2009) 
126 29 11,3 14 
Wilking(Wilking 
et al., 2011) 
49 151 136,15 15 
Chang(Chang et 
al., 2011) 
15 56 42,14 14 
anoted as a “Highly Cited Paper” on Web of Science. 
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Study Results 
 
Fourteen records were found to be discordant, with eight patients treated in the 
metastatic setting based on their primary tumor status and six patients treated 
based on their metastatic tumor status. The survival data for these 14 patients 
was consistent with my hypothesis that patients with treatment plans based on 
the primary tumor receptor status have a longer median life expectancy.  
Kaplan-Meier Survival Analysis 
The Kaplan-Meier method was used as the primary tool to understand and 
compare survival curves. This method is a common technique in survival analysis 
and employed extensively in the articles reviewed for this dissertation (Richard 
Van Noorden & Brendan Maher, 2014). All p-values quoted for survival analyses 
were from the log rank test utilizing JMP 10.0 Pro. 
Overall survival. Survival curves for metastatic breast cancer patients are 
difficult to find in the literature due to the fact that patients diagnosed with 
metastatic breast cancer are not tracked by the national databases. Although 
estimating a survival curve for patients with metastatic breast cancer was not 
one of the objectives of this analysis, a survival curve determination was 
important for context and for the cancer community as a whole, given the limited 
available data. The overall survival curve provided in Figure 17 represents all the 
complete records in the dataset (n=124). It shows a median survival time of 18 
months and a five year survival rate of just over 20%. These numbers were 
consistent with the limited data available (CTCA, 2014). Additionally, I analyzed 
the difference between those patients who had their receptors re-tested and 
those who did not. My a priori assumption was that patients diagnosed to be in a 
“worse” condition might get their receptors re-tested in an effort to find a better 
treatment plan. Thus, those re-tested would have a shorter survival than those 
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Figure 17. Overall Survival Curve 
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not re-tested. This assumption proved to be erroneous and the opposite result 
occurred as shown in Figure 18. While the literature review led me to believe 
that around 50% to 70% of patients may be re-tested based on current 
standards and less than 50% in the early 2000’s, at the University of Tennessee 
Cancer Center it was a common practice to re-test throughout those years. In 
most cases where the patient was not re-tested, the patient presented in such a 
dire situation that there either was no time to re-test or it was deemed too late 
for any treatment to succeed. Thus, those not re-tested (median survival of 
about 5 months) showed a much worse outcome than those who were re-tested 
(median survival of nearly 24 months). The two survival curves re-tested (Yes) 
versus not re-tested (No) were evaluated for equality using the log rank method. 
The result of the test indicated the two curves did not have the same survival 
rate; therefore I rejected the null hypothesis of equality, with a p-value of .0002.  
 
 
Figure 18. Re-test versus Not Re-tested Survival Curve 
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In order to judge discordance for a metastatic patient, the patient must be re-
tested. Therefore, all remaining analyses were performed on patients who were 
re-tested, with the exception of one multivariate analysis performed on the 
complete data set. 
Discordance survival.  As discussed in the literature review, the survival 
outcome of patients with discordant receptor results tended to be less favorable 
than those with concordant results. However, in my data set, the results indicate 
the two groups had similar survival curves. That is, the null hypothesis that the 
two curves were the same was not rejected (p-value = .986). These results are 
shown in Figure 19. Sample size limitations (only 14 discordant cases) and the 
fact that only 6 of 14 (43%) patients had their treatment plan based on the 
metastatic tumor receptor status reasonably explained the results of similar 
survival curves. In Chapter 2, I estimated that 60% to 75% of patients had their 
treatment plans determined based on the metastatic tumor receptor status; my 
sample results proved to be lower than this, which yielded more patients in the  
 
 
Figure 19. Concordant versus Discordant Survival Curves 
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discordant sample that performed well based on their treatment plans being 
determined by their primary tumor receptor status. 
Treatment strategy survival. The primary purpose of this study was to 
compare the clinical outcomes of patients with discordant results on the basis of 
whether their primary or metastatic tumor receptor status was utilized to develop 
their first-line treatment plan. Figure 20 shows the results of this comparison. 
The graph clearly indicats that those patients whose first-line treatment plan was 
based on the receptor status of the primary tumor (n=8) had better survival 
outcomes than those who had their plans based on the metastatic tumor (n=6)  
 
 
Figure 20. Metastatic Versus Primary 
 
with a p-value of .049. The statistical results showed that metastatic breast 
cancer (MBC) patients who were treated based on the receptor status of their 
primary tumor had a median survival time of 48 months versus only eight 
months for those patients whose treatment plan was based on the metastatic 
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receptor status. This sample result of a 40 month difference in life expectancy 
was consistent with the important article by Liedtke et al. (2009) in the literature 
review and exceeded my qualitative a priori estimate of 12 months. Given the 
small sample size, other limitations discussed in Chapter 5 and the general poor 
prognosis of MBC patients, I would hypothesize the effect of utilizing the primary 
tumor receptor status to determine first-line treatment plans will likely be closer 
to 12 months than 40 months when larger samples sizes are studied. Regardless 
of the exact number, this finding provides a significant increase in life expectancy 
for metastatic breast cancer patients. Given the small sample size, and other 
limitations listed in Chapter 5, I described my results as consistent with my 
hypothesis rather than utilize the a priori decision that stated the results support 
my hypothesis when a p-value less than .05 was found.  
Chi-Square Analysis (RECIST Standard) 
Figure 21 shows the breakdown of discordant patients based on the RECIST 
standard and whether their treatment plan was based on their primary or  
 
 
Figure 21. RECIST Chi Square Analysis 
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metastatic tumor receptor status. In chapter 3, I defined the RECIST standard 
and the intention to utilize that standard to code the results of the first follow-up 
examination performed by the patients’ doctor, which occurs approximately 90 
days after treatment begins for the metastatic disease. This metric was 
developed as a means to measure the immediate effect of the first-line 
treatment plan, since numerous plans might be implemented before the patient 
died, as all treatments lose efficacy over time. Based on the small sample size, I 
expected the Chi-Square analysis on the RECIST standard would not be 
statistically significant, and it was not with a p-value = .164 using Fisher’s exact 
test for contingency tables. However, the results were consistent with my 
hypothesis, given that a) of the five patients who had progressive disease (PD) 
at the first re-scan, four were treated based on their metastatic tumor receptors; 
b) five of the seven patients with stable disease (SD) were treated based on their 
primary tumor; and c) the only patient with a partial response (PR) was treated 
based on their primary tumor receptor status.  
 
Multivariate Analysis 
 
My statistical results were consistent with my hypothesis that metastatic patients 
with discordant receptor results whose first-line treatment plans utilize the 
primary tumor receptor status instead of the metastatic status had increased 
median life expectancy. To further substantiate these results, it was necessary to 
detect any covariates that might impact or influence the observed sample life 
expectancy. To examine the impact of covariates, the Cox Proportional Hazards 
method was used to analyze the data. Multivariate statistical analysis requires 
relatively larger sample sizes than univariate analyses. The number of variables 
that can be analyzed at once is strictly limited by the number of observations and 
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further impacted by nominal variables with multiple levels. Due to the small 
sample size of patients with discordant results in my study, effective multivariate 
analysis was not feasible on that subset of my data. Only a few variables could 
be tested at one time and the results were unlikely to be statistically significant. I 
employed various analyses with a small number of variables and verified the 
small sample size did not lead to statistically significant results. To determine 
whether potential covariates could impact the survival of patients and potentially 
bias the univariate results, I utilized the complete dataset and the re-tested 
patients to investigate the covariates. These findings are discussed below and in 
the Limitation section in Chapter 5. 
Complete Dataset Results 
The covariates available for analysis (referenced in Chapter 3) were utilized in a 
Cox regression analysis. Due to the relatively small sample size and the high 
number of nominal variables, I did not attempt to test any interactions between 
available covariates, only main effects were tested on the variables. The results 
of the initial analysis are shown in Appendix 10, Figure 33. The final model 
utilized is shown in Figure 22.  This model was based on several iterations of the  
 
 
Figure 22. Whole Dataset Final Results 
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analysis where any variable with a p-value of .2 or less was initially kept in the 
model. Fourteen variables were found to be statistically significant with a p-value 
of .20 or less in the initial analysis. The 14 significant variables were iteratively 
re-analyzed, removing variables with a p-value greater than .10, and the final 
results indicated that six variables (Grade, Size, nPos, Chemo, pPheno, Retested) 
were statistically significant with a p-value of .10 or less. I kept variables with p-
values less than .1 as a conservative measure to ensure I identified any 
covariates that could potentially impact the survival time of patients. For 
demonstration purposes, the graphical illustration of the effect of the variable 
pPheno, the receptor status of the primary tumor, on survival time is shown in 
Figure 23. The key point to note is that TNBC patients perform more poorly 
(shorter survival time) than do the other three phenotypes. It was important to 
review the breakdown of TNBC patients in my discordant sample, noting whether 
treatment were plans based on the primary tumor versus the metastatic tumor.  
 
 
Figure 23. pPheno KM Analysis 
  87
If, for instance, there were significantly more patients in the metastatic tumor 
group who were TNBC than in the primary tumor group, a potential explanation 
for the differences between the groups would be the effect of the variable 
pPheno, rather than the impact the first-line treatment plan determination being 
based on the receptor status of the metastatic or primary tumor. This point is 
further explored in the Univariate Statistical Analysis section of this chapter. 
Multivariate Results for Re-Tested Patients 
A previous analysis indicated that those patients whose metastatic tumors were 
re-tested had better survival outcomes than those patients not re-tested. 
Therefore, I conducted a multivariate analysis on the re-tested patients. Utilizing 
the Cox regression analysis on the re-tested patients, I employed the same 
procedure I used on the complete dataset. The final results of the analysis is 
shown in Figure 24. These results showed three of the six variables that were 
deemed statistically significant in the complete dataset, were also significant in 
the re-tested dataset. Additionally, two variables (Herceptin, LocoRegion) were 
 
 
Figure 24. Multivariate Results for Re-Tested Patients 
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Statistically significant, yielding a total of eight variables identified as covariates 
that impacted patient survival and could potentially bias the univariate analysis 
performed on the discordant data. These eight variables warranted further 
univariate analysis. 
 
Univariate Statistical Analysis 
 
A two-sample univariate analysis was performed on each available covariate for 
the 14 discordant patients. Each analysis tested whether there were statistically 
significant differences between the subset of patients who had their treatment 
plan based on their primary tumor receptor status (n=8) and those who had 
treatment plans based on the metastatic tumor (n=6). For continuous variables, 
a two sample t-test was performed on the sample averages. For nominal 
variables, the exact Fisher test for contingency tables was used to test the 
equality of the percentage of patients in each nominal category. The analysis 
results are listed in Table 21. The eight covariates found in the multivariate 
analysis to be statistically significant are indicated with and asterisk. Given the 
small combined sample size of 14, the fact that no results were statistically 
significant was not unexpected.  
To be thorough in the examination of the covariates, I reviewed the numerical 
differences between the two cohorts in spite of the lack of statistical significance 
for any variable. From a purely numerical standpoint, there was very little 
difference between the two samples for all but one covariate. For instance, the 
age at diagnosis for each sample differed numerically by only .2 years. 
Additionally, neither of the two cohorts had patients with TNBC primary tumors. 
Given that the multivariate analysis demonstrated that patients with TNBC  
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Table 21. Univariate Analysis 
Variable 
First-line 
Treatment Based 
on Metastatic 
Tumor Receptors 
(n=6) 
First-line 
Treatment 
Based on 
Primary Tumor 
Receptors 
(n=8) 
Statistical 
Significance 
(P-value) 
Age 56.1 55.3 .890 
TTR 1596.5 1390.9 .729 
Grade* 2.6 2.6 .935 
Size* 35.8 27.0 .463 
nPos* 7.0 8.0 .832 
Age DX 51.7 51.5 .975 
pPheno* 
Her2+(1), HR+(2), 
PBC(3), TNBC(0) 
Her2+(1), HR+(6), 
PBC(1), TNBC(0) .450 
mPheno 
Her2+(1), HR+(1), 
PBC(0), TNBC(4) 
Her2+(0), HR+(1), 
PBC(2), TNBC(5) .723 
AJCC Simple S1(0), S2(3), S3(3) S1(2), S2(3),S3(3) .600 
LocoRegion* 
Distant(6),  
Regional(0) 
Distant(6),  
Regional(2) .473 
Visceral Non(0), Visceral(6) Non(4), Visceral(4) .085 
Hormone Yes(3), No(3) Yes(4), No(3) .999 
Chemo* Yes(5), No(1) Yes(5), No(3) .580 
Rad Yes(5), No(1) Yes(5), No(3) .580 
Herceptin* Yes(4), No(1) Yes(2), No(5) .242 
*Variables found statistically significant in one of the multivariate analyses. 
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primary tumors had shorter life expectancies, had the two cohorts contained a 
different number of TNBC patients there would have been cause for concern 
about a possible bias in the survival analysis. The one variable that did present 
some concern was Visceral.  The Visceral variable is an indication of the location 
of the metastatic tumors. Visceral tumors are located in essential organs such as 
the lung, liver or brain. Non-visceral tumors are generally located in the bones 
and lymphatic system. All patients whose treatment plans were based on their 
metastatic tumor receptor status had metastatic tumors rated as visceral, while 
only 4 of 8 patients whose first-line treatment plan was based on their primary 
tumor were rated as visceral. Visceral and metastatic treatment plan were thus 
statistically confounded in this study. Figure 25 shows she KM survival analysis 
curve  
 
 
Figure 25. Visceral versus Non-Visceral 
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comparing visceral and non-visceral patients. The curves indicated that visceral 
patients performed worse (about 6 months shorter median PRS) than the non-
visceral patients, although this result was not statistically significant with a p-
value of .210. I made two evaluations of the impact the variable Visceral had on 
the primary versus metastatic tumor comparison results. First, I performed a Cox 
regression analysis on the discordant patients with the variable FLD (whether the 
primary or metastatic tumor receptor status was used to determine the first-line 
treatment plan) and Visceral in the model. The analysis results indicated that 
Visceral is not statistically significant and that even with Visceral in the model, 
FLD still had a hazard ratio of 4.2. These results are shown in Figure 26. This 
analysis indicated that patients whose first-line treatment plans were based on 
their metastatic tumor were 4.2 times more likely to die at a given point in time 
than those patients whose plans were based upon the primary tumor, even after 
accounting for the effect of the variable Visceral. Second, I performed a KM  
 
 
Figure 26. Cox Regression with Visceral 
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survival analysis on the discordant patients with only the visceral cases, which 
removed four of the patients whose first-line treatment plans were based on 
their primary tumor receptor status. These results are shown in Figure 27. The 
numerical and graphical results were nearly identical to the test results with the 
non-visceral patients included in the analysis. Of course, with the smaller sample 
size of 10 instead of 14, the p-value for the test of equal curves changed from 
.049 to .152. While there was certainly a difference in the two groups being 
compared based on the variable Visceral, I found no evidence that this fact was 
biasing or influencing the conclusions of this dissertation. Based on the entirety 
of the univariate analyses, I found no concern that a covariate biased the 
conclusions of this dissertation. 
   
 
Figure 27. Visceral Patients Only 
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Sensitivity Analysis 
 
As previously discussed, the four records in Table 19 represented data where the 
interpretation of the records could have yielded different variable values and thus 
impact the analysis of the discordant cases. I conducted two additional analyses 
with this data; one where the data was coded with a reasonable interpretation of 
the record such that the interpretation yielded data that was less supportive of 
my hypothesis, and a second analysis where each record was interpreted such 
that the coding resulted in data more supportive of my hypothesis. The analysis 
in Figure 28 (best case) represents the data where those four records were 
coded to support of my hypothesis. Obviously, the results showed a better 
numerical difference compared to the results with the originally coded data, with 
a best case median survival time of 42 months compared to the previously 
discussed estimate of 40 months shown in Figure 20.  This result was statistically 
significant with a p-value of .0006.  
 
 
Figure 28. Best Case Curves 
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The analysis in Figure 29 (worst case) represents the data where the four 
records were coded to not be supportive of my hypothesis. Understandably, the 
results showed a worse numerical result compared to the originally coded data, 
with a worst case median survival time of 22 months compared to the previously 
discussed estimate of 40 months shown in Figure 20. These results were not 
statistically significant with a p-value of .41.  
 
 
Figure 29. Worst Case Curves 
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CHAPTER 5 
Conclusions and Recommendations 
 
Conclusion 
 
The purpose of this dissertation was to determine the impact on patient 
outcomes in recurrent metastatic breast cancer diagnoses when the first-line 
treatment plan was based on the receptor status of metastatic tumor(s) instead 
of the receptor status of the primary tumor(s).  
Restatement of Hypothesis 
For discordant cases, if the first-line treatment plan is based on the receptor 
status of the primary tumor, the median life expectancy of MBC patients will be 
longer than MBC patients whose first-line treatment plan is based on the 
receptor status of the metastatic tumor. 
The weight of the evidence in this research is consistent with my hypothesis. The 
evidence is supported by: a literature review of historical data that built a strong 
case indicating that discordant MBC patients performed worse than concordant 
patients; the log rank test results with a p-value of .049; the covariate analysis; 
and the sensitivity analysis. A priori, based on the literature review, I expected a 
minimum of a one year median increase in life expectancy for patients with 
discordant receptor statuses whose first-line treatment plan was based on the 
primary tumor’s receptor status instead of the metastatic receptor status. 
Ultimately, the sample data showed that discordant MBC patients, whose first-
line treatment plan was based on their primary tumor rather than their 
metastatic tumor, had a longer median life expectancy of 40 months. The 
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sensitivity analysis resulted in a worst case scenario of a 22 month median 
difference, which still reinforces my hypothesis. Regardless of which life 
expectancy estimate is theorized, 12, 22, or 40 months, my research provides a 
distinct directive for determining first-line treatment plans for discordant MBC 
patients. I proposed that if the data analysis supported my hypothesis this would 
indicate a need for revised standards of care for MBC patients whose metastatic 
tumor receptor statuses differed from that of the primary tumor.  
 
Recommendation 
 
Since 1989, the clinical impact of testing metastatic tumors for receptor status to 
inform first-line treatment plans has been studied (Kamby et al., 1989). Prior to 
my research, researchers had drawn no definitive conclusions regarding the 
impact of re-testing receptor statuses on the clinical outcomes of metastatic 
breast cancer patients. In Chapter 1, I stated the ultimate goal of this 
dissertation was to influence changes in international and national standards 
regarding the determination of first-line treatment plans in discordant cases of 
MBC, and to provide a higher level of evidence for those standards.  
Proposed Standard of Care 
To assist physicians as they consult the relevant ABC2 and NCCN guidelines and 
levels of evidence concerning the care of metastatic breast cancer patients with 
discordant receptor statuses, I propose the implementation of the following over-
arching standard of care: 
Where discordance between the primary and metastatic tumor receptor status 
would indicate different treatments, the status of the primary tumor should take 
precedent when developing the first-line treatment plan for a newly diagnosed 
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recurrent metastatic breast cancer patient. Strong clinical evidence to the 
contrary must be present to warrant basing the treatment plan on the metastatic 
tumor receptor status.  
Level of Evidence 
The NCCN and ABC2 standards discussed in the Literature Review section of my 
paper are not consistent with my research findings (Cardoso et al., 2014; 
NCCN.org, 2014). As reported in Chapter 2, neither entity supports the standards 
recommendations relevant to my hypothesis with citations from existing 
literature. The ABC2 committee states their recommendation is based on expert 
opinion only. Considering the ABC2 level of evidence definitions, I recommend 
the level of evidence for my proposed standard of care be rated at 2B. Level 2B 
is defined as “RCTs with important limitations or exceptionally strong evidence 
from observational studies” and clinical implications of a “weak recommendation, 
best action may differ depending on circumstances or patients’ or societal 
values” (Cardoso et al., 2014, p. 2).  
 
Research Limitations 
 
Below I discuss five limitations of this research that could potentially impede the 
application of my results to patient medical decisions. I then review how my 
research design minimized or compensated for these limitations. While other 
limitations may exist, I consider these five to be the most relevant. 
Sample Size 
My research sample size of discordant cases (n=14), included eight cases whose 
treatment plan was determined by the primary tumor receptor status, and six 
cases whose treatment plan was determined by the metastatic tumor receptor 
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status. This sample size was statistically small, and it provided little statistical 
power, as illustrated by the simulation results in Chapter 3. In addition to 
statistical matters, practical concerns arose about the impact that data quality 
could have on analyses, given that each record carried more weight in the 
statistical calculations since the sample size was small. While my total sample 
size (n=124) and the number of discordant cases (n=14) was small, such sample 
sizes are common in the published literature and several heavily cited articles on 
this topic (Table 20). For future studies, a larger sample size would be desirable 
and may be obtained by including more and larger cancer centers. 
Data Quality 
Working with three sources of data, the tumor registry, electronic records and 
paper patient charts, presented several data challenges. The most important 
data quality challenge was that of applying operational definitions when 
physicians utilized an interpretation of lab results that differed from the lab 
report itself. Additionally, incomplete electronic records and lack of access to 
paper charts diminished the available sample of patients. With a small sample 
size, data quality was even more important since one or two inaccurate 
observations could impact the analytical results and resultant conclusions. Data 
quality issues and challengers were discussed in the Data Acquisition and 
Sensitivity Analysis sections of Chapter 4. Understanding the importance of data 
quality when working with small sample sizes meant that I needed to employ 
safeguards as checks on data quality. I believe that the sensitivity analysis 
performed provided protection against any data quality issues and thus limited 
any impact on the accuracy of my results and conclusions. The best protection 
against data quality issues was clear operational definitions, which I had, and 
larger sample sizes, which I strongly recommend in future research.  
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Inference Space 
The fact that this study was performed at only one cancer center was a 
limitation. Variation in cancer centers’ patient populations, policies and 
procedures could potentially impact the ability to infer the results of my research 
to other centers. While the results of my retrospective study are statistically most 
valid for the population from which they were derived, I believe they can be 
applied more widely from a practical standpoint. The fact that there have been 
no clear standards of care regarding first-line treatment plans for MBC patients 
with discordant receptor results created the opportunity to observe varied 
strategies employed by the doctors at the UT Cancer Center. This variation, 
based on doctor preferences, provides logical support for applying my results 
beyond just one cancer center and one set of doctors. The best method for 
ensuring a wider inference space for future research is to involve several cancer 
centers in the protocol.  
Limited Ability to Examine Covariates 
In retrospective observational studies, it is important to evaluate the potential 
effect of covariates on the research results. Such concern arises from the 
researchers’ lack of ability to control important variables when a study is 
retrospective rather than prospective. The importance of covariate analysis in the 
specific research performed in this dissertation is reviewed by several authors 
and discussed in the literature review (Dieci et al., 2012; Foukakis et al., 2012). 
In my research, the sample size hindered my ability to establish the impact of 
covariates on the results of this study. While I found no concerns for potential 
biasing of results based on the covariate analysis discussed in Chapter 4, it 
remains possible that confounding effects exist that bias the analysis results. 
Again, a larger sample size would help alleviate this limitation in future research. 
  100
Researcher Bias 
Creswell (2009), suggests researchers clarify through self-reflection any potential 
for researcher bias in the design and implementation of their research projects 
(p. 192). As the researcher for this dissertation, I certainly had an emotional 
attachment to my hypothesis, given that it was motivated as a result of my wife’s 
death. To avoid any bias or appearance of bias on my part, I applied various 
protections in the design and implementation of my research. The design of this 
research was reviewed by two IRB boards and my dissertation committee that 
had a practicing research oncologist as a member. Given the research design 
was fully vetted, the remaining potential for researcher bias was in the collection 
and analysis of the data. To eliminate bias in the analysis phase, the analysis 
plans and standards were established a priori. These plans and standards were 
ultimately implemented as the research design indicated. 
My initial idea for removing potential researcher bias in the data collection phase 
was to have someone else collect the data, such as a medical resident. My 
committee chair and the oncologist member of my committee both 
recommended that I collect the data myself for two reasons: First, relying on 
someone else would mean the length of data collection time was out of my 
control. Second, the committee members believed collecting my own data 
provided an important learning experience, since I had never before collected 
medical data. Once the decision was made that I would collect the data, I 
developed three strategies to protect against potential data collection researcher 
bias. I first created detailed operational definitions of each data variable in an 
attempt to eliminate the need for judgement calls when evaluating patient 
records. Next, my quality review process involved an independent expert, the 
Tumor Registry manager, who reviewed all the discordant cases and other 
samplings of records. Lastly, I meticulously documented every step of the data 
acquisition, cleaning and collection process. My records allow an independent 
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observer to retrace any of my data records to the original patient records or to 
track any patient ID to the documented and analyzed data.  
The advice of the committee members to collect my own data proved invaluable.  
Because of the complexity of the data collection process, I believe an 
independent person, not immersed in the topic of this research endeavor, could 
not have completed the collection process without being in constant consultation 
with me, thus clouding the intended independence. The discovery, outlined in 
Chapter 4, that those patients who did not have their metastatic tumor receptor 
status re-tested performed poorly, was a surprising and important finding. 
Because I personally conducted the record reviews, I was able to discern that in 
most cases where the patient was not re-tested, the patient had presented in 
such a dire situation that there either was no time to re-test or it was deemed 
too late for any treatment to succeed. An independent data collector would have 
likely missed this subtlety in the medical records since this information was not 
part of the pre-planned data collection process. Had I not collected the data 
myself, the interpretation of this one aspect of the data would have added an 
additional limitation to my results.  
 
Contribution 
 
At the time of completing this dissertation, I was unaware of any published 
scholarly paper or unpublished work that had expressly addressed the clinical 
impact of utilizing the metastatic receptor status of patients to determine their 
first-line treatment plan. For over 20 years, researchers have studied issues 
related to this topic; however, the precise question I examined in this 
dissertation was never evaluated. For the first time, the clinical impact of utilizing 
the receptor status of metastatic tumors, when determining MBC patients’ first-
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line treatment plan has been studied and reported. Additionally, my stated goal 
has always been to impact the national and international standards of care for 
discordant MBC patients. Proposing the over-arching standard recommending 
medical decisions for discordant MBC patients focus on the receptor status of the 
primary tumor and upgrading the level of evidence for that standard to 2B is a 
further contribution of my research. My intent is that this research leads to 
physicians consulting and implementing the over-arching standard of care I 
proposed, thus extending the lives of MBC patients. 
 
Future Research 
 
The primary need for future research is the engagement of additional cancer 
centers to utilize the protocols of this study to increase the sample size of data 
specifically targeting my hypothesis and expand the inference space for 
implementing the conclusions I have reached. Since the current medical 
standards on the appropriate treatment plan for discordant cases of recurrent 
metastatic cancer are weak, it would be beneficial to have data from various 
cancer centers that perhaps utilize different criteria about re-testing receptors 
and how that data is used to determine treatment plans. For example, in my 
personal experience with my wife and consulting the oncologist on my 
committee, I encountered three cancer centers (Piedmont in Atlanta, MD 
Anderson in Houston, and UT Knoxville) with at least three different approaches 
to determining first-line treatment plans. At one center, I witnessed a physician 
who did not make it a practice of re-testing the metastatic receptors to 
determine the first-line treatment plan. At a second center, the physician’s 
standard practice was to re-test and utilize the results of that test to assist in 
treatment decisions. At the third center, there was no written standard; there 
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was a general practice of re-testing when possible, and each doctor then decided 
independently how to utilize the information on the metastatic tumor receptor 
status. I see two paths for expanding the number of cancer centers involved in 
my research. First, I will seek to engage other researchers, identified through my 
literature review, who have studied the impact of discordant receptor statuses. 
Based on my review, I believe some authors already have the data available 
from previous research to implement the analysis on cohorts E and F of my 
study. Other authors would need to add a new variable to their existing data 
identifying whether the first-line treatment plan was based on the primary or 
metastatic tumor receptor status. That additional variable would allow the 
researcher to determine the impact of the first-line treatment plan decisions. 
Second, I will seek to engage other cancer centers to grant me access to their 
data. With additional patients from different cancer centers, the amount of data 
would mount and contribute to an even higher level of evidence to inform the 
determination of first-line treatment plans for MBC patients with discordant 
tumor receptor statuses.   
Unanswered Question 
One unexplored question in my research and in the literature is: Why does 
determining first-line treatment plans based on the primary tumor receptor 
status, as opposed to the metastatic tumor, result in better patient outcomes?  
The only answer proposed in the literature is measurement error. Liedtke et al. 
(2009), provides a good discussion of the potential impact of measurement error 
in the testing of MBC patients metastatic tumor receptor status. My belief is that 
measurement error is certainly part of the explanation, but to what extent is 
unknown. Presently I am content to know what the right decision is without 
having to understand why that decision is the correct one. If others wish to 
investigate this question, then that knowledge may lead to enhancements in the 
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first-line treatment plan decision making process and an increased understanding 
of the metastatic disease. 
Definition of Discordance 
One of the challenges during my literature review was that several definitions of 
discordance were utilized by researchers. I provided a clear and logical definition 
for discordance in Chapter 3. From a scientific point of view, having a universally 
applied definition of discordance is important. Such a definition would promote 
better research designs, produce clearer analyses, allow for more effective 
comparisons across studies and enable quantitative meta-analyses to be 
performed.  
 
Impact 
 
In September of 2013, Amy Foster was given four years to live. She died four 
months later after her treatment plan was modified based on the discordant 
receptor status of her metastatic tumor. As discussed in chapter 1, an estimated 
60,000 women per year world-wide are faced with a decision because their test 
results show discordant receptor statuses. For the majority of those women, 
their first-line treatment plan will be based on their metastatic tumor and they 
will suffer the consequence of a shortened median life expectancy of one to 
three years. It is my hope that this dissertation will help affect a change in the 
standards of care for women with discordant receptor statuses. With the data I 
have, I will personally recommend to anyone faced with this particular medical 
decision to base their first-line treatment plan on the primary tumor receptor 
status. As new and better data is developed, then the level of evidence can be 
raised and the relevant standards updated appropriately. Cardoso (2009), calls 
metastatic breast cancer patients the forgotten heroes because today’s breast 
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cancer research focuses on early detection and treatment of primary tumor 
breast cancer, not on challenges and issues facing metastatic patients. She 
laments, and I agree, “it is clearly a time for change!” (Cardoso, 2009, p. 271). 
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Appendix 1: List of Abbreviations 
 
Table 22. Appendix 1- List of Abbreviations 
 
Abbreviation Definition 
ABC1 First International Advanced Breast Cancer Conference 
ABC2 Second International Advanced Breast Cancer Conference 
ER Estrogen Receptor status 
HER2 Human Epidermal growth factor Receptor 2 
HER2+ HER2 positive. HR Negative 
HR+ Hormone receptor positive (ER and/or PR positive), and      
LDS Limited Data Set 
LoE Level of Evidence 
MBC Metastatic Breast Cancer 
MDA M.D. Anderson Medical Center 
NCCN National Comprehensive Cancer Network® 
OS Overall Survival 
PBC Positive Breast Cancer (HR+ and HER2+) 
PR Progesterone Receptor status 
PRS Post Recurrence Survival 
SAS Statistical Analysis System (statistical software) 
TNBC Triple Negative Breast Cancer 
KM Kaplan-Meier Survival analysis method 
HR Hazard Ratio 
PHI Protected Health Information 
AJCC American Joint Committee on Cancer 
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Appendix 2: Incidence Rate 
Table 23. Appendix - Seer Breast Cancer Incidence Rates 
Year of 
Diagnosis 
All Races, Females, 
All Ages Deaths All 
1975 105.07 31.45 
1976 101.92 31.8 
1977 100.82 32.48 
1978 100.64 31.73 
1979 102.14 31.21 
1980 102.26 31.68 
1981 106.37 31.92 
1982 106.5 32.19 
1983 111.15 32.07 
1984 116 32.9 
1985 124.26 32.98 
1986 126.86 32.87 
1987 134.5 32.66 
1988 131.33 33.2 
1989 127.22 33.23 
1990 131.86 33.14 
1991 133.85 32.69 
1992 132.05 31.64 
1993 129.22 31.39 
1994 131 30.92 
1995 132.63 30.55 
1996 133.7 29.49 
1997 137.99 28.21 
1998 141.39 27.54 
1999 141.46 26.61 
2000 136.48 26.64 
2001 138.76 26.01 
2002 135.73 25.62 
2003 126.92 25.27 
2004 128.03 24.49 
2005 126.51 24.14 
2006 126.14 23.56 
2007 128.06 22.96 
2008 128.11 22.55 
2009 130.52 22.24 
2010 126.46 21.92 
2011 129.56 21.54 
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Appendix 3: Permissions 
 
Periodical Permissions 
 
 
Figure 30. Periodical Permissions 
 
NCCN Permission 
NCCN allows students to utilize NCCN content without specific permission. The 
NCCN website states “Students using NCCN content in academic thesis or 
presentations for research purposes do not require written permission from 
NCCN. However, a credit line acknowledging NCCN, the name of the NCCN 
Guideline, and NCCN's website (www.nccn.org) should be included”(NCCN.org). 
 
Appendix 4: Operational Definitions 
1. Recurrence date 
a. Earliest known date of; 
i. Symptom occurrence that led to doctor visit 
ii. Date of doctor visit where indications of metastatic disease 
are identified 
iii. Date of confirmation of metastatic disease 
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2. Description 
a. Loco-regional  
b. Distant  
c. Non-visceral  
d. Visceral   
e. Visceral Crisis 
 
3. Receptors Retested?   Reason Codes 
a. A- No, Not feasible/safe 
b. B- No, Standard practice 
c. C- No, No indication of need 
d. D- Yes, Primary results missing, old or suspect 
e. E- Yes, Standard practice 
f. F- Yes, Clinical indications  
 
Result – as interpreted by the doctor 
Location of biopsy? Tissue, location 
 
4. Results Concordant?   By 4 phenotype definition 
a. TNBC : Triple Negative Breast Cancer 
b. HR+ : Hormone receptor positive (ER and/or PR positive), and 
HER2 negative 
c. HER2+ : HER2/neu positive. HR Negative 
d. PBC: Positive Breast Cancer HR positive and HER2 positive 
5. First-Line Treatment Plan based on?       Primary             
Metastatic 
- By doctor notes preferably. By doctor interview. By comparing 
receptor status with NCCN guidelines if necessary. 
a. Why?   
i.  A- Standard Practice 
ii.  B- Doctor preference 
iii.  C- Clinical indications 
iv.  D- Primary results missing, old or suspect  
v.  E- Other 
 
6. First Line Treatment?   
a. A- Chemotherapy  
b. B- Endocrine Therapy 
c. C- Targeted Therapy 
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d. D- Chemo + Targeted 
e. E- Other 
 
7. First Reassessment Result  (RECIST criteria) 
a. D – Deceased  
b. CR- Complete Response – Signifies that all target lesions have 
disappeared during the course of treatment. 
c. PR-  Partial Response - Signifies that decreases of at least 30% 
have been noted in the lesion that has the largest diameter (LD) 
d. SD-  Stable Disease – Signifies that there has been no significant 
decrease or increase in the size of target lesions 
e. PD- Progressive Disease – Signifies that there has been an increase 
of at least 20% in the sum of the LD of targeted lesions 
 
8. Date Deceased or Last Contact 
a. Last contact verifying the whether the patient was alive or 
deceased. Could be a phone call, email or doctor’s visit.  
b. Where doubt, obituary records may be searched 
c. Patients will not be contacted for this information for this study 
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Appendix 5: Data Collection Sheet 
 
 
Figure 31. Data Collection Sheet 
 
 
  119
Appendix 6: Data Breakdown Flowchart 
 
 
Figure 32. Data Breakdown Flowchart 
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Appendix 7: Variables Utilized 
Table 24. List of Variables Utilized 
Variable 
Name 
Description Source Comment 
PRS 
Post Recurrence 
Survival – the length 
of time after the 
patient was 
diagnosed with a 
recurrence until 
death or last contact 
Most of this data 
is from the 
Tumor Registry. 
The data was 
validated and 
updated if 
necessary during 
the data 
collection process 
This is the main 
metric of the 
study. It is 
measured in days 
and will be 
graphically 
reported in years 
Status 
The final Status of 
the patient at last 
contact 
Most of this data 
is from the 
Tumor Registry. 
The data was 
validated and 
updated if 
necessary during 
the data 
collection process 
0= Deceased 
1= Alive at last 
contact 
FSD 
Final Status Date – 
the date of last 
contact or death 
Same as above  
Rdate 
Recur Date – The 
date the metastatic 
recurrence was 
validated 
Same as above  
Retested 
Was the metastatic 
tumor(s) retested for 
the receptor status? 
Found in the 
patient records. 
Assumed “No” if 
no evidence. 
Yes/No 
mPheno 
Phenotype of the 
metastatic tumor 
when retested 
Found in the 
patient records 
Found in either a 
lab report or 
doctors’ notes or 
both.   
pPheno 
Phenotype of the 
primary tumor when 
retested 
Found in the 
patient records 
and/or the tumor 
registry 
Cross-checked if 
found in both 
sources 
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Table 24. List of Variables Utilized, Continued 
Variable 
Name 
Description Source Comment 
Concordant 
Where Retested = 
“Yes”, do the primary 
and metastatic tumor 
receptor statuses 
match? 
Found in the 
patient records.  
Does mPheno 
match pPheno? 
Yes/No. 
No = Discordant 
FLTP 
First-line Treatment 
Plan. Only 
determined for 
discordant results. 
Found in patient 
records 
Coded per data 
collection sheet in 
Appendix 4 
FLD 
First-line Decision – 
Was the first-line 
treatment plan based 
on the metastatic or 
primary tumor. Only 
determined for 
discordant results. 
Found in patient 
records.  
Required 
comparing the 
plan to NCCN 
standard 
treatments by 
phenotype to the 
metastatic and 
primary 
phenotypes 
LocoRegion 
Is/are the metastatic 
tumor(s) local to the 
breast, distant or 
both? 
Found in patient 
records 
 
Visceral 
Based on the extent 
of the disease and 
the condition of the 
patient 
Found in patient 
records 
Judgement call by 
me 
rLocation 
Where in the body 
are metastatic 
tumors located? 
Found in patient 
records 
 
RECIST 
The patient status at 
their first post 
treatment evaluation, 
usually around 3 
months after 
beginning treatment. 
Only determined 
for discordant 
results. 
Found in doctors’ 
notes in patient 
records 
This required 
interpretation by 
me. The patient 
status using the 
RECIST 
terminology was 
not used in the 
doctors’ notes.  
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Table 24. List of Variables Utilized, Continued 
Variable 
Name 
Description Source Comment 
Age 
Age at the time of 
recurrence. 
Calculated from age 
at primary diagnosis 
Age at primary 
diagnosis was 
found in Tumor 
Registry in whole 
years.  
 
TTR 
Time to recurrence. 
Calculated from 
primary diagnosis 
date and recurrence 
diagnosis date 
Found in Tumor 
Registry, with 
recurrence date 
verified in patient 
records 
Measured in days 
pER 
Estrogen receptor 
status of the primary 
tumor 
Found in the 
Tumor Registry 
and patient 
records. Most 
data is from 
patient records. 
All data was 
verified by 
patient records 
Used to determine 
phenotype and 
concordance. Not 
used in any 
analysis as an 
individual variable 
pPR 
Progesterone 
receptor status of the 
primary tumor 
Found in the 
Tumor Registry 
and patient 
records. Most 
data was from 
patient records. 
All data was 
verified by 
patient records 
Used to determine 
phenotype and 
concordance. Not 
used in any 
analysis as an 
individual variable 
pHER2 
HER2 Status of the 
primary tumor 
Found in the 
Tumor Registry 
and patient 
records. Most 
data was from 
patient records. 
All data was 
verified by 
patient records 
Used to determine 
phenotype and 
concordance. Not 
used in any 
analysis as an 
individual variable 
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Table 24. List of Variables Utilized, Continued 
Variable 
Name 
Description Source Comment 
SSS 
Documents the order 
of systematic therapy 
and surgery 
Found in Tumor 
Registry. Not 
verified in patient 
records 
Coded as Before, 
After, Both, None 
or Missing 
Hormone 
Did the patient 
receive hormone 
therapy for the 
primary tumor 
Based on the 
review of several 
fields in the 
Tumor Registry 
Yes, No or Missing 
Chemo 
Did the patient 
receive 
chemotherapy for the 
primary tumor 
Based on the 
review of several 
fields in the 
Tumor Registry 
Yes, No or Missing 
Rad 
Did the patient 
receive radiation 
therapy for the 
primary tumor 
Based on the 
review of several 
fields in the 
Tumor Registry 
Yes, No or Missing 
Herceptin 
Did the patient 
receive Herceptin 
therapy for the 
primary tumor 
Based on the 
review of several 
fields in the 
Tumor Registry 
Yes, No or Missing 
Grade Primary tumor grade 
Tumor Registry 
coded field 
Coded 
Size Primary tumor size 
Tumor Registry 
field 
 
nPos 
Number of positive 
lymph nodes 
associated with the 
primary tumor 
Tumor Registry 
field 
 
AJCC Simple 
AJCC cancer stage 
coding (pg. 
47)("Breast Cancer," 
2015) 
Tumor Registry 
field 
AJCC stage 
without the letter 
designation, 
utilizing just 
0,1,2,3,4 
Type Chemo 
The type of 
chemotherapy 
provided for adjuvant 
therapy for the 
primary tumor 
Created from a 
Tumor Registry 
text field 
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Table 24. List of Variables Utilized, Continued 
Variable 
Name 
Description Source Comment 
Age DX 
Patient age at 
diagnosis of primary 
tumor 
Tumor Registry 
field 
Used to calculate 
other variables 
dDate 
Date of diagnosis of 
primary tumor 
Tumor Registry 
field 
Used to calculate 
other variables 
 
Appendix 8: Information Only Variables 
 
Table 25. Information Variables 
Variable 
Name 
Description Source Comment 
Gen Stage 
General staging of 
the primary disease 
Tumor Registry 
field 
Used to validate 
other variables 
ID Code 
Used to link patient 
ID to data records 
Created by me 
Patient ID kept in 
a separate file 
Random 
Used to link patient 
ID to data records 
Created by me 
Used to randomly 
assign codes so no 
pattern is present 
SSF 15 
HER2 status 
summary code 
Tumor Registry 
field 
Used to help 
validate 
administration of 
Herceptin for the 
primary diagnosis 
SSF 16 
Phenotype summary 
of the primary tumor 
Tumor Registry 
field 
Used to validate 
other variables 
Rad Start 
Radiation start date 
for primary tumor 
Tumor Registry 
field 
Used to validate 
other variables 
Rad End 
Radiation end date 
for primary tumor 
Tumor Registry 
field 
Used to validate 
other variables 
Dose 
Radiation dose for 
primary tumor 
Tumor Registry 
field 
Used to validate 
other variables 
Chemo Text 
Text field describing 
the chemotherapy 
treatment for the 
primary tumor 
Tumor Registry 
field 
Used to validate 
other variables 
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Table 25. Information Variables, Continued 
Variable 
Name 
Description Source Comment 
Horm Start 
Date 
Hormone treatment 
start date for 
primary tumor 
Tumor Registry 
field 
Used to validate 
other variables 
RSN No 
Horm 
Text field for reason 
hormone therapy 
was not performed 
Tumor Registry 
field 
Used to validate 
other variables 
Recur Type 
Type of recurrence 
by location 
Tumor Registry 
field 
Used to validate 
other variables 
2nd Recur 
Date of a 2nd 
recurrence 
Tumor Registry 
field 
Used to validate 
other variables 
2nd Type 
Type of 2nd 
recurrence 
Tumor Registry 
field 
Used to validate 
other variables 
Order 
Ties record to 
original dataset 
Created by me 
Used for quality 
control 
Prim 
Primary Surgeon of 
record 
Tumor Registry 
field 
Information 
purposed only 
Mng 
Managing doctor of 
record 
Tumor Registry 
field 
Information 
purposed only 
Fol 
Following doctor of 
record 
Tumor Registry 
field 
Information 
purposed only 
Med Oncologist of record 
Tumor Registry 
field 
Information 
purposed only 
Complete 
Used to indicate 
when the data 
collection on a given 
record is complete 
Created by me  
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Appendix 9: Discordant Patient Variables 
 
ID 
CODE 
AGE 
DX 
pPheno 
AGE at 
Recur 
Rdate mPheno FLD FLTP Status Visceral 
PRS 
(Years) 
6 53 PBC 55.5 9/9/2008 TNBC M Chemo Deceased Visceral 1.41 
7 60 HR+ 61.6 5/23/2003 TNBC P Endocrine Deceased Non 1.43 
15 37 PBC 39.1 2/8/2005 HR+ P 
Chemo + Targeted 
then Endocrine 
Deceased Non 4.44 
99 61 HER2+ 62.5 6/28/2010 TNBC P Therapy Alive Non 4.99 
188 38 HER2+ 41.4 2/21/2011 TNBC M Chemo Alive Visceral 4.17 
233 46 HR+ 49.2 7/19/2012 TNBC P Endocrine Alive Visceral 2.9 
259 58 HR+ 65.2 12/2/2005 PBC P Endocrine Deceased Visceral 0.88 
312 35 HR+ 44 1/12/2002 PBC P 
Chemo then 
Endocrine 
Deceased Visceral 4.03 
355 56 HR+ 56.2 10/23/2012 TNBC P Endocrine Deceased Non 0.88 
399 59 HR+ 64.7 1/4/2007 TNBC P Endocrine Alive Visceral 8.55 
439 60 PBC 69.5 4/14/2011 HR+ M Endocrine Deceased Visceral 0.66 
535 59 PBC 61.2 10/4/2001 HER+ M Chemo + Targeted Deceased Visceral 0.72 
538 47 HR+ 51.8 11/7/2014 TNBC M Chemo Deceased Visceral 0.32 
558 53 HR+ 56.9 1/5/2004 TNBC M No Endocrine Deceased Visceral 0.55 
 
Table 26. Discordant Patients Variables 
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Appendix 10: Initial Cox Regression Results 
 
 
Figure 33. Initial Complete Cox Regression 
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Appendix 11: Power Tables 
Coding descriptions for the power tables: 
• Lambda 
o L3.5 for Lambda = 3.5 
o L2.0 for Lambda = 2.0 
o L5.0 for Lambda = 5.0 
• Binning 
o C = Continuous 
o B10 = 10 bins 
o B5 = 5 bins 
o B2 = 2 bins 
• Alpha (Type 1 error) 
o .05 
o .01 
• Censoring 
o C0 = no censoring 
o C25 = 25% censoring 
o C50 = 50% censoring 
• Sample Size 
o n1 = n2 unless otherwise noted 
o N70/30 = 70%, 30% split of total N 
o N85/15 = 85%, 15% split of total N 
• Hazard Ratios 
o 1 = both populations equal, thus type 1 error rate 
o 1.25, 1.5, 1.75, 2.0 and 3.0 
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Table 27. L3.5 C0 C .01 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0067 0.0116 0.0249 0.0467 0.0736 0.234 
20 
0.006 0.0179 0.0542 0.122 0.2256 0.6535 
50 
0.0088 0.0448 0.1994 0.4516 0.6989 0.9933 
100 
0.007 0.1021 0.4804 0.8282 0.9702 1 
200 
0.0086 0.2582 0.854 0.9929 1 1 
500 
0.0069 0.7015 0.9997 1 1 1 
1000 
0.0117 0.9693 1 1 1 1 
 
 
Table 28. L3.5 C0 C .05 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0342 0.047 0.0882 0.1408 0.2016 0.4819 
20 
0.0349 0.0744 0.1599 0.2992 0.4566 0.8585 
50 
0.0437 0.1439 0.4075 0.6893 0.8752 0.9994 
100 
0.0394 0.2584 0.7111 0.9447 0.9946 1 
200 
0.0434 0.4881 0.952 0.9989 1 1 
500 
0.0436 0.8761 0.9999 1 1 1 
1000 
0.0511 0.9931 1 1 1 1 
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Table 29. L3.5 C0 B10 .01 
 Hazard Ratio 
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0055 0.0096 0.0213 0.0387 0.0615 0.207 
20 
0.0055 0.0173 0.0509 0.1148 0.2165 0.6346 
50 
0.0081 0.0435 0.1941 0.441 0.6876 0.9926 
100 
0.007 0.0993 0.4746 0.8231 0.9689 1 
200 
0.0083 0.2538 0.8521 0.9925 1 1 
500 
0.0068 0.6997 0.9997 1 1 1 
1000 
0.0118 0.9681 1 1 1 1 
 
 
Table 30. L3.5 C0 B10 .05 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0315 0.0429 0.0808 0.131 0.1918 0.4611 
20 
0.0334 0.0697 0.1498 0.2899 0.4401 0.8472 
50 
0.0433 0.1415 0.4035 0.6843 0.8708 0.9994 
100 
0.0383 0.2559 0.7075 0.943 0.9938 1 
200 
0.0435 0.4829 0.9503 0.9988 1 1 
500 
0.0431 0.8735 0.9999 1 1 1 
1000 
0.0515 0.9931 1 1 1 1 
  131
Table 31. L3.5 C0 B5 .01 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0064 0.008 0.0176 0.0362 0.0545 0.1788 
20 
0.0053 0.0137 0.0471 0.1102 0.2004 0.5981 
50 
0.0065 0.0414 0.1822 0.4166 0.6609 0.9911 
100 
0.0075 0.1044 0.4652 0.8211 0.9651 1 
200 
0.0095 0.2542 0.8431 0.9932 0.9997 1 
500 
0.0097 0.708 0.9996 1 1 1 
1000 
0.0085 0.9663 1 1 1 1 
 
 
Table 32. L3.5 C0 B5 .05 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.028 0.0409 0.0731 0.1255 0.182 0.4404 
20 
0.0331 0.0607 0.1526 0.284 0.4262 0.8272 
50 
0.036 0.1348 0.3917 0.6644 0.8533 0.9995 
100 
0.041 0.2623 0.702 0.9383 0.9926 1 
200 
0.0441 0.4854 0.9494 0.9989 0.9999 1 
500 
0.0462 0.8738 1 1 1 1 
1000 
0.0438 0.9928 1 1 1 1 
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Table 33. L3.5 C0 B2 .01 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.002 0.003 0.0061 0.0135 0.0183 0.0457 
20 
0.0042 0.0115 0.0342 0.0785 0.135 0.3964 
50 
0.0053 0.0346 0.1564 0.3537 0.5768 0.9663 
100 
0.0066 0.084 0.4038 0.7585 0.9398 0.9997 
200 
0.008 0.2243 0.8015 0.986 0.9994 1 
500 
0.0075 0.6644 0.9989 1 1 1 
1000 
0.0087 0.957 1 1 1 1 
 
 
Table 34. L3.5 C0 B2 .05 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.018 0.028 0.0489 0.083 0.1141 0.2697 
20 
0.0253 0.0513 0.1182 0.2218 0.3333 0.689 
50 
0.035 0.1145 0.3502 0.6027 0.8041 0.9947 
100 
0.0367 0.2317 0.6534 0.9081 0.9842 1 
200 
0.0401 0.4556 0.9289 0.9977 1 1 
500 
0.0436 0.8499 0.9999 1 1 1 
1000 
0.0469 0.9909 1 1 1 1 
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Table 35. L2.0 C0 C .01 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0072 0.013 0.0283 0.049 0.0779 0.2406 
20 
0.0077 0.021 0.0645 0.14 0.2358 0.6713 
50 
0.0087 0.0558 0.2339 0.5107 0.7465 0.9958 
100 
0.0067 0.1346 0.5486 0.8876 0.9814 1 
200 
0.0089 0.3163 0.9012 0.9981 1 1 
500 
0.01 0.7845 1 1 1 1 
1000 
0.0097 0.9851 1 1 1 1 
 
Table 36. L2.0 C0 C .05 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0364 0.0549 0.0952 0.1556 0.224 0.5013 
20 
0.036 0.0804 0.1829 0.3243 0.4825 0.8694 
50 
0.0408 0.1655 0.4552 0.7447 0.9063 0.999 
100 
0.0415 0.3103 0.7702 0.9693 0.9965 1 
200 
0.0471 0.5577 0.971 0.9998 1 1 
500 
0.0504 0.9217 1 1 1 1 
1000 
0.0465 0.9972 1 1 1 1 
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Table 37. L5.0 C0 C .01 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0051 0.0107 0.023 0.0423 0.069 0.2288 
20 
0.0066 0.0159 0.0499 0.1063 0.1922 0.6151 
50 
0.0058 0.0399 0.1634 0.3818 0.6166 0.9869 
100 
0.0073 0.0867 0.4059 0.7686 0.9438 1 
200 
0.009 0.2175 0.7875 0.9865 0.9998 1 
500 
0.0096 0.6188 0.9982 1 1 1 
1000 
0.01 0.9354 1 1 1 1 
 
Table 38. L5.0 C0 C .05 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0287 0.0452 0.0786 0.1301 0.1913 0.4714 
20 
0.0333 0.0634 0.1464 0.2635 0.3946 0.8225 
50 
0.0387 0.1239 0.3479 0.6206 0.8232 0.9979 
100 
0.0376 0.2221 0.644 0.9069 0.9874 1 
200 
0.0468 0.4232 0.9242 0.997 1 1 
500 
0.0456 0.8189 0.9999 1 1 1 
1000 
0.0475 0.981 1 1 1 1 
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Table 39. L3.5 C25 C .01 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0067 0.0078 0.0162 0.0338 0.0516 0.1437 
20 
0.0063 0.0151 0.0387 0.0871 0.1492 0.4595 
50 
0.0081 0.0329 0.1409 0.3163 0.514 0.9459 
100 
0.0065 0.0779 0.3364 0.6755 0.893 0.9998 
200 
0.0077 0.1781 0.7157 0.9625 0.998 1 
500 
0.0088 0.5412 0.9936 1 1 1 
1000 
0.0107 0.8896 1 1 1 1 
 
Table 40. L3.5 C25 C .05 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0282 0.0388 0.0656 0.1069 0.1521 0.3431 
20 
0.0313 0.0624 0.1238 0.2261 0.3323 0.7033 
50 
0.0405 0.1115 0.3085 0.5509 0.7452 0.9897 
100 
0.0404 0.2048 0.5733 0.8605 0.9667 1 
200 
0.041 0.3816 0.8762 0.991 0.9999 1 
500 
0.0454 0.7639 0.999 1 1 1 
1000 
0.0469 0.9651 1 1 1 1 
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Table 41. L3.5 C25 B10 .01 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0053 0.0061 0.0125 0.0264 0.0415 0.1113 
20 
0.0056 0.0133 0.0349 0.0766 0.1274 0.402 
50 
0.0078 0.0297 0.1293 0.2869 0.4769 0.9226 
100 
0.0071 0.0729 0.3158 0.6415 0.8693 0.9996 
200 
0.0077 0.1676 0.6864 0.95 0.9967 1 
500 
0.0083 0.5156 0.9896 1 1 1 
1000 
0.0104 0.8722 1 1 1 1 
 
Table 42. L3.5 C25 B10 .05 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0262 0.0338 0.0584 0.0939 0.1356 0.2978 
20 
0.0287 0.0566 0.115 0.2096 0.3111 0.655 
50 
0.0391 0.1071 0.2884 0.5243 0.7163 0.9809 
100 
0.0411 0.1956 0.5506 0.8398 0.9578 0.9999 
200 
0.0396 0.3636 0.8603 0.9871 0.9996 1 
500 
0.0459 0.7451 0.9983 1 1 1 
1000 
0.0475 0.9579 1 1 1 1 
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Table 43. L3.5 C50 C .01 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0047 0.0084 0.0122 0.0193 0.0283 0.0737 
20 
0.006 0.0106 0.0258 0.0526 0.0823 0.2521 
50 
0.0075 0.0237 0.081 0.1744 0.3146 0.7703 
100 
0.0071 0.0473 0.1935 0.4579 0.6767 0.9879 
200 
0.0086 0.1112 0.4814 0.8258 0.9645 1 
500 
0.0091 0.3512 0.9328 0.9995 1 1 
1000 
0.0078 0.6991 0.9993 1 1 1 
 
Table 44. L3.5 C50 C .05 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0277 0.0361 0.0512 0.0738 0.0966 0.2133 
20 
0.029 0.0482 0.0872 0.1497 0.2081 0.4711 
50 
0.0348 0.0856 0.209 0.3738 0.539 0.9059 
100 
0.0396 0.1429 0.4006 0.6915 0.8648 0.9981 
200 
0.0448 0.269 0.7135 0.9439 0.9926 1 
500 
0.0444 0.5867 0.9801 1 1 1 
1000 
0.0438 0.8722 0.9999 1 1 1 
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Table 45. L3.5 C50 B10 .01 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0024 0.0048 0.0078 0.0113 0.0191 0.0505 
20 
0.0044 0.0082 0.0192 0.0426 0.0654 0.1991 
50 
0.0061 0.0213 0.0697 0.1483 0.2687 0.6885 
100 
0.007 0.0412 0.1711 0.407 0.6147 0.9725 
200 
0.0083 0.0978 0.4331 0.7786 0.9443 1 
500 
0.0091 0.3176 0.9044 0.9974 1 1 
1000 
0.0075 0.6525 0.9985 1 1 1 
 
Table 46. L3.5 C50 B10 .05 
 Hazard Ratio  
n1=n2 1 1.25 1.5 1.75 2 3 
10 
0.0187 0.0272 0.0393 0.0575 0.0792 0.1637 
20 
0.0255 0.0411 0.0767 0.1304 0.1812 0.4133 
50 
0.0336 0.0786 0.1884 0.3398 0.4903 0.8686 
100 
0.0367 0.1318 0.3665 0.6438 0.8232 0.9936 
200 
0.0436 0.2477 0.67 0.9203 0.9856 1 
500 
0.0435 0.5521 0.9706 0.9998 1 1 
1000 
0.0435 0.8408 0.9999 1 1 1 
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Table 47. L3.5 C0 C N70/30 .01 
 Hazard Ratio  
n1,n2 1 1.25 1.5 1.75 2 3 
6, 14 
0.0088 0.0093 0.0146 0.0267 0.0392 0.1273 
12, 28 
0.0062 0.012 0.0379 0.0762 0.1347 0.4558 
30, 70 
0.0085 0.0308 0.1257 0.2981 0.5105 0.9483 
60, 140 
0.0074 0.0649 0.3289 0.6795 0.8867 1 
120, 280 
0.0079 0.1777 0.7042 0.9632 0.9982 1 
300, 700 
0.0096 0.5342 0.991 1 1 1 
600, 1400 
0.0103 0.8946 1 1 1 1 
 
Table 48. L3.5 C0 C N70/30 .05 
 Hazard Ratio  
n1,n2 1 1.25 1.5 1.75 2 3 
6, 14 
0.0338 0.0399 0.0628 0.0979 0.1394 0.3377 
12, 28 
0.0366 0.0547 0.1227 0.2108 0.323 0.713 
30, 70 
0.0405 0.1098 0.3051 0.541 0.7449 0.9889 
60, 140 
0.0401 0.1983 0.5684 0.8608 0.9653 1 
120, 280 
0.0402 0.379 0.878 0.9923 0.9999 1 
300, 700 
0.0455 0.763 0.999 1 1 1 
600, 1400 
0.0467 0.969 1 1 1 1 
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Table 49. L3.5 C0 C N85/15 .01 
 Hazard Ratio  
n1,n2 1 1.25 1.5 1.75 2 3 
3, 17 
0.0134 0.0031 0.0029 0.0009 0.001 0.0004 
6, 34 
0.0098 0.0074 0.0129 0.0255 0.0483 0.1861 
15, 85 
0.0078 0.0132 0.0544 0.1332 0.249 0.7401 
30, 170 
0.0088 0.0322 0.1535 0.3732 0.6184 0.9848 
60, 340 
0.0084 0.0829 0.4055 0.7743 0.9474 1 
150, 850 
0.0076 0.3005 0.9001 0.998 0.9999 1 
300, 1700 
0.0094 0.6544 0.9985 1 1 1 
 
Table 50. L3.5 C0 C N85/15 .05 
 Hazard Ratio  
n1,n2 1 1.25 1.5 1.75 2 3 
3, 17 
0.035 0.031 0.0358 0.0486 0.0641 0.1487 
6, 34 
0.0377 0.0387 0.0628 0.1097 0.1666 0.4378 
15, 85 
0.0374 0.0622 0.1773 0.33 0.5009 0.9019 
30, 170 
0.0439 0.1194 0.3555 0.6332 0.825 0.9972 
60, 340 
0.0392 0.231 0.6571 0.9212 0.9858 1 
150, 850 
0.0423 0.5445 0.9714 0.9998 1 1 
300, 1700 
0.0479 0.843 0.9999 1 1 1 
 
  141
Appendix 12: Simulation Definitions 
Key words and concepts utilized in the simulation analysis are defined below: 
• Censoring – A statistical term that describes that fact that not all subjects 
in a survival analysis can/are observed until the event (death) occurs. The 
subject may be alive at the end of the study or may be lost to observation 
for various reasons (Lee & Wang, 2013, pp. 2-5). 
• Kaplan-Meier (KM) – A method of survival analysis created by Kaplan and 
Meier in 1958 that utilizes survival data that has censoring (Lee & Wang, 
2013, pp. 68-92). 
• Hazard Rate (Failure Rate) – The rate of failure (death) per a given unit of 
time (p. 10). 
• Exponential Distribution – A common statistical distribution used in 
survival analysis with a constant failure rate (pp. 133–138). 
• Lambda (λ) – The parameter of an exponential distribution where the 
mean time to failure (death) is λ.  
• Survival Curve – A graphical curve with percent survival on the Y-axis and 
time on the x-axis showing the percent of subjects still alive at a given 
point in time (pp. 8-11). 
• Log Rank – A semi-parametric statistical test used to evaluate the 
difference between two or more KM survival curves (pp. 112–113). 
• Hazard Ratio (HR) – The ratio of two hazard functions. The ratio indicates 
the difference in the instantaneous risk of death between two groups. A 
HR of 2 would mean that one group has twice the risk of dying at any 
point in time than another group (pp. 282–284). 
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• Proportional Hazards – For the purposes of this dissertation, all analyses 
assume proportional hazards, that is, the HR is constant over time (pp. 
282–284). 
• Sample Proportions – The proportion of the total sample N = n1 + n2, 
that are in each group in an analysis (only two groups were considered in 
this analysis). For n1 = n2, the proportions are 50% and 50%.  
• Delta – The hypothesized difference in the metric of interest between 
experimental groups that is of interest to the investigator. In the case of 
survival analysis the hazard ratio (HR) was used. For example, the 
experimenter may wish to statistically detect a difference between two 
groups of HR = 1.4 (Sharpe, Veaux, & Vellman, 2010, pp. 289-301). 
• False Positive (Type 1 Error) – The probability that a statistical test will 
indicate a difference between groups (two in this case) on the metric of 
interest when in fact there is no difference. A priori, this risk is set by the 
experimenter and is commonly called alpha. A risk of .05 or 5% is a 
common risk taken by practitioners (Sharpe et al., 2010, pp. 289-301). 
• P-value – After a statistical analysis is performed, this is the a posteriori 
probability of getting the observed result assuming the null hypothesis is 
true. Commonly reported to allow each person assessing a statistical 
analysis to apply their own type 1 risk (pp. 289-301). 
• False Negative (Type 2 Error) – The probability that a statistical test will 
indicate there is not a difference between two groups when in fact there 
is. This risk is called beta.  A priori, beta can be controlled by the 
experimenter and is impacted by the Delta chosen. A typical type 2 risk is 
10% (pp. 289–301). 
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Power – Mathematically this number is 1 – beta. The interpretation is that power 
is the probability of discovering the desired Delta given the parameters of the 
experiment (pp. 289-301). 
 
Appendix 13: Table of MATLAB Programs 
Table 51. MATLAB Programs Descriptions 
Program Description 
Generate_Data_v3_2p1p2 
Exponential random variables generated for two 
populations of various sample sizes and hazard 
ratios for a given lambda, censor rate and sample 
size ratio. Lambda, censor rate and sample size 
ratio are manually changed for each run. Bin size 
can be changed as well. The code is found in 
Appendix 14.  
Generate_Data_v3_2Bin Bin size can be changed as well. Appendix 15. 
Compute_log_rank_v2 
This code calls a MATLAB M-file (Log Rank) routine 
to calculate the p-value for the log rank test 
comparing two groups. The p-values are stored in 
output files for each sample size/hazard ratio 
combination. Appendix 16. 
Power_from_pval 
An output table is create for alpha = .01 and alpha 
= .05 from the p-values for each combination of 
sample size and hazard ratio. See Appendix 17. 
Compute_ndeaths 
For each run of the simulation and each 
combination of variables, the number of actual 
“deaths” in the simulation is recorded. This data is 
used to correlate with various input variables. See 
Appendix 18. 
ndeaths_vs_pval 
This code combines the “deaths” with p-values and 
other input variables for analysis. See Appendix 19.  
kmplot 
This is a MATLAB provided file that plots KM curves. 
See Appendix 20 for the code.  
logrank 
This is a MATLAB provided file that calculates Log 
Rank statistics for comparing two survival curves. 
See Appendix 21 for the code description. 
  144
Appendix 14: MATLAB Program 1 
 
% Copyright 2015, Tyler J. Massaro, all rights reserved. 
% Date: 9 June 2015 
% 
% Generating exponential random survival data. 
clc; 
clear all; 
close all; 
  
  
% Allocate storage 
N = [10 20 50 100 200 500 1000]; no_N = length(N); 
p1=.30; p2=.70;% Create unequal sample size 70/30 or 85/15 split 
p = 0.05; 
lamda = 3.5; %simlilar to p = .05 
censor_rate = 0.00; 
delta = [1 1.25 1.5 1.75 2 3]; no_delta = length(delta); 
ntrials = 10000; 
  
  
% Create baseline survival data (exponential) 
for i = 1:no_N 
     
    NN = 2*p1*N(i); 
    SURV = exprnd(lamda, NN, ntrials);%changed from 3 to lamda 
    X = (12*SURV); 
    binSURV = X; 
   binSURV(X<=6) = 6; 
    binSURV(X>6 & X<=12)= 12; 
      binSURV(X>12 & X<=18)= 18; 
       binSURV(X>18 & X<=24)= 24; 
         binSURV(X>24 & X<=30)= 30; 
          binSURV(X>30 & X<=36)= 36; 
           binSURV(X>36 & X<=42)= 42; 
              binSURV(X>42 & X<=48)= 48; 
                binSURV(X>48 & X<=54)= 54; 
                  binSURV(X>54 )= 60; 
     
    Y = rand(NN, ntrials); 
     
    % Fixing the CENS data 
    CENS = double(Y < censor_rate); 
    CENS(SURV > 5) = 1; 
     
    % Store information 
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    NN = N(i); 
    csvwrite(['EXP_SURV_N_is_' num2str(NN) '.csv'], SURV); 
    csvwrite(['EXP_BIN_SURV_N_is_' num2str(NN) '.csv'], binSURV); 
    csvwrite(['EXP_CENS_N_is_' num2str(NN) '.csv'], CENS); 
     
    assignin('base', ['EXP_SURV_N_is_' num2str(NN)], SURV); 
    assignin('base', ['EXP_BIN_SURV_N_is_' num2str(NN)], binSURV); 
    assignin('base', ['EXP_CENS_N_is_' num2str(NN)], CENS); 
end 
  
  
% Create new data (exponential) 
for i = 1:no_N 
     
    NN = 2*p2*N(i); 
     
    for d = 1:no_delta 
        dd = delta(d); 
        SURV = exprnd(lamda/dd, NN, ntrials);%changed from 3 to lamda 
         X = (12*SURV); 
    binSURV = X; 
    binSURV(X<=6) = 6; 
    binSURV(X>6 & X<=12)= 12; 
    binSURV(X>12 & X<=18)= 18; 
      binSURV(X>18 & X<=24)= 24; 
        binSURV(X>24 & X<=30)= 30; 
          binSURV(X>30 & X<=36)= 36; 
            binSURV(X>36 & X<=42)= 42; 
              binSURV(X>42 & X<=48)= 48; 
                binSURV(X>48 & X<=54)= 54; 
                  binSURV(X>54 )= 60; 
        Y = rand(NN, ntrials); 
         
        % Fixing the CENS data 
        CENS = double(Y < censor_rate); 
        CENS(SURV > 5) = 1; 
         
        % Store information 
        NN = N(i); 
        csvwrite(['EXP_SURV_N_is_' num2str(NN) ... 
            '_d_is_' num2str(100*dd) '.csv'], SURV); 
        csvwrite(['EXP_BIN_SURV_N_is_' num2str(NN) ... 
            '_d_is_' num2str(100*dd) '.csv'], binSURV); 
        csvwrite(['EXP_CENS_N_is_' num2str(NN) ... 
            '_d_is_' num2str(100*dd) '.csv'], CENS); 
         
        assignin('base', ['EXP_SURV_N_is_' num2str(NN) ... 
            '_d_is_' num2str(100*dd)], SURV); 
        assignin('base', ['EXP_BIN_SURV_N_is_' num2str(NN) ... 
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            '_d_is_' num2str(100*dd)], binSURV); 
        assignin('base', ['EXP_CENS_N_is_' num2str(NN) ... 
            '_d_is_' num2str(100*dd)], CENS); 
    end 
end 
 
Appendix 15: MATLAB Program 2 
 
% Copyright 2015, Tyler J. Massaro, all rights reserved. 
% Date: 9 June 2015 
% 
% Generating exponential random survival data. 
clc; 
clear all; 
close all; 
  
  
% Allocate storage 
N = [10 20 50 100 200 500 1000]; no_N = length(N); 
p1=.15; p2=.85;% Create unequal sample size 70/30 split 
p = 0.05; 
lamda = 3.5; %simlilar to p = .05 
censor_rate = 0.00; 
delta = [1 1.25 1.5 1.75 2 3]; no_delta = length(delta); 
ntrials = 10000; 
  
  
% Create baseline survival data (exponential) 
for i = 1:no_N 
     
    NN = 2*p1*N(i); 
    SURV = exprnd(lamda, NN, ntrials);%changed from 3 to lamda 
    X = (12*SURV); 
    binSURV = X; 
   % binSURV(X<=6) = 6; 
    %binSURV(X>6 & X<=12)= 12; 
   % binSURV(X<=12)= 12 
   % binSURV(X>12 & X<=18)= 18; 
    %  binSURV(X>12 & X<=24)= 24; 
        % binSURV(X>24 & X<=30)= 30; 
          %binSURV(X>24 & X<=36)= 36; 
          binSURV(X<=36)= 36; 
           % binSURV(X>36 & X<=42)= 42; 
             % binSURV(X>36 & X<=48)= 48; 
               % binSURV(X>48 & X<=54)= 54; 
                  binSURV(X>36 )= 60; 
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    Y = rand(NN, ntrials); 
     
    % Fixing the CENS data 
    CENS = double(Y < censor_rate); 
    CENS(SURV > 5) = 1; 
     
    % Store information 
    NN = N(i); 
    csvwrite(['EXP_SURV_N_is_' num2str(NN) '.csv'], SURV); 
    csvwrite(['EXP_BIN_SURV_N_is_' num2str(NN) '.csv'], binSURV); 
    csvwrite(['EXP_CENS_N_is_' num2str(NN) '.csv'], CENS); 
     
    assignin('base', ['EXP_SURV_N_is_' num2str(NN)], SURV); 
    assignin('base', ['EXP_BIN_SURV_N_is_' num2str(NN)], binSURV); 
    assignin('base', ['EXP_CENS_N_is_' num2str(NN)], CENS); 
end 
  
  
% Create new data (exponential) 
for i = 1:no_N 
     
    NN = 2*p2*N(i); 
     
    for d = 1:no_delta 
        dd = delta(d); 
        SURV = exprnd(lamda/dd, NN, ntrials);%changed from 3 to lamda 
         X = (12*SURV); 
    binSURV = X; 
  % binSURV(X<=6) = 6; 
    %binSURV(X>6 & X<=12)= 12; 
   % binSURV(X<=12)= 12 
   % binSURV(X>12 & X<=18)= 18; 
    %  binSURV(X>12 & X<=24)= 24; 
        % binSURV(X>24 & X<=30)= 30; 
          %binSURV(X>24 & X<=36)= 36; 
          binSURV(X<=36)= 36; 
           % binSURV(X>36 & X<=42)= 42; 
             % binSURV(X>36 & X<=48)= 48; 
               % binSURV(X>48 & X<=54)= 54; 
                  binSURV(X>36 )= 60; 
        Y = rand(NN, ntrials); 
         
        % Fixing the CENS data 
        CENS = double(Y < censor_rate); 
        CENS(SURV > 5) = 1; 
         
        % Store information 
        NN = N(i); 
  148
        csvwrite(['EXP_SURV_N_is_' num2str(NN) ... 
            '_d_is_' num2str(100*dd) '.csv'], SURV); 
        csvwrite(['EXP_BIN_SURV_N_is_' num2str(NN) ... 
            '_d_is_' num2str(100*dd) '.csv'], binSURV); 
        csvwrite(['EXP_CENS_N_is_' num2str(NN) ... 
            '_d_is_' num2str(100*dd) '.csv'], CENS); 
         
        assignin('base', ['EXP_SURV_N_is_' num2str(NN) ... 
            '_d_is_' num2str(100*dd)], SURV); 
        assignin('base', ['EXP_BIN_SURV_N_is_' num2str(NN) ... 
            '_d_is_' num2str(100*dd)], binSURV); 
        assignin('base', ['EXP_CENS_N_is_' num2str(NN) ... 
            '_d_is_' num2str(100*dd)], CENS); 
    end 
end 
 
Appendix 16: MATLAB Program 3 
 
% Copyright 2015, Tyler J. Massaro, all rights reserved. 
% Date: 9 June 2015 
% Compute_log_rank_v2 
  
% Compute log-rank for binned and for continuous survival data.  Also, 
% storing p-values for later use. 
clc; 
clear all; 
close all; 
  
alpha = 0.05; 
N = [ 10 20 50 100 200 500 1000]; no_N = length(N); 
delta = [1 1.25 1.5 1.75 2 3]; no_delta = length(delta); 
ntrials = 10000; 
results_table = zeros(no_N, no_delta); 
results_table_bin = zeros(no_N, no_delta); 
  
for n = 1:no_N 
    NN = N(n); 
     
    Sbase = csvread(['EXP_SURV_N_is_' num2str(NN) '.csv']); 
    Cbase = csvread(['EXP_CENS_N_is_' num2str(NN) '.csv']); 
     
    Sbinbase = csvread(['EXP_BIN_SURV_N_is_' num2str(NN) '.csv']); 
     
    for d = 1:no_delta 
        dd = delta(d); 
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        Sfname = ['EXP_SURV_N_is_' num2str(NN) '_d_is_' ... 
            num2str(100*dd) '.csv']; 
        Cfname = ['EXP_CENS_N_is_' num2str(NN) '_d_is_' ... 
            num2str(100*dd) '.csv']; 
         
        Sbinfname = ['EXP_BIN_SURV_N_is_' num2str(NN) '_d_is_' ... 
            num2str(100*dd) '.csv']; 
         
        S = csvread(Sfname); 
        C = csvread(Cfname); 
        Sbin = csvread(Sbinfname); 
         
        nreject = 0; 
        nreject_bin = 0; 
         
        pvals = zeros(ntrials, 1); 
        pvals_bin = zeros(ntrials, 1); 
         
        for i = 1:ntrials 
            X = [Sbase(:, i) Cbase(:, i)]; 
            Y = [S(:, i) C(:, i)]; 
             
            Xbin = [Sbinbase(:, i) Cbase(:, i)]; 
            Ybin = [Sbin(:, i) C(:, i)]; 
             
            pval = logrank(X, Y); 
            pval_bin = logrank(Xbin, Ybin); 
             
            pvals(i) = pval; 
            pvals_bin(i) = pval_bin; 
             
            if pval < alpha 
                nreject = nreject + 1; 
            end 
             
            if pval_bin < alpha 
                nreject_bin = nreject_bin + 1; 
            end 
        end 
         
        pwr = nreject/ntrials; 
        results_table(n, d) = pwr; 
         
        pwr_bin = nreject_bin/ntrials; 
        results_table_bin(n, d) = pwr_bin; 
         
        csvwrite(['EXP_p_vals_N_is_' num2str(NN) ... 
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            '_d_is_' num2str(100*dd) '.csv'], pvals); 
        csvwrite(['EXP_BIN_p_vals_N_is_' num2str(NN) ... 
            '_d_is_' num2str(100*dd) '.csv'], pvals_bin); 
    end 
end 
 
Appendix 17: MATLAB Program 4 
 
% Copyright 2015, Tyler J. Massaro, all rights reserved. 
% Date: 12 June 2015 
% 
% Powers from p-values 
clc; 
clear all; 
close all; 
  
alpha = [0.01 0.05]; 
N = [10 20 50 100 200 500 1000]; no_N = length(N); 
delta = [1 1.25 1.5 1.75 2 3]; no_delta = length(delta); 
ntrials = 10000; 
  
for i = 1:length(alpha) 
    a = alpha(i); 
     
    results_table = zeros(no_N, no_delta); 
    results_table_bin = zeros(no_N, no_delta); 
     
    for j = 1:no_N 
        NN = N(j); 
         
        for d = 1:no_delta 
            dd = delta(d); 
             
            Pbin = csvread(['EXP_BIN_p_vals_N_is_' num2str(NN) ... 
                '_d_is_' num2str(100*dd) '.csv']); 
            P = csvread(['EXP_p_vals_N_is_' num2str(NN) ... 
                '_d_is_' num2str(100*dd) '.csv']); 
             
            Xbin = Pbin < a; 
            X = P < a; 
             
            results_table(j, d) = sum(X)/ntrials; 
            results_table_bin(j, d) = sum(Xbin)/ntrials; 
        end 
    end 
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    assignin('base', ['CONT_alpha_' num2str(100*a)], results_table); 
    assignin('base', ['BIN_alpha_' num2str(100*a)], results_table_bin); 
end 
 
Appendix 18: MATLAB Program 5 
 
% Copyright 2015, Tyler J. Massaro, all rights reserved 
% Date: 27 July 2015 
% Compute_ndeaths 
% Compute the number of deaths based on censored data 
clc; 
clear all; 
close all; 
  
N = [10 20 50 100 200 500 1000]; no_N = length(N); 
delta = [1 1.25 1.5 1.75 2 3]; no_delta = length(delta); 
  
for i = 1:no_N 
    n = N(i); 
     
    for j = 1:no_delta 
        d = delta(j); 
         
        X = csvread(['EXP_CENS_N_is_' num2str(n) '_d_is_' ... 
            num2str(100*d) '.csv']); 
         
        ndeaths = n - sum(X); 
         
        csvwrite(['ndeaths_N_is_' num2str(n) '_d_is_' ... 
            num2str(100*d) '.csv'], ndeaths); 
    end 
end 
 
Appendix 19: MATLAB Program 6 
 
% Copyright 2015, Tyler J. Massaro, all rights reserved. 
% Date: 27 July 2015 
% 
% Number of deaths vs p-values 
clc; 
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clear all; 
close all; 
  
alpha = [0.01 0.05]; 
N = [10 20 50 100 200 500 1000]; no_N = length(N); 
delta = [1 1.25 1.5 1.75 2 3]; no_delta = length(delta); 
  
bin_corr_table = zeros(no_N, no_delta); 
cont_corr_table = zeros(no_N, no_delta); 
  
  
% Compute the correlation coefficient between p-val and ndeaths  
for j = 1:no_N 
    NN = N(j); 
     
    for d = 1:no_delta 
        dd = delta(d); 
         
        Pbin = csvread(['EXP_BIN_p_vals_N_is_' num2str(NN) ... 
            '_d_is_' num2str(100*dd) '.csv']); 
        P = csvread(['EXP_p_vals_N_is_' num2str(NN) ... 
            '_d_is_' num2str(100*dd) '.csv']); 
         
        ndeaths = csvread(['ndeaths_N_is_' num2str(NN) '_d_is_' ... 
            num2str(100*dd) '.csv']); 
         
        rho_bin = corrcoef(Pbin, ndeaths); 
        rho_cont = corrcoef(P, ndeaths); 
         
        bin_corr_table(j, d) = rho_bin(1, 2); 
        cont_corr_table(j, d) = rho_cont(1, 2); 
    end 
end 
  
  
% Compute the variation 
ndeaths_avg = zeros(no_N, no_delta); 
ndeaths_var = zeros(no_N, no_delta); 
for j = 1:no_N 
    NN = N(j); 
     
    for d = 1:no_delta 
        dd = delta(d); 
         
        ndeaths = csvread(['ndeaths_N_is_' num2str(NN) '_d_is_' ... 
            num2str(100*dd) '.csv']); 
         
        ndeaths_avg(j, d) = mean(ndeaths); 
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        ndeaths_var(j, d) = var(ndeaths); 
    end 
end 
  
  
% Compute the variation by normalizing wrt N 
ndeaths_avg_norm = zeros(no_N, no_delta); 
ndeaths_var_norm = zeros(no_N, no_delta); 
for j = 1:no_N 
    NN = N(j); 
     
    for d = 1:no_delta 
        dd = delta(d); 
         
        ndeaths = csvread(['ndeaths_N_is_' num2str(NN) '_d_is_' ... 
            num2str(100*dd) '.csv']); 
         
        ndeaths_avg_norm(j, d) = mean(ndeaths/NN); 
        ndeaths_var_norm(j, d) = var(ndeaths/NN); 
    end 
end 
 
Appendix 20: MATLAB Program 7 
 
function varargout=kmplot(varargin) 
% KMPLOT Plot the Kaplan-Meier estimation of the survival function 
% Survival times are data that measure follow-up time from a defined 
% starting point to the occurrence of a given event, for example the %timefrom the beginning to 
the end of a remission period or the time %from the diagnosis of a disease to death. Standard 
statistical %techniques cannot usually be applied because the underlying %distribution is rarely 
Normal 
% and the data are often "censored". A survival time is described as 
% censored when there is a follow-up time but the event has not yet 
% occurred or is not known to have occurred. For example, if remission %time is being studied 
and the patient is still in remission at the end %of the study, then that patientï¿½s remission 
time would be censored. %If a patient for some reason drops out of a study before the end of 
%the study period, then that patientï¿½s follow-up time would also be %considered to be 
censored. The survival function S(t) is defined as %the probability of surviving at least to time t. 
The graph of S(t) %against t is called the survival curve. The Kaplanï¿½Meier method can % be 
used to estimate this curve from the observed survival times      % without the assumption of an 
underlying probability distribution. 
% 
% Syntax:   kmplot(x,alpha,censflag) 
%       
%     Inputs: 
%           X (mandatory)- Nx2 data matrix: 
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%                          (X:,1) = survival time of the i-th subject 
%                          (X:,2) = censored flag  
%                                   (0 if not censored; 1 if censored) 
%        note that if X is a vector, all the flags of the second column 
%           will be set to 0 (all data are not censored). 
%           ALPHA (optional) - significance level (default 0.05)  
%           CENSFLAG (optional) - Censored Plot flag (default 0). If 0 
%           censored data will be plotted spreaded on the horizontal 
%    segment; if 1 they will be plotted at the given time of censoring. 
%     Outputs: 
%           Kaplan-Meier plot 
% 
%      Example: (+ indicate that patient is censored) 
%   
%                   --------------------- 
%                   Patient     Survival 
%                               time        
%                   --------------------- 
%                      1        7     
%                      2        12    
%                      3        7+     
%                      4        12+   
%                      5        11+   
%                      6        8     
%                      7        9     
%                      8        6 
%                      9        7+ 
%                     10        2     
%                   ---------------------- 
%    X=[7 0; 12 0; 7 1; 12 1; 11 1; 8 0; 9 0; 6 0; 7 1; 2 0]; 
% 
%  Calling on Matlab the function: kmplot(X) the function will plot the 
%    Kaplan-Meier estimation of the survival function 
% 
%           Created by Giuseppe Cardillo 
%           giuseppe.cardillo-edta@poste.it 
% 
% To cite this file, this would be an appropriate format:Curve 
% Cardillo G. (2008). KMPLOT: Kaplan-Meier estimation of the survival 
% function. 
% http://www.mathworks.com/matlabcentral/fileexchange/22293 
  
%Input Error handling 
args=cell(varargin); 
nu=numel(args); 
if isempty(nu)  
    error('Warning: Data vectors are required') 
elseif nu>3 
    if nu>4 
        error('Warning: Max two input data are required') 
    end 
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end 
default.values = {[7 0; 12 0; 7 1; 12 1; 11 1; 8 0; 9 0; 6 0; 7 1; 2 0],0.05,0,1}; 
default.values(1:nu) = args; 
[x alpha cflag flag] = deal(default.values{:}); 
if ~all(isfinite(x(:))) || ~all(isnumeric(x(:))) 
    error('Warning: all X values must be numeric and finite') 
end 
if isvector(x)  
    x(:,2)=0; 
else 
    if ~isequal(size(x,2),2) 
        error('KMPLOT requires Nx2 matrix data.'); 
    end 
    if ~all(x(:,2)==0 | x(:,2)==1) 
        error('Warning: all X(:,2) values must be 0 or 1') 
    end 
end 
if nu>1 
    if isempty(alpha) 
        alpha=0.05; 
    else 
        if ~isscalar(alpha) || ~isnumeric(alpha) || ~isfinite(alpha) 
            error('Warning: it is required a numeric, finite and scalar ALPHA value.'); 
        end 
        if alpha <= 0 || alpha >= 1 %check if alpha is between 0 and 1 
            error('Warning: ALPHA must be comprised between 0 and 1.') 
        end 
    end 
end 
if nu==3 
    if isempty(cflag) 
        cflag=0; 
    else 
        if ~isscalar(cflag) || ~isnumeric(cflag) || ~isfinite(cflag) 
            error('Warning: it is required a numeric, finite and scalar CENSFLAG value.'); 
        end 
        if cflag~=0 && cflag~=1 
            error('Warning: CENSFLAG value must be 0 or 1') 
        end 
    end 
end     
clear args default nu 
%string for LEGEND function 
str1=[num2str((1-alpha)*100) '% confidence interval'];  
  
%sort data by survival time 
x=sortrows(x,1); 
%table of patients observed for each survival time 
%the TABULATE function sets up this matrix: 
%table1=[time count percent(on total)] 
table1=[0 size(x,1) 1; tabulate(x(:,1))]; 
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%if all observed time are integers remove not observed time added by 
%TABULATE function 
table1(table1(:,3)==0,:)=[]; 
  
%Table of censored data 
table12=tabulate(x(x(:,2)==1)); 
if ~isempty(table12) 
    % remove not observed time added by TABULATE function 
    table12(table12(:,3)==0,:)=[]; 
    % setup the vector of the censored data 
    [cens,loc]=ismember(table1(:,1),table12(:,1)); %find censored data 
end     
  
%the percents stored in the the third column are unuseful; 
%so, place in the third column how many subjects are still alive at the 
%beginning of the i-th interval. 
a1=[table1(1,2); -1.*table1(2:end,2)]; 
table1(:,3)=cumsum(a1); table1(2:end,3)=table1(1:end-1,3); 
%number of deaths in the intervals (don't take in account the censored 
%data) 
if ~isempty(table12) 
    table1(cens,2)=table1(cens,2)-table12(loc(cens),2); 
end 
%finally, delete the first row that is now useless 
table1(1,:)=[]; 
  
t1=[0;table1(:,1)]; %this is the x variable (time); 
%this is the y variable (survival function) 
T1=[1;cumprod(1-(table1(:,2)./table1(:,3)))]; 
if flag %if this function was not called by LOGRANK function 
    %compute the standard error of the survival function 
    SE=[0;T1(2:end).*sqrt(cumsum(table1(:,2)./(table1(:,3).* ... 
        (table1(:,3)-table1(:,2)))))]; 
end 
  
%censored data plotting 
if ~isempty(table12)  
    %if there are censored data after max(t1), add a new cell into the t1, 
    %T1 and SE arrays 
    if table12(end,1)>=t1(end,1) 
        t1(end+1,1)=table12(end,1)+1; 
        T1(end+1,1)=T1(end,1); 
        if flag %if this function was not called by LOGRANK function 
            SE(end+1,1)=SE(end,1); 
        end 
    end 
    if ~cflag 
        %vectors preallocation 
        xcg=zeros(1,sum(table12(:,2))); ycg=xcg; J=1; 
        %for each censored data into the i-th time interval... 
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        for I=1:size(table12,1) 
            %compute how many position into the array they must occupy 
            JJ=J+table12(I,2)-1; 
            %find the correct time interval in which censored data must be 
            %placed 
            A=find(t1<=table12(I,1),1,'last'); 
            B=find(t1>table12(I,1),1,'first'); 
            %equally divide this interval 
            int=linspace(table12(I,1),t1(B,1),table12(I,2)+2); 
            %put all in the vectors of the plotting variables 
            xcg(J:JJ)=int(2:end-1); 
            ycg(J:JJ)=T1(A); 
            %update the counter 
            J=JJ+1; 
        end 
    else 
        xcg=table1(table1(:,2)==0,1); 
        ycg=T1(table1(:,2)==0); 
    end 
else 
    if ~flag %if this function was called by LOGRANK function 
        xcg=[]; ycg=[]; 
    end 
end 
%compute the hazard rate 
c1=T1.*numel(x); 
c2=-(diff(log(c1(1:end-1)))./diff(t1(1:end-1))); 
lambda=mean(c2(c2~=0)); 
  
if flag %if this function was not called by LOGRANK function 
    %compute the (1-alpha)*100% confidence interval curves 
    cv=realsqrt(2)*erfcinv(alpha); %critical value 
 %lower curve (remember that: the lower curve values can't be negative) 
    lowc=max(0,T1-SE.*cv); 
 %if the lower curve reaches the 0 earlier than survival %function, trim the data. 
    if isequal(lowc(end-1:end),[0; 0]) 
        lowcend=find(lowc==0,1,'first'); 
    else 
        lowcend=length(lowc); 
    end 
    %upper curve (remember that the upper curve values can't be >1) 
    upc=min(1,T1+SE.*cv); 
    %eventually, correct the data. 
    if isequal(upc(end),1)  
        cupend=find(upc<1,1,'last'); 
        upc(cupend:end)=upc(cupend); 
    end 
  
    %compute the median survival time (if exist...) 
    if isempty(T1(T1==0.5)) %if there is not a point where T=0.5... 
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        I=find(T1>0.5,1,'last'); %find the first point where T>0.5 
        J=find(T1<0.5,1,'first'); %find the first point where T<0.5 
        if isempty(J) %if all points are >0.5... 
            mt=0; %...there is no median time 
        else  
            %compute the median time by linear interpolation. 
            p=polyfit([t1(I) t1(J)],[T1(I) T1(J)],1); 
            mt=(0.5-p(2))/p(1); 
            str2=['Median time ' num2str(mt)]; 
 %string for LEGEND function 
        end 
    else 
        mt=t1(T1==0.5); 
        str2=['Median time ' num2str(mt)]; %string for LEGEND function 
    end 
  
    %plot all the data 
    clf 
    hold on 
    S2=stairs(t1(1:lowcend),lowc(1:lowcend),'g--');  
%lower confidence interval curve 
    stairs(t1,upc,'g--'); %upper confidence interval curve 
    S1=stairs(t1,T1,'b'); %Kaplan-Meier survival function 
    if mt>0 %if exist a median time... 
        S3=plot([0 mt mt],[0.5 0.5 0],'k:');  
    end 
    if ~isempty(table12) %if there are censored data... 
        S4=plot(xcg,ycg,'r+'); 
    else 
        S4=[]; 
    end 
    hold off 
  
    %set the axis properly 
    xmax=max(t1)+1; 
    axis([0 xmax 0 1.2]); 
    axis square 
    %add labels and legend 
    txt=sprintf('Kaplan-Meier estimate of survival function (hazard rate: %0.4f)\n',lambda); 
    title(txt,'FontName','Arial','FontSize',14,'FontWeight','Bold');  
    ylabel('Estimated survival function','FontName','Arial','FontSize',14,'FontWeight','Bold');  
    xlabel('Time','FontName','Arial','FontSize',14,'FontWeight','Bold');  
    if mt 
        if isempty(S4) 
            legend([S1 S2 S3],'Data',str1,str2) 
        else 
            legend([S1 S2 S3 S4],'Data',str1,str2,'Censored') 
        end 
    else 
        if isempty(S4) 
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            legend([S1 S2],'Data',str1) 
        else 
            legend([S1 S2 S4],'Data',str1,'Censored') 
        end 
    end 
    disp('HAZARD RATE IS AN EXPERIMENTAL FUNCTION!!!!') 
end 
if nargout 
    varargout(1)={table1} 
    varargout(2)={table12}; 
    varargout(3)={t1}; 
    varargout(4)={T1}; 
    varargout(5)={xcg}; 
    varargout(6)={ycg}; 
    varargout(7)={lambda}; 
end 
 
Appendix 21: MATLAB Program 8 
 
function out = logrank(varargin) 
% LOGRANK Comparing survival curves of two groups using the log rank %test Comparison of 
two survival curves can be done using a statistical 
% hypothesis test called the log rank test. It is used to test the null 
% hypothesis that there is no difference between the population %survival curves (i.e. the 
%probability of an event occurring at any %time point is the same for each population). This 
%function use the %Kaplan-Meier procedure to estimate the survival function, so it is 
%mandatory to download 
% KMPLOT (http://www.mathworks.com/matlabcentral/fileexchange/22293). 
% 
% Syntax:   logrank(x1,x2,alpha,censflag) 
%       
%     Inputs: 
%           X1 and X2 (mandatory)- Nx2 data matrix: 
%                     (X:,1) = survival time of the i-th subject 
%                     (X:,2) = censored flag  
%                             (0 if not censored; 1 if censored) 
%        note that if X is a vector, all the flags of the second column 
%           will be set to 0 (all data are not censored). 
%           ALPHA (optional) - significance level (default 0.05)  
%           CENSFLAG (optional) - Censored Plot flag (default 0). If 0 
%           censored data will be plotted spreaded on the horizontal 
%           segment; if 1 they will be plotted at the given time of 
%           censoring. 
%     Outputs: 
%           Kaplan-Meier plot 
%           Log-rank statistics 
% 
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%      Example:  
%           load logrankdata x1 x2 
%           logrank(x1,x2) 
% 
%LOG-RANK TEST FOR KAPLAN-MEIER SURVIVAL FUNCTIONS 
% 
%---------------------------------------------------------------------- 
%UL             S.E.            z               p-value (2-tailed test)     alpha 
%---------------------------------------------------------------------- 
%6.57226        2.80788         2.16258         0.03057           0.050 
%---------------------------------------------------------------------- 
%       The survival functions are statistically different 
% 
%           Created by Giuseppe Cardillo 
%           giuseppe.cardillo-edta@poste.it 
% 
% To cite this file, this would be an appropriate format: 
% Cardillo G. (2008). LogRank: Comparing survival curves of two groups 
% using the log rank test 
% http://www.mathworks.com/matlabcentral/fileexchange/22317 
  
%Input Error handling 
args=cell(varargin); 
nu=numel(args); 
if isempty(nu) || nu<2 
    error('Warning: Data vectors are required') 
elseif nu>4 
    error('Warning: Max four input data are required') 
end 
default.values = {[],[],0.05,0}; 
default.values(1:nu) = args; 
[x1 x2 alpha,cflag] = deal(default.values{:}); 
if ~all(isfinite(x1(:))) || ~all(isnumeric(x1(:))) ... 
        || ~all(isfinite(x2(:))) || ~all(isnumeric(x2(:))) 
    error('Warning: all X1 and X2 values must be numeric and finite') 
end 
if isvector(x1)  
    x1(:,2)=0; 
else 
    if ~isequal(size(x1,2),2) 
        error('LOGRANK requires Nx2 matrix data.'); 
    end 
    if ~all(x1(:,2)==0 | x1(:,2)==1) 
        error('Warning: all X1(:,2) values must be 0 or 1') 
    end 
end 
if isvector(x2)  
    x2(:,2)=0; 
else 
    if ~isequal(size(x2,2),2) 
        error('LOGRANK requires Nx2 matrix data.'); 
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    end 
    if ~all(x2(:,2)==0 | x2(:,2)==1) 
        error('Warning: all X2(:,2) values must be 0 or 1') 
    end 
end 
if nu>=3 
    if isempty(alpha) 
        alpha=0.05; 
    else 
        if ~isscalar(alpha) || ~isnumeric(alpha) || ~isfinite(alpha) 
            error('Warning: it is required a numeric, finite and scalar ALPHA value.'); 
        end 
        if alpha <= 0 || alpha >= 1 %check if alpha is between 0 and 1 
            error('Warning: ALPHA must be comprised between 0 and 1.') 
        end 
    end 
end 
if nu==4 
    if isempty(cflag) 
        cflag=0; 
    else 
        if ~isscalar(cflag) || ~isnumeric(cflag) || ~isfinite(cflag) 
            error('Warning: it is required a numeric, finite and scalar CENSFLAG value.'); 
        end 
        if cflag~=0 && cflag~=1 
            error('Warning: CENSFLAG value must be 0 or 1') 
        end 
    end 
end 
clear args default nu 
  
%recall KMPLOT function to construct tables of data (table1 and table2), 
%tables of censored data (table12 and table 22), Kaplan-Meier variables 
%(t1, t2, T1 and T2) and Kaplan-Meier graphical data for censored data  
%(xcg and ycg). 
try 
    [table1 table12 t1 T1 xcg1 ycg1 lambda1]=kmplot(x1,0.05,cflag,0); 
    [table2 table22 t2 T2 xcg2 ycg2 lambda2]=kmplot(x2,0.05,cflag,0); 
catch ME 
   disp('Download KMPLOT: http://www.mathworks.com/matlabcentral/fileexchange/22293') 
   rethrow(ME); 
end 
  
%plot both Kaplan-Meier curves 
clf 
hold on 
S1=stairs(t1,T1,'b'); %Kaplan-Meier curve for treatment 1 
if ~isempty(table12) 
    S3=plot(xcg1,ycg1,'k+'); %Censored data for treatment 1 
% (if there are) 
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else 
    S3=[]; 
end 
  
S2=stairs(t2,T2,'r'); %Kaplan-Meier curve for treatment 2 
if ~isempty(table22) 
    S3=plot(xcg2,ycg2,'k+'); %Censored data for treatment 2  
%(if there are) 
end 
hold off 
%set the axis properly 
xmax=max([t1;t2])+1; 
axis([0 xmax 0 1.2]); 
axis square 
%add labels and legend 
title('Kaplan-Meier estimate of survival functions') 
ylabel('Estimated survival functions') 
xlabel('Time') 
if isempty(S3) 
    legend([S1 S2],'Treatment 1','Treatment 2') 
else 
    legend([S1 S2 S3],'Treatment 1','Treatment 2','Censored') 
end 
  
clear S1 S2 S3 xmax xcg1 ycg1 xcg2 ycg2 t1 t2 T1 T2 
  
%Full-blown LOGRANK procedure 
%Merge the first columns of Table1 and Table2 (time intervals) 
%and pick-up unique values 
A=unique([table1(:,1);table2(:,1)]); 
table=zeros(length(A),9); %matrix preallocation 
%Out in the first column the time intervals 
table(:,1)=A;  
%Put in the columns 2 and 3 and in the proper rows the deaths and alive 
%taken from table1 columns 2 and 3 
[~, ia ib]=intersect(table1(:,1),A); 
table(ib,2:3)=table1(ia,2:3); 
%Put in the columns 4 and 5 and in the proper rows the deaths and alive 
%taken from table2 columns 2 and 3 
[~, ia ib]=intersect(table2(:,1),A); 
table(ib,4:5)=table2(ia,2:3); 
%remove the rows where there arent't deaths in both treatments 
table((table(:,2)==0 & table(:,4)==0),:)=[]; 
clear A c ia ib table1 table2 
%fill the "pigeon-holes" 
c=find(table(:,3)==0); %find the "pigeon-holes" of treatment 1 
for I=1:length(c) 
    if c(I)~=1 
  %find the first interval time before the hole where there is almost 1 
        %death 
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        J=find(table(1:c(I)-1,3)>0,1,'last'); 
        table(c(I),3)=table(J,3)-table(J,2); 
        if ~isempty(table12) 
        %find eventually censored data 
            K=find((table12(:,1)<table(c(I),1) & table12(:,1)>=table(J,1)),1,'last'); 
  %Put in the hole how many subject were alive before the interval time 
            %of the hole 
            if ~isempty(K) 
                table(c(I),3)=table(c(I),3)-sum(table12(K,2)); 
            end 
        end 
    else 
        table(1,3)=length(x1); 
    end 
end 
%Do the same for tratment 2 
c=find(table(:,5)==0); 
for I=1:length(c) 
    if c(I)~=1 
        J=find(table(1:c(I)-1,5)>0,1,'last'); 
        table(c(I),5)=table(J,5)-table(J,4); 
        if ~isempty(table22) 
            K=find((table22(:,1)<table(c(I),1) & table22(:,1)>=table(J,1)),1,'last'); 
            if ~isempty(K) 
                table(c(I),5)=table(c(I),5)-sum(table22(K,2)); 
            end 
        end 
    else 
        table(1,5)=length(x2); 
    end 
end 
clear c I J K table12 table22 
  
%Fill the table and compute the statistic variable 
%Compute the total deaths and alive before the i-th time interval 
table(:,6:7)=[sum(table(:,[2 4]),2) sum(table(:,[3 5]),2)]; 
%Compute the difference between observed deaths for treatment 1 and 
%expected deaths in the hyphthesis that the treatments are similar 
table(:,8)=table(:,2)-table(:,3).*table(:,6)./table(:,7); 
%Log-rank statistic is the sum of column 8 values 
J=sum(table(:,8)); UL=abs(J); 
%Compute the contribute to the standard error 
table(:,9)=prod(table(:,[3 5 6]),2).*(table(:,7)-table(:,6)) ... 
    ./(table(:,7).^2.*(table(:,7)-ones(size(table,1),1))); 
%find if there is some NaN (i.e. 0/0) 
loc=isnan(table(:,9)); 
if any(loc) 
    table(loc,9)=0; 
end 
V=sum(table(:,9)); SUL=sqrt(V); %Compute the totale standard error 
K=J/V; HR=exp(K); HRci=[exp(K-1.96/SUL) exp(K+1.96/SUL)]; 
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z=abs((UL-0.5)/SUL); %normalized UL with Yates'es correction 
p=2*(1-0.5*erfc(-z/realsqrt(2))); %p-value 
  
%display results 
% disp('LOG-RANK TEST FOR KAPLAN-MEIER SURVIVAL FUNCTIONS') 
% disp(' ') 
% tr=repmat('-',1,110); 
% disp(tr) 
% disp('HAZARD RATE IS AN EXPERIMENTAL FUNCTION!!!!') 
% fprintf('Treatment 1: Hazard rate: %0.4f\n',lambda1) 
% fprintf('Treatment 2: Hazard rate: %0.4f\n',lambda2) 
% fprintf('\n') 
% fprintf('Mantel-Haenszel Hazard ratio: %0.4f\n',HR) 
% fprintf('95%% confidence interval: %0.4f - %0.4f\n',HRci) 
% disp(tr) 
% fprintf('UL\t\t\tS.E.\t\tz\t\tp-value (2-tailed test)\t\talpha\n') 
% disp(tr) 
% %fprintf('%0.5f\t\t\t%0.5f\t\t%0.5f\t\t%0.5f\t\t\t\t%0.3f\n',UL,SUL,z,p%,%alpha) 
% disp(tr) 
% if p<alpha 
%     fprintf('\t\tThe survival functions are statistically %different\n') 
%  else 
%     fprintf('\t\tThe survival functions are not statistically %different\n') 
% end 
out = p; 
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